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Abstract 
Vitamin D deficiency is prevalent throughout the world. Even in a temperate climate such as 
Australia, one-third of the adult population has insufficient levels of serum vitamin D (25-
hydroxyvitamin D levels <50 nmol/L). Epidemiological studies have shown significant associations 
between vitamin D deficiency and an increased risk of various neuropsychiatric and 
neurodegenerative disorders, such as schizophrenia, depression, Alzheimer’s disease and cognitive 
impairment. However, studies based on observational epidemiology cannot address questions of 
causality; they cannot determine if vitamin D deficiency is a causal factor leading to the adverse 
health outcome. The use of animal experiments can examine the biological plausibility of the 
relationship between vitamin D deficiency and adverse brain outcomes.  
Vitamin D is a neurosteroid that has a wide range of functions within the brain including calcium 
maintenance, regulation of neurotrophic factors, neurogenesis, and neuroprotection. Using a model 
of adult vitamin D (AVD) deficiency in BALB/c mice, we have previously shown alterations in a 
range of behaviours and an imbalance between excitatory and inhibitory neurotransmission, which 
may be relevant to a range of neuropsychiatric disorders. Therefore, we have provided experimental 
evidence demonstrating that vitamin D deficiency in adulthood impacts on a range of brain 
functions, and is therefore a biologically plausible risk factor for the development of 
neuropsychiatric disorders. However, there is currently insufficient evidence to account for the 
mechanism(s) by which this occurs.  
There were four main aims of the thesis; to determine whether AVD deficiency impacts on (1) 
cognition, (2) adult hippocampal neurogenesis, and (3) glutamate and GABA signaling in BALB/c 
mice; and to determine if AVD deficiency would (4) exacerbate the effects of a secondary exposure, 
in this case social stress, in BALB/c mice and in the more resilient C57BL/6J mice. 
To address these aims I assessed attentional processing in BALB/c mice using the 5 choice serial 
reaction time task and found sex-dependent impairments in AVD-deficient male mice only. 
Structural and diffusion tensor imaging was assessed using MRI in male mice, however we found 
no significant alterations in gross brain structure or connectivity within the brain in the group 
exposed to AVD deficiency. I used immunohistological techniques to assess two measures of 
hippocampal neurogenesis, cell proliferation and survival of newborn neurons, and found that 
hippocampal neurogenesis was not affected by AVD deficiency at baseline or following wheel 
running stimulated neurogenesis.  
 iii 
Despite no cellular level change in neurogenesis, the analysis of the proteomics of the hippocampus, 
although preliminary, provided clues that AVD deficiency may have an effect on synapse formation 
and plasticity, and dendritic arborisation and that these changes may be responsible for impaired 
learning and memory. The proteomics also provided convergent evidence of an effect on glutamate 
and GABA signaling and an effect on glutathione synthesis that would lead to elevated levels of 
oxidative stress.  
Based on the preliminary proteomics results, levels of glutathione were assessed in whole brain and 
showed that AVD-deficient mice had reduced glutathione levels, which would potentially leave 
them exposed to oxidative stress. I then used a specific hippocampal-dependent learning and 
memory task, active place avoidance, in male mice and showed that AVD-deficient mice took 
longer to learn the task than did controls. Although, AVD deficiency did not impact on numbers of 
newly born neurons, it is possible that the function of these neurons were altered through changes to 
dendritic arborisation, spine density or synaptic plasticity.  
Finally, I examined a second-hit exposure, social stress, in both BALB/c and C57BL/6J strains to 
determine if AVD deficiency would exacerbate the effects of stress on behaviour. I found that 
AVD-deficient mice were more vulnerable to the effects of social stress using a social avoidance 
test, and this was dependent on strain. 
Overall, the experiments covered in this thesis found that while AVD deficiency was not associated 
with changes in gross brain morphology or measures of adult hippocampal neurogenesis, we did 
find neurochemical alterations in glutathione synthesis, cognitive impairments, convergent evidence 
of an effect of AVD deficiency on glutamate and GABA signaling and preliminary proteomic 
results showing an effect of AVD deficiency on a number of proteins involved in synaptic 
plasticity. 
Furthermore, the results from the two-hit study have provided evidence that vitamin D deficiency 
may exacerbate behavioural outcomes in mice vulnerable to stress, a finding that can help guide 
future studies. Importantly, the discoveries outlined in this thesis provide convergent evidence to 
support the epidemiological link between vitamin D deficiency and neuropsychiatric and 
neurodegenerative disorders; and has provided clues that can guide future studies related to 
unravelling the mechanisms of action linking adult vitamin D deficiency and adverse brain related 
outcomes.  
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Chapter 1 General Introduction 
 2 
1.1 Introduction  
Vitamin D deficiency is prevalent throughout the world, particularly in high-risk groups including 
pregnant woman, infants, dark-skinned migrants and the elderly (Lips, 2010). In Australia, a recent 
study showed that 31% of the population has vitamin D deficiency, which is defined as a serum 
concentration of 25-hydroxyvitamin D [25(OH)D] below 50 nmol/L (Daly et al., 2012). Although 
vitamin D is essential for calcium homeostasis and bone metabolism, it also has a role in other 
physiological functions, such as an immune modulator (Baeke et al., 2010) and in cell proliferation 
and differentiation (Bikle, 2009). Research over the past 15 years has revealed many functions of 
vitamin D in brain development and adult brain function (Eyles et al., 2011). More recently, 
evidence has accumulated to suggest that low vitamin D levels during adulthood may also be 
associated with adverse brain-related outcomes. A growing body of evidence from epidemiology 
and neuroscience links vitamin D deficiency with a range of neuropsychiatric disorders and 
neurodegenerative diseases (Eyles et al., 2013). If low vitamin D is associated with adverse brain 
outcomes, this could have important public health implications because the treatment of vitamin D 
insufficiency (i.e. supplementation) is safe, cheap and publicly acceptable. 
This review has three broad aims: (a) to summarise the role vitamin D plays within the healthy 
developing and adult brain, (b) to highlight the impact that vitamin D deficiency has on brain 
function in health and disease, and (c) to provide up-to-date evidence supporting the links between 
vitamin D deficiency and neuropsychiatric disorders and neurodegenerative diseases.  
1.1.1 Vitamin D synthesis 
Vitamin D is synthesized from 7-dehydrocholesterol within the skin via UVB radiation. For a 
review of the major pathway for the synthesis of vitamin D, see Figure 1.1. The amount of synthesis 
is dependent on a wide range of factors including latitude, season, atmospheric conditions, skin 
pigmentation and age; as well as personal habits including type of attire worn during exposure to 
sunlight (Holick, 1995), sunscreen use, and time spent outdoors (Chen et al., 2007). Importantly, at 
high latitudes during winter and spring months, it is not possible to synthesize sufficient vitamin D 
from sunlight, and therefore dietary intake and supplementation are vital to maintain adequate 
levels of vitamin D (Engelsen et al., 2005). 
The conversion of 7-dehydrocholesterol in the skin of humans and animals forms vitamin D3, 
whereas the conversion of ergosterol in plants, yeast and fungi forms vitamin D2 (Lehmann & 
Meurer, 2010). Both forms can be converted to the biologically active vitamin, but they may not 
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have equal nutritional value in people (Heaney et al., 2011), although this is likely to vary in 
different species, such as rodents (Horst et al., 1982; Hohman et al., 2011).  Vitamin D3 is reported 
to be 87% more potent in raising and maintaining serum 25(OH)D levels compared to vitamin D2 in 
people, and it provides two- to threefold greater storage capacity of vitamin D in adipose tissue 
(Heaney et al., 2011). Additionally, vitamin D2 supplementation may even suppress endogenously 
formed vitamin D3 (Stephensen et al., 2012). 
Vitamin D is converted to its biologically active form via two enzymatic steps, the first of which 
occurs in the liver. Vitamin D is hydroxylated to 25(OH)D via either the microsomal (CYP2R1) or 
the mitochondrial (CYP24A1) P450 25-hydroxylase enzymes (Schuster, 2011). 25(OH)D is then 
converted to the biologically active, 1,25-dihydroxyvitamin D [1,25(OH)2D] in the kidney via 1α-
hydroxylase (CYP27B1). 1α-hydroxylase is tightly controlled via feedback mechanisms from 
parathyroid hormone, calcium, phosphate, calcitonin, fibroblast growth factor 23, and vitamin D 
itself (Lehmann & Meurer, 2010).  
Although the main expression of 1α-hydroxylase is within the kidney, a variety of other tissues also 
express this enzyme, including the skin, immune cells, placental tissue, and pancreas (Zehnder et 
al., 2001; Eyles et al., 2005). The presence of extra-renal 1α-hydroxylase suggests that an 
autocrine/paracrine mechanism plays a role in localized effects of vitamin D (Hewison et al., 2007).  
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Figure 1.1 Synthesis, localisation and overview of known functions of vitamin D 
The major pathway for the production of 1,25(OH)2D is via UVB radiation of 7-hydrocholesterol in the skin, 
followed by two further hydroxylation steps in the liver and kidney respectively. Local production of the 
active form of vitamin D can be produced in other locations throughout the body including the brain. 
1,25(OH)2D has been shown to have a wide array of functions including calcium and bone homeostasis and 
immune function. There is also evidence for functional effects of 1,25(OH)2D in the regulation of cell 
proliferation and differentiation as well as a role in neuroprotection. Within astrocytes, 1,25(OH)2D regulates 
the synthesis of various neurotrophins and can upregulate γ-GT to increase GSH levels and inhibit iNOS to 
limit the production of NO, resulting in neuroprotection for neurons. Finally, there is also evidence that 
1,25(OH)2D can activate cell death pathways in tumour cells via p75. Abbreviations: NGF, nerve growth 
factor; NT3, neurotrophin 3; GDNF, glial cell line-derived neurotrophic factor; γ-GT, γ-glutamyl 
transpeptidase; NT4, neurotrophin 4; TNFα, tumour necrosis factor alpha; M-CSF, macrophage colony-
stimulating factor; GSH, glutathione; iNOS, inducible nitric oxide synthase; NO, nitric oxide; p75, low 
affinity NGF receptor; VDR, vitamin D receptor. Figure modified from Garcion et al. (2002); Hart et al. 
(2011).  
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1.1.2 Genomic versus nongenomic pathways of action 
Vitamin D exerts its effects via both genomic and nongenomic pathways (Bouillon et al., 2008). 
The genomic pathway begins with vitamin D binding to the vitamin D receptor (VDR), which is a 
member of the steroid/thyroid superfamily of nuclear transcription factors (Tsai & O'Malley, 1994). 
VDR is present throughout the body in almost all tissue types (Eyles et al., 2005; Barchetta et al., 
2012; Wang et al., 2012b; Girgis et al., 2013). Once vitamin D is bound to the receptor, VDR is 
phosphorylated to induce a change in conformation to release co-repressors and allow VDR to 
heterodimerise with the retinoid X receptor (Bouillon et al., 2008). This heterodimer then recruits 
coregulatory protein complexes and binds one of many vitamin D response elements (VDREs) 
within the genome to influence gene transcription. The VDRE is composed of two hexameric 
binding sites on DNA, arranged as either direct repeats interspaced with a small but varying number 
of nucleotides or as inverted palindromes interspaced by nine nucleotides (Schrader et al., 1997; 
Haussler et al., 1998). 
The ability of this heterodimer to influence gene transcription is dependent upon the range of co-
regulatory protein complexes, such as steroid receptor co-activators and VDR-interacting protein, 
which determines whether repression or activation occurs (Fernandes de Abreu et al., 2009). The 
recently established genome-wide map of VDR binding identified over 2,700 genomic positions 
occupied by the VDR, showing the pleiotropic nature of vitamin D (Ramagopalan et al., 2010).  
Like other neurosteroid hormones, vitamin D initiates nongenomic rapid responses via either a 
membrane-bound VDR (Menegaz et al., 2011) or a protein-disulfide isomerase-associated 3 protein 
(PDIA3) (Chen et al., 2010). The variety of signal transduction systems that are rapidly activated by 
vitamin D include influx of calcium; intracellular release of calcium stores; modulation of adenylate 
cyclase, phospholipase C, and protein kinases; and alteration of the phosphorylation states of 
cellular proteins (Falkenstein et al., 2000; Chen et al., 2010).  
Rapid nongenomic effects of vitamin D may therefore play a role in a variety of cellular processes, 
with evidence supporting the role of vitamin D in proliferation and immune function (Khanal & 
Nemere, 2007). Importantly, both the VDR and PDIA3 receptors are present in the adult brain 
(Eyles et al., 2007; Pendyala et al., 2012). 
1.1.3 Vitamin D metabolism in the brain 
The activating enzyme of vitamin D, 1α-hydroxylase, is found in a wide variety of tissues 
throughout the body, including the brain (Zehnder et al., 2001; Eyles et al., 2005), along with 25-
hydroxylase (Garcion et al., 2002) and the enzyme required for the degradation of the biologically 
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active form of vitamin D, 24-hydroxylase (CYP24A1) (See Figure 1.1) (Balden et al., 2012). 
Animal studies have shown that the VDR is also found within specific brain regions, including the 
hippocampus, amygdala, hypothalamus, thalamus, cortex, and cerebellum (Prufer et al., 1999; 
Walbert et al., 2001).  
The distribution of the VDR and 1α-hydroxylase has also been elucidated in the adult human brain 
and is similar to that found in the rat (Eyles et al., 2005). The VDR and the 1α-hydroxylase enzyme 
are co-localized and are found in both neurons and glial cells. The VDR seems to be exclusively 
nuclear in mature neurons, whereas 1α-hydroxylase is located within the cytosol (Eyles et al., 
2005). One recent study showed some immunohistochemical staining of VDR in the soma of 
mature dopaminergic cells; however, western blots confirmed that the VDR was restricted to the 
nucleus of both the developing and mature midbrain (Cui et al., 2013b). In contrast, previous 
studies have shown that unliganded VDR constantly shuttles between nucleus and the cytoplasm 
(Prufer & Barsony, 2002). 
The VDR is present early in the development of the rat, between embryonic day (E)12 and E15, 
with levels of VDR increasing until weaning (postnatal day 21) and still present in the adult brain 
(Veenstra et al., 1998; Burket et al., 2003; Cui et al., 2013b). The time-dependent expression of 
VDR in the brain during fetal development supports a role for vitamin D in brain development. The 
initial VDR expression in brain corresponds within the appearance of dopaminergic neurons within 
the mesencephalon. Additionally, VDR is present within dopaminergic neurons in the adult 
substantia nigra (Cui et al., 2013b). 
1.2 The actions of vitamin D within the brain 
Growing evidence shows that vitamin D has many functions in both the developing and adult brain, 
including maintaining calcium balance and signaling, regulating neurotrophic factors, providing 
neuroprotection, modulating neurotransmission, and contributing to synaptic plasticity.  
1.2.1 Vitamin D and calcium signaling within the brain 
A high level of calcium in the brain leads to neurotoxicity, and one action of vitamin D within the 
brain is associated with a reduction in calcium levels. Vitamin D has been shown to downregulate 
or modulate L-type voltage-gated calcium channels (L-VGCCs) (Zanatta et al., 2012; Zhu et al., 
2012). This occurs through downregulation of L-type voltage-sensitive calcium channel (L-VSCC)-
A1C subunit mRNA and protein, mediated by VDR mechanisms (Gezen-Ak et al., 2011). Vitamin 
D treatment has also been shown to downregulate L-VSCC-A1D subunit mRNA, but this does not 
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occur via VDR (Gezen-Ak et al., 2011). In mice lacking vitamin D, L-VGCCs are shown to be 
upregulated, leading to increased calcium influx (Zhu et al., 2012). Evidence suggests that vitamin 
D can directly provide neuroprotection against excitotoxic insults in vitro by its downregulation of 
L-VGCCs (Brewer et al., 2001). 
Vitamin D also regulates the gene expression of a number of calcium-binding proteins, including 
parvalbumin and calbindin D28k (Van Cromphaut et al., 2001; Dursun et al., 2011), and proteins 
associated with calcium homeostasis (Eyles et al., 2007). The evidence suggests that the effects of 
vitamin D on calcium occur via both genomic and nongenomic actions (Eyles et al., 2007; Nemere 
et al., 2012; Zanatta et al., 2012). 
1.2.2 Neurotrophic properties 
The first evidence to support the role of vitamin D in neuronal differentiation, maturation, and 
growth came from in vitro studies showing that treatment with vitamin D led to changes in several 
neurotrophic factors, with increased synthesis of nerve growth factor (NGF) (Wion et al., 1991; 
Neveu et al., 1994b), glial cell line-derived neurotrophic factor (GDNF) (Naveilhan et al., 1996b) 
and neurotrophin 3 (NT-3), and with decreased synthesis of NT-4 (Neveu et al., 1994a). Vitamin D 
treatment was also shown to increase levels of the low-affinity neurotrophin receptor (p75NTR) in 
vitro (Naveilhan et al., 1996a). Depletion of vitamin D during rat fetal development leads to a 
reduction in NGF, GDNF and p75NTR in newborn pups (Eyles et al., 2003).  
NGF is essential for the survival and differentiation of sensory and sympathetic neurons as well as 
the cholinergic basal forebrain neurons (Korsching et al., 1985) and GDNF is integral to the 
development of dopaminergic (Tomac et al., 1995) and noradrenergic systems (Quintero et al., 
2004). Although NT-3 stimulates the production of neurons and has widespread effects on their 
function and survival (Maisonpierre et al., 1990), the p75NTR, along with NGF, is essential for 
necessary programmed cell death in the brain (Chao, 1994). 
Initial in vitro work in several cancer cell lines including mouse myeloid leukemia cells and 
melanoma cells, showed that the addition of vitamin D inhibited cell growth, led to a reduction in 
proliferation and increased differentiation (Pols et al., 1990). Vitamin D’s ability to induce 
differentiation was shown to be extended to normal bone marrow progenitor cells in vitro (Miyaura 
et al., 1982), and its antiproliferative effects were confirmed in vivo against malignant cancers 
(Eisman et al., 1987). Furthermore, the addition of vitamin D to cultured embryonic hippocampal 
cells was shown not only to increase NGF but also to increase neurite outgrowth and decrease 
mitosis (Brown et al., 2003). 
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1.2.3 Neuroprotection 
Evidence indicates that vitamin D provides neuroprotection by regulating NGF and GDNF. In vitro 
studies have shown that NGF protects against glutamate toxicity and calcium ionophore and nitric 
oxide (NO) donor toxicity (Kume et al., 2000). Animal studies have shown that NGF is able to 
protect against excitotoxic injury (Frim et al., 1993), and in an animal model of Parkinson’s disease, 
GDNF is neuroprotective against ischemia (Wang et al., 2002b), 6-hydroxydopamine (6-OHDA) 
toxicity (Kearns et al., 1997) and injury (Gash et al., 1998).  
Vitamin D itself has also been shown to provide neuroprotection against excitotoxic injury from 6-
OHDA, both in vitro and in vivo (Wang et al., 2001), which may occur by its downregulation of L-
VGCCs (Brewer et al., 2001). Pretreatment with vitamin D ameliorated the locomotor deficits seen 
with 6-OHDA lesions into the medial forebrain bundle. In addition, pretreatment protected against 
6-OHDA-mediated depletion of dopamine and metabolites within the substantia nigra (Wang et al., 
2001). Injection of vitamin D into adult rats leads to an increase in GDNF mRNA and protein 
expression within the striatum (Sanchez et al., 2002), and pretreatment with vitamin D has also 
been shown to significantly increase GDNF protein expression and tyrosine hydroxylase (TH) 
immunoreactivity in the substantia nigra after 6-OHDA-lesioning (Sanchez et al., 2009). 
It is well known that vitamin D has an effect on the immune system and directly affects immune 
cells (Mora et al., 2008). Within the CNS, vitamin D exerts immunomodulatory effects directly on 
infiltrating macrophages and parenchymal microglia (Nataf et al., 1996). Treatment of microglia in 
vitro with vitamin D inhibits the production of tumor necrosis factor-α (TNFα), interleukin-6 (IL-
6), and NO by activated microglia, which suggests an anti-inflammatory role for vitamin D within 
the brain (Lefebvre d'Hellencourt et al., 2003). Vitamin D has been shown to downregulate the 
expression of inducible nitric oxide synthesis (iNOS) (Garcion et al., 1998) and to regulate the 
expression of gamma glutamyl transpeptidase (Garcion et al., 1999), an enzyme important in the 
glutathione pathway; these findings suggest that vitamin D has an important role in antioxidant 
metabolism. Vitamin D-deficient aged (22-month-old) male Fischer 344 rats have elevated 
inflammatory proteins in the brain, including TNFα and IL-6, indicating that baseline brain 
inflammation may be increased even without injury (Cekic et al., 2011). Furthermore, in middle-
aged (9-11-month-old) female Sprague-Dawley rats, a vitamin D-deficient diet produced elevated 
IL-6 levels within the brain and reduced insulin-like growth factor 1 (IGF-1) levels within plasma 
and brain following ischemia (Balden et al., 2012). 
A recent animal study showed elevated levels of vitamin D metabolism enzymes, VDR, and 
25(OH)D in the hippocampus following a chronic unpredictable mild stress paradigm in rats when 
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compared to controls (Jiang et al., 2013). Vitamin D is known to be neuroprotective, and therefore 
it may be that upregulation of vitamin D can protect against the damaging effects of stress within 
otherwise-healthy subjects.  
1.2.4 Neurotransmission 
Vitamin D has been shown to regulate a number of neurotransmitter systems. For example, vitamin 
D treatment leads to increased choline acetyltransferase activity in specific brain regions, which 
may impact on cholinergic neurotransmission (Sonnenberg et al., 1986). In rats, vitamin D has been 
shown to protect against methamphetamine-induced reductions in dopamine and serotonin in both 
the striatum and accumbens (Cass et al., 2006). Vitamin D treatment has also been shown to 
increase both potassium- and amphetamine-evoked overflow of striatal dopamine as well as 
increase substantia nigra tissue levels of dopamine and its main metabolites (Cass et al., 2012). 
Not only can vitamin D act to transiently alter neurotransmitters upon exposure, but there is also 
evidence to suggest that hormonal imprinting that occurs during the neonatal period permanently 
alters biogenic amine levels in adulthood. For example, male rats treated with vitamin D at birth 
showed altered brain stem dopamine and striatal and hypothalamus homovanillic acid (HVA) levels 
three months later (Tekes et al., 2009a). In addition, hormonal imprinting with vitamin D that 
occurred during the neonatal period in female rats was shown to alter biogenic amine levels in two-
month-old offspring.  Alterations included increased norephinephrine, dopamine, and serotonin 
levels in the brainstem; decreased serotonin levels in the hippocampus; and decreased serotonin and 
HVA levels in the frontal cortex. These changes most likely occurred as a result of epigenetic 
mechanisms (Tekes et al., 2009b). 
1.2.5 Synaptic plasticity 
Long-term potentiation (LTP) is a long-lasting enhancement of signal transmission between 
neurons. LTP is one of the mechanisms underlying synaptic plasticity and is important in learning 
and memory. Prenatal vitamin D deficiency has been shown to alter many genes involved in 
synaptic plasticity (Eyles et al., 2007), and evidence suggests that prenatal vitamin D deficiency 
induces a long-lasting enhancement of hippocampal LTP, in freely moving adult rats. Treatment 
with haloperidol, a high-affinity dopamine D2 receptor antagonist, reverses the enhanced LTP 
(Grecksch et al., 2009).  
Optimal levels of vitamin D were shown to be required for the induction of LTP within the adult rat 
brain (Salami et al., 2012). However in that study, vitamin D-deficient adult rats also showed a 
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reduction in serum calcium, which may have led to the impaired LTP (Salami et al., 2012), because 
increased postsynaptic intracellular calcium is necessary for the induction of LTP (Brown et al., 
1988).  
1.3 Rodent models of vitamin D deficiency 
In rodents, vitamin D deficiency from weaning, during adulthood, or throughout life has produced a 
range of significant impairments, including reduced body weight, musculoskeletal deficits, impaired 
prepulse inhibition of the acoustic startle response, and spatial learning deficits (Altemus et al., 
1987; Burne et al., 2004b; Taghizadeh et al., 2013). Neurochemical changes have also been noted, 
with significant increases in norephinephrine, dopamine, dihydroxyphenylacetic acid (a breakdown 
product of dopamine), and γ-aminobutyric acid (GABA) (Baksi & Hughes, 1982; Tenenhouse et 
al., 1991). However, all of these studies (Baksi & Hughes, 1982; Altemus et al., 1987; Tenenhouse 
et al., 1991; Burne et al., 2004b; Taghizadeh et al., 2013) found a reduction in serum calcium levels 
with vitamin D deficiency, which suggests that the impairments may have been due to altered 
calcium metabolism. This demonstrates the importance of maintaining normal serum calcium levels 
and appropriate musculoskeletal function. 
1.3.1 Developmental vitamin D deficiency 
A developmental vitamin D (DVD)-deficient model was first created in Sprague-Dawley rats, in 
which vitamin D is removed from the diet for 6 weeks prior to and throughout conception. Under 
these conditions, dams have a serum concentration of 25(OH)D at the lower limit of detection (<5 
nmol/L), which represents a frank vitamin D deficiency seen in less than 4% of the Australian 
population (Daly et al., 2012). However, dams are placed back on normal rat chow at the birth of 
the pups, and 25(OH)D concentrations return to control levels within 2 weeks (Eyles et al., 2013). 
Use of this model of transient prenatal vitamin D deficiency in rodents has provided compelling 
proof-of-principle evidence for the association between DVD deficiency and a wide range of 
alterations in neuroanatomical, neurochemical, and behavioural measures while normal serum 
calcium levels are maintained. The DVD-deficient rodent model is reviewed in detail elsewhere 
(Harms et al., 2011; Kesby et al., 2013). 
1.3.1.1 Neurogenesis  
Vitamin D deficiency has been shown to alter the gene expression of many cell cycle genes and 
apoptotic genes during foetal development, leading to changes in cell proliferation and apoptosis 
(Ko et al., 2004). Cells dissociated from neonatal rat subventricular zone following vitamin D 
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deficiency during gestation showed increased neurosphere production, which suggests that the 
absence of vitamin D leads to greater proliferation of neuroprogenitor cells (Cui et al., 2007). One 
study looked at the effects of maternal vitamin D deficiency on adult hippocampal neurogenesis and 
found that the prenatal vitamin D deficiency resulted in decreased neurogenesis in adult rats and 
that the decrease in neurogenesis could be reversed by treatment with haloperidol, a dopamine 
inverse agonist (Keilhoff et al., 2010).  
The 1α-hydroxylase knockout mouse lacks the ability to make 1,25(OH)2D, and this is associated 
with increased cell proliferation in the hippocampal dentate gyrus and a reduction in the survival of 
newborn neurons at 8 weeks of age (Zhu et al., 2012). The 1,25(OH)2D deficiency also significantly 
increased apoptosis in the hippocampal dentate gyrus, which suggests that this deficiency may be 
responsible for the loss of the newborn neurons. These results were independent of extracellular 
calcium (Zhu et al., 2012).  
1.3.1.2 Proliferation, differentiation, and apoptosis  
In the rat model of DVD deficiency, the vitamin D-depleted pups had brains that were larger and 
longer, with larger ventricular volume and a thinner neocortex, than brains from control pups. It 
was shown that the changes in brain morphology were at least in part due to an increase in cell 
proliferation (Eyles et al., 2003). Moreover, analysis of genes involved in the regulation of 
apoptosis found that the DVD-deficient pups had a significant reduction in apoptosis during 
gestation compared with control pups (Ko et al., 2004). Lack of vitamin D during development also 
led to a multitude of changes in gene expression of pro-apoptotic and cell cycle genes, which 
corresponded to observed changes in apoptosis and increased cell proliferation (Ko et al., 2004). 
These studies confirmed that loss of vitamin D leads to alterations in cell proliferation, 
differentiation and apoptosis during critical periods of brain development. 
1.3.1.3 Vitamin D and dopaminergic pathways 
A consistent finding from the DVD-deficient rat model is altered dopamine signaling. In neonatal 
rats, DVD deficiency decreases dopaminergic turnover by a reduction in the expression of catechol-
O-methyl transferase enzyme, which is responsible for the breakdown of a dopamine metabolite 
(Kesby et al., 2009). DVD deficiency has also been shown to significantly reduce factors crucial for 
specifying dopaminergic phenotype, such as Nurr1 and p57Kip2, during fetal development (Cui et 
al., 2010). Nurr1 knockout animals have complete agenesis of dopamine neurons (Zetterstrom et 
al., 1997), and p57Kip2 knockouts have no TH-positive mesencephalic cells at E18.5 (Joseph et al., 
2003). 
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Adult female DVD-deficient rats have a significantly increased dopamine transporter density in the 
caudate putamen and binding affinity in the nucleus accumbens compared with controls and are 
more sensitive to amphetamine, a dopamine-releasing agent (Kesby et al., 2010). It was recently 
confirmed that the VDR is present in the nucleus of TH-positive neurons in both human and rat 
substantia nigra (Cui et al., 2013b).  
1.3.1.4 DVD-deficient model and schizophrenia 
A wide range of epidemiological findings have pointed to developmental vitamin D deficiency as a 
risk factor for the development of schizophrenia (McGrath, 1999); these findings are discussed in 
more detail in section 1.4.4 Schizophrenia. In this section we discuss findings in the DVD-deficient 
animal model that are relevant to schizophrenia. 
The enlarged lateral ventricles and reduced cortical thickness seen in DVD-deficient rat pups are 
frequently reported in schizophrenia patients (Harrison, 1999). Adult DVD-deficient 129svJ mice 
(Harms et al., 2008) and adult DVD-deficient rats had greater spontaneous hyperlocomotion (Burne 
et al., 2004a) compared with controls. DVD-deficient rats also showed increased locomotion in 
response to dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor 
antagonist, and a reduction in both MK-801-induced and spontaneous hyperlocomotion with 
haloperidol, a dopamine receptor antagonist, which was selective for DVD-deficient rats (Kesby et 
al., 2006). DVD-deficient adult rats also showed impaired latent inhibition (Becker et al., 2005), 
another feature of schizophrenia (Williams et al., 1998). 
DVD deficiency also led to cognitive impairments in mice (Fernandes de Abreu et al., 2010b) and 
impaired response inhibition on the rodent version of the continuous performance task in rats 
(Turner et al., 2013), a key feature of the cognitive deficits seen with schizophrenia. These 
impairments were reversed by acute treatment with clozapine, an atypical antipsychotic (Turner et 
al., 2013). Although the DVD-deficient model does not replicate all of the features of schizophrenia 
[sensorimotor gating [prepulse inhibition (PPI)] is normal (Kesby et al., 2006)], and the effects are 
dependent on type of rodent and strain; it is a plausible model that can be used to explore the 
neurobiological mechanisms in schizophrenia. 
1.3.2 Adult vitamin D deficiency in rodents 
Vitamin D deficiency has recently been investigated in adult Sprague-Dawley rats to determine 
whether similar disruptions occur in both the developing and adult brain. In the adult vitamin D 
(AVD)-deficient model, rats were placed on a vitamin D-deficient diet at 10 weeks of age and at 16 
weeks began behavioural testing. They were tested on a wide range of behavioural domains, and 
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overall, AVD deficiency was not associated with an altered phenotype. In a cognitive test of 
attention and vigilance, the AVD-deficient rats had no learning or attentional deficits but showed a 
mildly impulsive phenotype. The AVD-deficient rats had increased levels of GABA and an 
increased dihydroxyphenylacetic acid/HVA ratio in the striatum. The AVD-deficient rats were 
shown to be vitamin D deficient and importantly, had normal calcium levels after eight to ten weeks 
on the diet (Byrne et al., 2013).  
The impact of AVD deficiency on brain function and behaviour was also investigated in two strains 
of inbred mice, C57BL/6J and BALB/c. The mice were placed on a vitamin D-deficient diet at 10 
weeks of age for a period of 10 weeks prior to behavioural testing. This procedure resulted in serum 
calcium levels and body weight in AVD-deficient mice that were not different from those of 
controls. AVD deficiency was found to result in spontaneous hyperlocomotion in both strains 
(Groves et al., 2013). The C57BL/6J strain showed no other behavioural effects of AVD deficiency. 
However, the BALB/c AVD-deficient mice showed altered behaviour on the elevated plus maze, a 
test used to measure anxiety levels, as well as altered responses to heat, shock, and sound. (Groves 
et al., 2013). 
Brain neurochemistry was also analysed, and the effects of AVD deficiency in the two strains 
differed markedly. In the C57BL/6J strain, dopamine and 5-hydroxytryptamine turnover was 
increased by AVD deficiency, whereas the BALB/c strain showed decreases in levels of glutamate 
and glutamine and increased levels of GABA and glycine. Of particular interest, both strains 
showed a small but significant decrease in the level of an enzyme involved in GABA synthesis, 
glutamic acid decarboxylase (GAD65/67) (Groves et al., 2013).  
These studies show the importance of background strain, with BALB/c mice more susceptible to 
AVD deficiency than C57BL/6J mice or Sprague-Dawley rats. These general bodies of research 
also indicate that the timing of exposure to low vitamin D has different impacts on brain outcomes. 
The absence of vitamin D during development alters the orderly cascade of brain development, 
which results in a range of neurobiological outcomes as discussed above and reviewed by (Kesby et 
al., 2013). In contrast, low vitamin D during adulthood is associated with only subtle changes in 
some behaviours and selective changes in neurochemistry that may be related to 
excitatory/inhibitory systems.  
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1.3.3 Two-hit animal models 
1.3.3.1 Vitamin D and experimental autoimmune encephalomyelitis: an animal model 
of multiple sclerosis  
The experimental autoimmune encephalomyelitis (EAE) animal model is a model of multiple 
sclerosis (MS). Using this model, a number of studies have looked at the effects of both vitamin D 
treatment and a vitamin D deficient diet on EAE outcomes (Lemire & Archer, 1991; Cantorna et 
al., 1996; Nataf et al., 1996).  
Treatment with vitamin D before or during the induction of EAE is effective in preventing EAE, 
and treatment with vitamin D after the induction of EAE is effective in decreasing the clinical signs 
of EAE (Lemire & Archer, 1991; Cantorna et al., 1996; Nataf et al., 1996). In addition, vitamin D 
deficiency increases the susceptibility to EAE and increases the clinical signs of EAE (Cantorna et 
al., 1996; Garcion et al., 2003). Recently, an animal model of MS pretreated with high-dose vitamin 
D was shown to have a reduction in demyelination and attenuated microglia activation and 
macrophage infiltration (Wergeland et al., 2011).  
Vitamin D is known to be an immune modulator with immunosuppressant activity. Its actions in the 
EAE animal model and in human MS are most likely to involve, in part, the regulation of 
inflammatory cytokines. For example, vitamin D decreases the production of pro-inflammatory 
cytokines and increases the production of anti-inflammatory cytokines (Manolagas et al., 1985; 
Cantorna et al., 1998). One study showed that vitamin D treatment for MS patients significantly 
increased serum levels of transforming growth factor-β1, which is an anti-inflammatory cytokine 
(Mahon et al., 2003). Vitamin D also directly affects cellular immunity. It has been shown to inhibit 
Th1 cell development in EAE, as well as dendritic cell maturation to suppress inflammatory activity 
(Lemire & Adams, 1992; Griffin et al., 2001) and regulate the actions of other T cells (Mayne et al., 
2011). 
Recently, studies have shown that vitamin D inhibits T-cell proliferation, inhibits the development 
of IL-6- and IL-17-producing cells, and enhances IL-10 production and the number of Tregs, all 
mechanisms to promote anti-inflammatory actions (Correale et al., 2009). It seems clear that 
vitamin D can alter the immune response, which is vitally important in autoimmune disorders such 
as MS. 
Unexpectedly, adult offspring of a DVD mouse model showed milder and delayed EAE when 
compared to control offspring (Fernandes de Abreu et al., 2010a). One hypothesis proposed was 
that mice deprived of vitamin D in utero and subsequently placed on a vitamin D diet from birth 
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actually grew up in an enriched-like environment (Fernandes de Abreu et al., 2010a). This 
hypothesis is supported by epidemiological data showing a reduced risk of MS is associated with 
higher sun exposure in children (van der Mei et al., 2003; Kampman et al., 2007). In mice it was 
shown that offspring born to either a DVD-deficient mother or father displayed early and more 
severe EAE when compared to control mice (Fernandes de Abreu et al., 2012). More studies are 
required to examine the molecular basis for the discordant effects between first and second 
generations. 
1.3.3.2 Vitamin D deficiency and stroke 
Studies with animal models of ischemic stroke have also looked at the effects of vitamin D on 
stroke severity and prognosis (Yasuhara et al., 2008; Balden et al., 2012). For example, a study 
examined the impact of vitamin D deficiency on stroke severity in the adult rat and found that 
vitamin D-deficient animals had greater infarct volumes compared to controls, and this 
corresponded with greater impairments, post-stroke, in sensorimotor behavioural testing. 
Investigations into the mechanism showed that vitamin D-deficient animals had significantly lower 
plasma, brain, and liver levels of IGF-1 compared to controls. IGF-1, a neuroprotectant that is 
usually elevated after injury to protect the tissue, has been attenuated with vitamin D deficiency, 
which indicates that lower IGF-1 levels may contribute to the greater infarct volume seen with 
vitamin D deficiency (Balden et al., 2012).  
The inflammatory response was also altered in the vitamin D-deficient rats compared to controls 
with a reduction in the levels of a variety of cytokines/chemokines including IL-1β, IL-10, and 
interferon-γ and with an increase in IL-6. These changes could also contribute to the greater infarct 
volume seen. The same study (Balden et al., 2012) also looked at the effects of an acute treatment 
with vitamin D immediately following stroke injury and found no effects on infarct volume or 
functional capabilities.  
1.3.3.3 Vitamin D deficiency and traumatic brain injury  
Vitamin D-deficient rats with traumatic brain injury show increased inflammation and greater open 
field test behavioural deficits in comparison with controls (Cekic et al., 2011). Although 
progesterone, a neurosteroid that has been beneficial as a treatment in traumatic brain injury in 
recent clinical trials (Wright et al., 2007; Xiao et al., 2008), was beneficial in injured control 
animals, there was no improvement with treatment in vitamin D-deficient animals.  This suggests 
that vitamin D deficiency exacerbates traumatic brain injury and diminishes the benefits of 
progesterone treatment (Cekic et al., 2011). 
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A combination treatment of progesterone and low-dose vitamin D after brain injury in vitamin D-
sufficient animals was found to preserve spatial and reference memory in comparison with controls, 
and the combination was more effective than progesterone treatment alone (Hua et al., 2012). The 
combination treatment also stimulated astrocytic activity around the injury site, which suggests that 
the neuroprotective effects are mediated through activated astrocytes (Hua et al., 2012).  
1.3.3.4 Vitamin D deficiency, ageing, and cognition  
Aged rats (20 months old) were analysed for the effects of vitamin D treatment on a spatial memory 
task and on a spontaneous object recognition task, inflammatory state, and amyloid-β (Aβ) load and 
clearance. Aged controls demonstrated significant learning and memory impairment compared to 
young control animals. However, vitamin D treatment significantly improved this age-related 
decline (Briones & Darwish, 2012). Age-related changes in inflammatory state were also mitigated 
by vitamin D treatment, with increased expression of the anti-inflammatory IL-10 and decreased 
expression of the inflammatory mediator IL-1β after treatment with vitamin D. The aged control 
animals showed an increase in amyloid burden compared to young controls. However, this was 
reduced by vitamin D treatment (Briones & Darwish, 2012).  
1.3.3.5 Vitamin D deficiency and amyloid-β  toxicity  
The introduction of Aβ into cortical neuron culture leads to neurodegeneration via upregulation of 
L-VGCCs and suppression of VDR, whereas additional treatment of vitamin D protected the 
neurons from cytotoxicity by downregulating L-VGCCs and upregulating VDR (Dursun et al., 
2011). Alzheimer’s disease (AD) believed to progress in part from inflammatory processes, 
including oxidative damage and elevated levels of NO, that occur via iNOS induction. In vitro 
studies using cortical neurons show that iNOS is elevated following Aβ treatment, whereas vitamin 
D treatment prevents Aβ-induced cytotoxicity and iNOS upregulation, via VDR (Dursun et al., 
2013). Previous studies have shown that vitamin D regulates the expression of iNOS (Garcion et 
al., 1998). Therefore, vitamin D supplementation could lead to a reduction in NO-mediated 
inflammation in AD, a possibility that should be further investigated.  
Furthermore, treatment with a PDIA3 receptor agonist has been shown to significantly improve 
performance of object recognition memory, reduce amyloid plaques and neurofibrillary tangles, and 
reduce degenerated axons and presynaptic terminals in a mouse model of AD (Tohda et al., 2012). 
Vitamin D, a known endogenous agonist of PDIA3, may therefore be important for anti-AD therapy 
(Tohda et al., 2012). 
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Polymorphisms in the VDR gene have been shown to be associated with the risk of AD (Beecham 
et al., 2009; Gezen-Ak et al., 2012). A recent genetic and functional study found that an AD risk 
allele was associated with lower VDR promoter activity and that overexpression of VDR or vitamin 
D treatment suppressed amyloid precursor protein transcription in vitro (Wang et al., 2012a). An 
analysis of mRNA expression following vitamin D treatment of mixed neuron-glia cell cultures 
showed upregulation of genes related to neurodegenerative disorders, including 10 genes that 
encode proteins that could possibly limit AD development (Nissou et al., 2013). Growing evidence 
supports a protective role of vitamin D against the progression of AD, which is highly relevant 
owing to endemic vitamin D deficiency, particularly in the elderly. Randomised controlled trials 
that examine the benefits of vitamin D supplements in AD subjects are needed. 
1.4 Links with neuropsychiatric and neurodegenerative disorders 
Recent convergent evidence indicates that vitamin D deficiency has an impact during brain 
development and on the adult brain, and that it is biologically plausible for vitamin D deficiency to 
affect human health in terms of neuropsychiatric and neurodegenerative disorders. These disorders 
tend to have a complex aetiology, with both gene and environmental influences. However, vitamin 
D deficiency seems to be a common risk factor. In this section, we provide the evidence from 
epidemiology, prospective studies, and clinical trials that links vitamin D deficiency to a range of 
disorders involving the central nervous system. The type of evidence that connects vitamin D 
deficiency to the range of disorders is shown in Error! Reference source not found.. 
1.4.1 Cognitive impairment 
Many epidemiological studies have found an association between serum 25(OH)D and cognitive 
function, including memory and orientation (Llewellyn et al., 2009) and executive function (Buell 
et al., 2009; Lee et al., 2009). In older adults living independently, low serum 25(OH)D 
concentrations were significantly associated with cognitive impairment (Peterson et al., 2012). In a 
recently published systematic review and meta-analysis, lower vitamin D concentrations were 
significantly associated with poorer cognitive function (Balion et al., 2012). However, an 
association is not always found (McGrath et al., 2007; Slinin et al., 2010) and moreover, from 
epidemiological studies it is not clear if low vitamin D levels precede the development of cognitive 
impairments or are a result of poor diet and disability.  
A prospective study found that patients identified as vitamin D deficient at initial assessment had 
greater impairment of cognitive function at baseline and during follow-up, three and six years later 
(Llewellyn et al., 2010). Cognition was measured using the Mini-Mental State Examination 
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(MMSE), a widely used neuropsychological test of cognitive function, and Trail-Making Tests A 
and B. At initial assessment, scores on all three tests were significantly worse in subjects who were 
vitamin D deficient or severely deficient compared to those who were vitamin D sufficient. At the 
six-year follow-up, subjects who were severely 25(OH)D deficient at baseline were more likely to 
experience substantial later cognitive decline as assessed by the MMSE and the Trail B, which 
measures executive functioning, but not on the Trail A, which measures attention (Llewellyn et al., 
2010). 
 
Figure 1.2 Representation of studies testing an association between vitamin D deficiency and various 
disorders 
Animal studies, clinical trials and epidemiological studies that show evidence of an association between 
vitamin D and various disorders, and studies that show no association between vitamin D and various 
disorders. Numbers in boxes correspond to reference numbers in the published review (Groves et al., 2014). 
1.4.2 Alzheimer’s disease 
AD is a neurodegenerative disorder characterized by progressive and irreversible cognitive deficits 
and behavioural alterations. The most common symptom is that of memory impairment and loss of 
spatial memory. A recent meta-analysis (Annweiler et al., 2013) looked at the association between 
low serum 25(OH)D and AD and found that serum 25(OH)D concentrations were overall 
significantly lower in AD cases than in controls. The meta-analysis revealed a large association of 
low 25(OH)D concentration with AD. A recent prospective study on the risk of AD in the general 
population showed an increasing risk of AD with decreasing levels of vitamin D (Afzal et al., 
2013). 
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One study showed an association between higher dietary vitamin D intake and a lower risk of 
developing AD among older women (Annweiler et al., 2012b). A small pilot study found that 
patients who took memantine, an NMDA receptor antagonist, plus vitamin D for six months had a 
statistically and clinically relevant gain in cognition, whereas those who took memantine or vitamin 
D alone showed no effect. This suggests that there may be a synergistic effect in combining the 
treatments (Annweiler et al., 2012a). 
1.4.3 Depression 
Clinical depression is characterized by an all-encompassing low mood and loss of interest in 
normally enjoyable activities (Lorr et al., 1967). It is generally associated with significant disability, 
due to an inability to function normally, and with a decreased health status (Moussavi et al., 2007). 
Epidemiological studies have shown a number of risk factors for depression, including gender 
(higher incidence in females), prior depression, low socioeconomic status, psychiatric comorbidity, 
medical illness, and major adverse life events (Kaelber et al., 1995) and, more recently, low vitamin 
D levels (Anglin et al., 2013). 
Many observational and prospective studies suggest an association between low vitamin D levels 
and depression, particularly in the elderly (Hoogendijk et al., 2008; Milaneschi et al., 2010; Hoang 
et al., 2011; Milaneschi et al., 2011). A recent large systematic review and meta-analysis found that 
low vitamin D was significantly associated with an increased risk of depression (Anglin et al., 
2013); however, from these types of studies, it is not clear whether low vitamin D levels precede 
depressive symptoms or are a result of having depression. 
A randomized, double-blind placebo-controlled trial examined the effects of vitamin D 
supplementation on depressive symptoms in overweight and obese subjects. At the start of the trial 
there was an association between low serum 25(OH)D and symptoms of depression. Treatment with 
20,000 or 40,000 IU vitamin D per week for 1 year, but not placebo, resulted in significant 
improvement in depressive symptoms. This study suggests a possible causal link between low 
vitamin D and depression, at least in the overweight and obese (Jorde et al., 2008).  
Treatment with fluoxetine, a serotonin selective reuptake inhibitor, is known to improve depressive 
symptoms; however, a recent study showed that combining vitamin D treatment with fluoxetine 
improved depressive symptoms significantly more than fluoxetine alone did (Khoraminya et al., 
2013). Another recent clinical trial (Mozaffari-Khosravi et al., 2013) was undertaken in adults who 
were vitamin D deficient and suffering from depression. Participants were given either a single dose 
of 150,000 IU or 300,000 IU vitamin D or no treatment and were tested again for depression three 
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months later. The single dose of 300,000 IU vitamin D not only proved safe but was also effective 
at significantly improving depression. This study shows that correcting vitamin D deficiency can 
improve the depression state (Mozaffari-Khosravi et al., 2013).  
However, in subjects who were not vitamin D deficient, high-dose vitamin D treatment did not have 
the same benefits (Jorde et al., 2013), nor did all studies find improvement of depression with 
vitamin D treatment (Kjaergaard et al., 2012). Randomised controlled studies based on general 
population samples have also not found an association between vitamin D supplementation and 
scores on measures of depression (Sanders et al., 2011). 
1.4.4 Schizophrenia 
Schizophrenia is a group of disorders with symptoms including hallucinations, delusions, thought 
disorder, blunted affect, social withdrawal, and cognitive impairments (Frith, 1996; Pearlson, 2000). 
It is most likely a neurodevelopmental disorder and is characterized by alterations in brain 
morphology and abnormal laminar organisation as well as altered expression of proteins related to 
the early migration of neurons and glia, cell proliferation, formation of neural circuitry, and 
apoptosis (Fatemi & Folsom, 2009). Risk factors for the development of schizophrenia include both 
genetic factors and environmental influences. Some environmental risk factors include pregnancy 
and birth complications, maternal infection, immigration, adverse life events, and substance abuse 
(Davis et al., 2016; Janoutova et al., 2016). 
Developmental vitamin D deficiency was first suggested as a risk factor for schizophrenia in 1978 
because people with schizophrenia tend to be born in winter (Moskovitz, 1978). Additional 
epidemiological findings, including increased schizophrenia in dark-skinned migrants to cold 
climates and in the urban versus rural setting and an increased risk of schizophrenia with prenatal 
famine, led McGrath (McGrath, 1999) to propose that vitamin D deficiency during development 
could adversely affect the developing brain and lead to an increased risk of adult-onset 
schizophrenia (McGrath, 1999). 
Recently, a case-controlled study analysed neonatal vitamin D status and risk of schizophrenia.  It 
was found that low neonatal vitamin D is significantly associated with an increased risk of 
schizophrenia (McGrath et al., 2010b). A recent genome-wide analysis comparing genes involved 
in schizophrenia and genes related to vitamin D, found a significant overlap of 70 genes (Amato et 
al., 2010). 
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1.4.5 Autism 
Autism is a neurodevelopmental disorder characterized by impaired social interaction, 
communication, and stereotypical behaviour. Although it is well known that autism has a strong 
genetic component, research has also shown that environmental factors are likely to contribute to 
the development of autism (Abrahams & Geschwind, 2008). Epidemiological data have shown a 
number of factors that are associated with autism, including prenatal exposure to mutagens and 
advanced paternal age. A number of the other exposures can be linked to vitamin D deficiency. 
These include regions at higher latitudes (especially for dark-skinned individuals), urban residence, 
and regions with high precipitation rates (Kinney et al., 2010). 
Studies have shown that autistic children have lower serum 25(OH)D levels compared to healthy 
controls (Meguid et al., 2010; Mostafa & Al-Ayadhi, 2012). For example, a cross-sectional study in 
Egypt showed that children with autism have significantly lower serum 25(OH)D, 1,25(OH)2D and 
calcium levels compared to controls (Meguid et al., 2010). Other studies have found no significant 
association between serum 25(OH)D and autism (Fernell et al., 2010). Recently, autism prevalence 
was shown to be inversely correlated with solar UVB doses in an ecological study, which suggests 
that vitamin D deficiency during fetal brain development or early life could be relevant to the 
development of autism (Grant & Cannell, 2013). 
1.4.6 Parkinson's disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disease. It is characterized by slow, 
selective dopaminergic neuronal loss. Symptoms include dyskinesia, rigidity, and tremor as well as 
postural instability and gait disorders (Bonnet & Houeto, 1999).  
Epidemiological evidence from cross-sectional studies provides some support for a link between 
vitamin D deficiency and PD incidence (Sato et al., 2005; Evatt et al., 2008). Furthermore, the first 
longitudinal study investigating the association between vitamin D status and subsequent 
occurrence of PD showed that low serum vitamin D levels predicted an elevated risk of PD (Knekt 
et al., 2010). Subsequent studies have shown that vitamin D deficiency is also associated with more 
advanced severity of disease (Ding et al., 2013). 
A recently published study related to PD has lent support for the neuroprotective properties of 
vitamin D. Using a placebo-controlled, randomised trial, Suzuki et al. (2013) examined the impact 
of vitamin D supplementation (1,200 IU per day, for one year) on various Parkinson's Disease 
related outcomes. Those on placebo had a steady worsening of PD-related outcomes. In contrast, 
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those on vitamin D supplements had no change in PD outcomes over the year. The results strongly 
suggest that low vitamin D status exacerbates disease progression of PD (Cui et al., 2013a). 
1.4.7 Stroke 
Studies in humans have revealed that low levels of serum vitamin D are independently predictive 
for the occurrence of strokes (Marniemi et al., 2005; Pilz et al., 2008), and a large population-based 
prospective study showed stepwise increases in the risk of ischemic stroke with decreasing serum 
25(OH)D (Brondum-Jacobsen et al., 2013). A further study in China not only showed that patients 
with acute ischaemic stroke had significantly lower vitamin D levels compared to controls, but also 
that vitamin D levels were a prognostic marker of short-term functional outcome and death in stroke 
patients (Tu et al., 2014). 
1.4.8 Epilepsy 
Epilepsy is a brain disorder characterized by recurrent and unpredictable interruptions in normal 
brain function (epileptic seizures) (Fisher et al., 2005). Epidemiological studies indicate that 
epilepsy is another brain disorder that shows seasonal variation of birth, with an excess of those 
with epilepsy born in winter compared to summer (Procopio et al., 1997; Procopio & Marriott, 
1998; Procopio et al., 2006). Additionally, epileptic seizures themselves show seasonal variation, 
with a reduction in seizures during summer (Clemens et al., 2013). A very early small controlled 
pilot study showed a reduction in the number of seizures following treatment with vitamin D 
compared to placebo (Christiansen et al., 1974). Nearly 40 years later this study was followed up 
with another pilot study showing a median reduction in seizures of 40% following vitamin D 
supplementation (Hollo et al., 2012). 
1.4.9 Multiple sclerosis 
MS is a slow progressive disorder of the central nervous system that is characterized by 
demyelination of the brain and spinal cord. Although its aetiology is unclear, it seems to be 
multidimensional, with environmental factors, genetic factors, and dysregulation of the immune 
response all playing a part (VanAmerongen et al., 2004). Environmental risk factors include 
infection, cigarette smoking, and low vitamin D (Pugliatti et al., 2008; O'Gorman et al., 2012). A 
significant positive association exists between MS prevalence and latitude globally, which supports 
the role of ultraviolet radiation and vitamin D in its development (Simpson et al., 2011). 
Additionally, studies show that vitamin D intake is inversely associated with the risk of MS 
(Munger et al., 2004; Munger et al., 2006) and serum 25(OH)D levels are significantly lower in 
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patients with MS compared to healthy subjects (Mazdeh et al., 2013). Furthermore, vitamin D 
concentrations correlate with the severity of MS (Shahbeigi et al., 2013). Genetic studies have 
shown links between MS susceptibility and both CYP27B1 and CYP24A1, vitamin D metabolism 
enzymes (Ramagopalan et al., 2011; Sawcer et al., 2011). However, not all studies show a 
significant effect of vitamin D on MS, and more work is required (Pozuelo-Moyano et al., 2013). 
1.5 Future directions 
Accumulating evidence supports the need for optimal vitamin D levels both during development 
and throughout adulthood for proper brain function. However, it is still unknown what the optimal 
vitamin D level is for the brain or how the timing or length of vitamin D deficiency can alter the 
risk of disease. Recommendations for optimal vitamin D concentrations are usually based on bone 
outcomes (e.g. parathyroid concentrations) (Holick et al., 2012). More research is required to 
determine if vitamin D treatment of brain diseases is an effective tool or if prevention of vitamin D 
deficiency is the only method to lower risk. 
The results from recent animal and human studies suggest that vitamin D deficiency during 
adulthood may exacerbate underlying brain disorders and/or worsen recovery from brain stressors. 
Therefore, research is required to determine the molecular mechanism behind this possible 
vulnerability. For example, the direct regulation of calcium by vitamin D within the brain may be a 
key molecular mechanism to protect against the neurotoxicity that can occur in disease and aging, 
or it may be vitamin D’s immunomodulatory and neurotrophic effects providing neuroprotection to 
maintain a healthy brain. Therefore, both animal experiments and in vitro research are required to 
explicate these mechanisms within the brain, such as electrophysiology of calcium transport. 
Research in animals that combines vitamin D deficiency with relevant animal models of 
neuropsychiatric and neurodegenerative disorders is also required.  
Additionally, with the extensive links between vitamin D deficiency and a wide range of 
neuropsychiatric, neurodegenerative, and other brain disorders now evident, there is a need for 
large, well-controlled clinical trials. 
1.6 Conclusion 
This review has shown that vitamin D is a neurosteroid that exerts a multitude of effects that are 
important in both the correct development of the brain and the proper functioning of the adult brain. 
In addition, mounting evidence suggests that maintaining optimal vitamin D levels may lower the 
risk of developing a wide range of brain disorders. With vitamin D deficiency widespread 
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throughout the world, it is no wonder that research is focusing on elucidating the mechanisms of 
vitamin D’s actions within the brain. In light of the advantage that vitamin D supplementation is 
readily available and affordable, this review highlights the need for further research.  
1.7 Gaps in the research addressed by this thesis 
There is a large body of evidence supporting the need for optimal vitamin D levels during 
development. However, despite the growing epidemiological data showing an association between 
vitamin D deficiency and a wide range of adverse brain outcomes in adulthood, animal studies of 
adult vitamin D deficiency so far have been mostly restricted to models of MS. There are only a 
limited number of animal studies that have addressed the effects of vitamin D deficiency in healthy 
adults and even fewer that have maintained normal calcium levels in the animals. In addition to the 
lack of animal models, most studies addressing possible mechanisms of action of vitamin D in the 
adult brain have been performed using vitamin D treatment; or the addition of vitamin D in vitro, 
and have failed to address the consequences of the absence of vitamin D in the adult brain.  
We have previously developed a model of AVD deficiency in mice, in which ten-week-old animals 
from two strains of mice were placed on a diet deficient in vitamin D for a ten-week period, 
following which a range of behavioural domains as well as neurochemical outcomes were studied 
(see Adult vitamin D deficiency in rodents section) (Groves et al., 2013). I have continued to use 
this model to study the effects of AVD deficiency on brain function in this thesis. One important 
issue about the use of vitamin D deficient models relates to possible confounding factors such as 
hypocalcemia (i.e. adverse brain impacts may only emerge in animals with more severe 
physiological disruption). Because hypocalcemia is less common in healthy adults with vitamin D 
deficiency (due to release of calcium from the bones and/or access to adequate dietary calcium), 
researchers need to develop rodent models that more closely approximate that seen in clinical and 
community-based epidemiological studies. Using this model, AVD-deficient mice had normal 
serum calcium levels and at the time of behavioural testing were around six months of age, 
depending on exact experimental protocol.  
1.8 Aims and outline of thesis 
The four main aims of the research covered in this thesis included determining if AVD deficiency 
in mice would impact on (1) cognition, (2) adult hippocampal neurogenesis, and (3) glutamate and 
GABA signaling; and to determine if AVD deficiency would (4) exacerbate the consequences of a 
secondary exposure, in this case social stress.  
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The first aim of this research was to determine the impact of AVD deficiency on cognitive 
processes. Based on the epidemiological association between vitamin D deficiency and cognitive 
impairments (Balion et al., 2012), it was hypothesised that AVD deficiency would lead to 
impairments on cognitive tasks, with relevance to attentional processes and executive function in 
humans. This was examined in Chapter 2. These results were followed up using diffusion tensor 
MRI to study connectivity in the brain. Vitamin D deficiency in elderly, cognitively impaired 
patients has been previously associated with disruption in neuronal integrity as measured by 
diffusion tensor imaging in conjunction with worse cognitive impairment (Moon et al., 2015). This 
was detailed in Chapter 3. 
A second aim of this research was to determine if adult hippocampal neurogenesis was altered by 
AVD deficiency. There is a large body of evidence supporting a role for vitamin D in cell 
proliferation, survival and differentiation, and based on this research it was hypothesised that AVD 
deficiency would alter hippocampal neurogenesis. This was assessed in Chapter 4. 
A third aim of the research presented in this thesis was to explore the proteomic correlates of AVD 
deficiency, with a preliminary proteomic study based on hippocampal tissue. It was hypothesised 
that proteins involved in glutamate and GABA signaling and metabolism would be altered 
following AVD deficiency. This was explored in Chapter 5. Based on some of the results from the 
proteomic analysis, we further hypothesised that AVD deficiency would deplete glutathione levels 
and impair hippocampal-dependent learning and memory and this was examined in Chapter 6. 
The final aim of this research was to explore if AVD-deficient mice were more vulnerable to a 
secondary exposure. Recent studies have suggested that vitamin D deficiency in adulthood will 
exacerbate the effects of a secondary insult or comorbid disorder or disease (Balden et al., 2012; 
Suzuki et al., 2013). Therefore, it was hypothesised that combining AVD deficiency with social 
stress would lead to greater detrimental outcomes compared to either treatment alone and this was 
examined in the final experimental chapter, Chapter 7. 
  
 26 
 
 
 
Chapter 2 Sex-Specific Attentional Deficits in Adult Vitamin D Deficient 
BALB/c Mice 
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2.1 Introduction 
Epidemiological studies have shown an association between vitamin D deficiency and a range of 
neurodegenerative and neuropsychiatric disorders, such as AD (Annweiler et al., 2013), depression 
(Anglin et al., 2013), schizophrenia (Yuksel et al., 2014), autism (Kocovska et al., 2014), and MS 
(Munger et al., 2006). Many of these disorders either contain a cognitive component or are found to 
be co-morbidly associated with cognitive impairments. There are a large number of epidemiological 
studies that have examined links between vitamin D deficiency and cognitive disorders. For 
example, an observational study with independently living older adults, found lower serum 
25(OH)D concentrations were significantly associated with cognitive impairment (Peterson et al., 
2012).  
Cross-sectional studies have shown significant associations between low serum 25(OH)D in adults 
and impairments in memory and orientation (Wilkins et al., 2006; Przybelski & Binkley, 2007; 
Llewellyn et al., 2009) and executive function (Buell et al., 2009; Lee et al., 2009). Moreover, 
prospective studies have also shown greater cognitive decline over time, to be independently 
associated with low 25(OH)D levels in elderly individuals (Llewellyn et al., 2010; Toffanello et al., 
2014). However, the majority of these studies involve elderly populations, which is not 
representative of the general population. Furthermore, an association between vitamin D deficiency 
and cognitive disorders are not always found (McGrath et al., 2007; Slinin et al., 2010). Therefore, 
epidemiological studies are unable to address causality and have been inconclusive in determining a 
link between vitamin D deficiency and cognitive impairment.  
Recent studies in adult rats have shown significantly lower performance on cognitive tasks only in 
vitamin D-deprived rats that were also hypocalcemic (Briones & Darwish, 2012; Byrne et al., 2013; 
Taghizadeh et al., 2013). However, in aged (20 month old) rats vitamin D treatment has 
significantly improved performance on cognitive tasks, although serum calcium levels were not 
measured in that study (Briones & Darwish, 2012).  
The effect of longer-term exposure (6 months) to diets containing varying amounts of vitamin D on 
cognitive performance was recently tested in middle-aged (5-6 month old) F344 rats (Latimer et al., 
2014). Rats on high vitamin D (10,000 IU/kg food) significantly outperformed low (100 IU/kg 
food) and medium vitamin D (1,000 IU/kg food) groups in a challenging memory task, 
demonstrating a causal link between vitamin D status and cognitive function in aging animals. 
Importantly in this study, all groups were normocalcemic (Latimer et al., 2014). However, another 
study in ageing C57BL/6J mice, showed no effect on cognitive performance of a long-term vitamin 
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D deficient diet (on diet at 10 months and tested at 22-23 months) (Brouwer-Brolsma et al., 2014), 
although the task design varied between studies (Latimer et al., 2014) (Brouwer-Brolsma et al., 
2014). 
We have previously developed a model of AVD deficiency in which mice are placed on a vitamin 
D deficient diet at 10 weeks of age and maintained on the diet for a further 10 weeks prior to and 
during behavioural testing and were shown to be normocalcemic (Groves et al., 2013). The controls 
were given the recommended amount of vitamin D (National Research Council, 2015) and the 
vitamin D deficient mice had serum levels at the lower level of detection, which is seen in clinically 
deficient humans (Chel et al., 1998; Saaf et al., 2011). 
Two strains of mice have been examined using this model, BALB/c and C57BL/6J mice, and 
significant differences between strains were observed. BALB/c mice showed significant effects of 
AVD deficiency across a range of behaviours while C57BL/6J mice had a subtle behavioural 
phenotype. The BALB/c AVD-deficient mice exhibited an imbalance between excitatory and 
inhibitory neurotransmitters, with reductions in glutamate and glutamine levels, elevated levels of 
GABA and a reduction in the levels of both GAD65 and GAD67 enzymes in the brain (Groves et 
al., 2013).  
There is convergent evidence suggesting that altered GABA and glutamate neurotransmission in the 
prefrontal cortex (PFC) is involved in cognitive disturbances in schizophrenia, as reviewed by 
Lewis and Moghaddam (2006). Although the alterations seen in the AVD-deficient BALB/c mouse 
model were opposite to those reported in schizophrenia, the neurotransmitter levels were measured 
in whole brain, not specifically in the PFC (Groves et al., 2013). Furthermore, the whole brain 
reduction in the levels of the GAD enzymes were consistent with post-mortem brain tissue from 
schizophrenia patients showing reductions in GAD67 levels in the PFC (Hashimoto et al., 2003) 
and impairments in working memory have been linked to deficits in GABAergic signaling in 
schizophrenia patients (Lewis et al., 2005). 
The 5 choice - serial reaction time (5C-SRT) task is a widely used rodent test that assesses 
attentional processing and can also be used to analyse impulsivity and perseverance (Robbins, 
2002; Young et al., 2009b). In addition to the standard 5C-SRT, further testing in the 5 choice - 
continuous performance test (5C-CPT) can be performed to assess additional aspects of attentional 
processing as the rodent has to also learn to withhold a response to a new stimulus in order to 
receive a reward. The addition of the withhold condition assesses response inhibition and sustained 
vigilance (Young et al., 2009a). Both of these rodent tests mirror tests that can be performed in 
humans to analyse deficits in cognitive function. Therefore, the aim of this study was to determine 
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if AVD deficiency results in impairments in attentional processing using the 5C-SRT task and the 
5C-CPT.  
2.2 Materials and methods 
2.2.1 Animals and housing 
A total of 27 BALB/c mice (14 males and 13 females) were used in this study. Ten-week old 
BALB/c mice (Animal Resources Centre, Canning Vale, WA, Australia) were obtained and housed 
in groups of up to four, in individually ventilated OptiMICE cages (Animal Care Systems, CO, 
USA). All cages were given bedding (Sanichips, Harlan Laboratories, USA) and nesting material 
and housed at the Queensland Brain Institute Animal House Facility, University of Queensland.  
The mice were maintained on a 12-hour light-dark cycle (lights on at 07:00 h) and were housed 
under incandescent lighting free from UVB radiation. All mice were housed with ad libitum access 
to food and water except during testing of the 5C-SRT task and 5C-CPT, during which they were 
food restricted to ~90% of their free feeding body weight. All experimental work was performed 
with approval from the University of Queensland Animal Ethics Committee 
(QBI/121/10/NHMRC), under the guidelines of the National Health and Medical Research Council 
of Australia. 
The mice were assigned to either a control diet (Standard AIN93G Rodent diet with 1,500 IU 
vitamin D3/kg (prior to irradiation with 25 kGy), Specialty Feeds, WA, Australia, Appendix 1) or a 
vitamin D-deficient diet (irradiated with 25 kGy) (Vitamin D Deficient AIN93G Rodent diet, 
Specialty Feeds, WA, Australia, Appendix 1) for 10 weeks prior to the start of behavioural testing; 
and for the entire duration of the experimental procedures. 
2.2.1.1 Food restriction during 5C-SRT and 5C-CPT 
Three days before the start of the 5C-SRT task mice were weighed and placed on a restricted 
feeding schedule to decrease body weight to ~90 % of their original free-feeding weight. Mice were 
given 0.075 g of food/g of starting body weight/mouse/day at1600 h. The mice were also given 1 ml 
of liquid reinforcer (Breaka strawberry milk, Parmalat, QLD, Australia) in their home cage for the 3 
days prior to testing to habituate them to the liquid reward used during operant testing. Mice were 
weighed daily throughout behavioural testing and the amount of food provided each day was 
adjusted to maintain weight ~90 % at all times, ensuring that their weight did not fall below 85 %. 
Mice had ad libitum access to water in the home cage throughout testing. Mice were housed in 
groups of three to four mice, unless weight loss between the mice became uneven, possibly from 
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more dominant mice in the cage consuming more food than the others, in which case the groups of 
four were split into pairs. 
2.2.1.2 Body weight and food intake 
The percentage of the original free-feeding body weight of the mice during training and testing was 
continuously monitored in order to balance the amount of food the mice were given each day to 
maintain appropriate body weights. The amount of food given to the mice each day was recorded.  
2.2.2 Behavioural testing  
After 10 weeks on the diet when the mice were 20-weeks old, 14 males (7 control and 7 AVD-
deficient) and 13 females (7 control and 6 AVD-deficient) were tested in the 5C-SRT task and 12 of 
the females (6 control and 6 AVD-deficient) continued on to perform the 5C-CPT. There were 
inadequate numbers of male AVD-deficient mice that passed criteria during training for 5C-CPT 
and therefore males were not tested on the second test.  
2.2.2.1 Operant chambers 
Training and testing for the 5C-SRT task and 5C-CPT was performed in four nine-hole nose poke 
mouse operant chambers (Med Associates, VT, USA). Only five of the nine holes were used in 
experiments (first, third, fifth, seventh and ninth). Each chamber was placed into a larger sound and 
light attenuated chamber to minimize exposure to external stimuli. A central device that was 
connected to a computer running MED-PC IV controlled the chambers. For all experiments, 
modified versions of the programs for the standard nine-choice serial reaction time task supplied 
with the system were used (Harms et al., 2012b). 
2.2.2.2 5 choice - serial reaction time task 
Mice were trained to perform the 5C-SRT task according to a standard protocol (Bari et al., 2008). 
Each mouse was trained or tested for one session per day for 5 to 7 days per week. Each session 
consisted of up to 100 trials or 30 min. To initiate a session, a reward was offered in the reward 
magazine and the reward light was illuminated. When the mouse nose poked into the reward 
magazine to drink the reward, the session began. In the first training level (Level 0) the mice needed 
to nose poke any hole while the reward light was lit, to receive a reward. Mice needed to nose poke 
80 times in one session to progress to the next training level. 
For the next level (Level 1), mice had to respond to a light presented in one of the five holes by 
nose poking in the lit hole, to receive a reward. This stimulus was presented for 30 sec during this 
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level. If the mouse failed to respond with a nose poke, this was recorded as an omission and if the 
mouse nose poked in an unlit hole, this was recorded as an incorrect response. Both omissions and 
incorrect responses were penalised by a timeout, a period of 5 s in which the house light was lit and 
no reward offered, before a new trial would begin. Premature responses (a response during the 
inter-trial interval) and perseverant responses (repeated nose pokes into the correct hole) were also 
recorded, as were the number of head entries into the reward magazine during each session.  
With each level, the stimulus duration was shortened until Level 7 in which the stimulus was 
presented for only 1 s. To reach criteria for the next level (for Levels 1-6), the mice had to perform 
with at least 80 % correct responses and no more than 20 % omissions. On Level 7, the mouse had 
to perform with at least 70 % correct responses and no more than 20 % omissions. Once the mice 
had passed level 7 on two consecutive days, they were tested for their response to multiple stimulus 
durations (Level 8) within a session (random stimulus durations between 0.2 and 1 s). Mice were 
tested for 3 consecutive days, regardless of performance and their results were averaged. After two 
further days on Level 7, the mice were then tested for their response to altering the inter-trial 
intervals (Level 9) within a session (random presentation of intervals between 1 s and 9 s). Mice 
were again tested for 3 consecutive days regardless of performance and their results were averaged. 
2.2.2.3 5 choice – continuous performance task 
After testing was completed for the 5C-SRT task, the mice were placed on training for 5C-CPT. 
Training consisted of 120 trials per session, within a 30 min time period, and random variable inter-
trial intervals of 3, 4, 5, 6 and 7 s (Level 10). To pass criteria, the mice were required to achieve 80 
% correct and have no more than 20 % omissions within a session. Once they passed criteria for 
level 10, they began testing on the 5C-CPT. The 5C-CPT consisted of 80 target trials and 40 non-
target trials, with variable inter-trial intervals as for Level 10. For the 40 non-target trials, the mouse 
had to withhold a response in order to receive a reward. For these trials, all nine holes were lit and 
the mouse had to withhold from responding for 3 s. If the mouse did nose poke during this time, it 
was counted as a false alarm and was penalised by a timeout. As for the 5C-SRT task, premature 
and perseverant responses were recorded. Mice were tested on the 5C-CPT for 20 consecutive days 
regardless of performance. 
2.2.3 Serum 25(OH)D levels 
We have shown in separate mice under the same conditions that there is no significant difference 
between males and females in serum 25(OH)D levels in BALB/c mice (Control males = 33.51 ± 
2.37, Control females = 31.56 ± 2.51, AVD-deficient males = 2.94 ± 0.56, AVD-deficient females 
 32 
= 3.17 ± 0.55; F1,19 = 0.25, p = 0.623), and that mice are deficient in serum 25(OH)D after 10 weeks 
on the Diet (F1,19 = 294.50, p < 0.001).  
2.2.4 Statistical analysis 
Data were analysed using SPSS version 20. All data were analysed for the main effects of Diet 
(control or AVD-deficient) and Sex using analysis of variance (ANOVA) or, where appropriate, 
repeated measures ANOVA. Significant differences (p<0.05) were followed up with post-hoc t-
tests. In the 5C-CPT, the following parameters were also calculated, as described previously 
(Young et al., 2009a), hit rate, p(Hit) as the proportion of target trials correctly detected; false alarm 
rate, p(FA) as the proportion of non-target trials with an incorrect response; discrimination index, d’ 
as a parametric measure of the ability to discriminate between target and non-target trials; and 
perceptual bias, B” a measure of the amount of signal required to generate a response, and these are 
outlined in Table 2.1. 
Table 2.1 Calculations for the additional variables used to analyse the 5C-CPT results 
Variable  
p(Hit) – probability of a hit response No. of correct responses 
Total no. of target trials 
p(FA) – probability of a false alarm No. of false alarm responses 
Total no. of non-target trials 
d’ – discrimination index Z score of p(Hit) – Z score of p(FA) 
B” – perceptual bias index {p(Hit)[1-p(Hit)]} – {p(FA){1-p(FA)]} 
{p(Hit)[1-p(Hit)]} + {p(FA)[1-p(FA)]} 
2.3 Results 
2.3.1 Mice weights and food intake 
The percentage of the original free-feeding body weight of the mice during training and testing was 
analysed and there was no significant effect of Diet (F1,23 = 0.08, p = 0.780) or Sex (F1,23 = 3.26, p = 
0.084) on body weight and no interaction (F1,23 = 0.53, p = 0.473). The main effect of Sex (F1,23 = 
4.10, p = 0.055) failed to reach significance for the amount of food given to the mice each day and 
there was no significant effect of Diet (F1,23 = 0.16, p = 0.696) and no interaction (F1,23 = 0.15, p = 
0.702). Therefore, we conclude that the dietary manipulation did not affect body weight or food 
intake during training and testing. 
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2.3.2 5 choice – serial reaction time task 
2.3.2.1 Days to criteria and training 
There was a main effect of Sex (F1,27 = 11.68, p = 0.002) but not of Diet (F1,27 = 0.70, p = 0.410) on 
days to criteria for all training levels (Figure 2.1), with female mice completing training in a shorter 
period of time. When analysing separately for Sex, there was no significant effect of Diet (F1,13 = 
0.62, p = 0.445) in males when analysing days to pass all training levels. However, there was a 
significant effect of Diet on the number of days required to pass Level 0 (F1,13 = 4.88, p = 0.046) 
and  Level 2 (F1,13 = 5.20, p = 0.040). In female mice, there was no effect of Diet (F1,13 = 0.44, p = 
0.836) on the number of days to reach criteria. Throughout training, the AVD-deficient female mice 
had a significantly shorter latency to receive reward (F1,13 = 6.41, p = 0.025) compared to control 
female mice. 
 
Figure 2.1 Days to pass criteria during training for the 5C-SRT task 
Days to pass criteria during each training level (0-6) as detailed in section 2.2.2.2 for the 5C-SRT task for 
males (a) and females (b). Mean ± SEM (n = 6-7/group, * p < 0.05) 
 
2.3.2.2 Multiple Stimulus Durations 
The effect of varying the stimulus duration during testing (0.2-1.0 s) was analysed and averaged 
over three days of testing. At low stimulus durations (0.2-0.4 s), all mice made more omissions 
(F1,23 = 163.38, p < 0.001) and were less accurate (F1,23 = 129.83, p < 0.001) when responding 
compared with longer stimulus durations (0.5-1.0 s). There was a main effect of Sex on the number 
of correct responses (F1,23 = 5.86, p = 0.024) and omission rate (F1,23 = 5.96, p = 0.023), but not on 
accuracy (F1,23 = 0.01, p = 0.952), the number of incorrect responses (F1,23 = 0.60, p = 0.446), 
premature responses (F1,23 = 3.21, p = 0.086) or perseverative responses (F1,23 = 0.04, p = 0.847). 
There were no main effects of Diet on any of these measures, but there was a Sex x Diet interaction 
(F1,23 = 4.44, p = 0.046) on the number of correct responses. In males, the AVD-deficient mice 
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made significantly fewer correct responses (F1,12 = 4.85, p = 0.048, Figure 2.2a) compared to the 
control mice. They were also less accurate (F1,12 = 5.34, p = 0.039) and made significantly more 
omissions (F1,12 = 5.87, p = 0.032, Figure 2.2c) during the longer stimulus durations (0.6-1.0 s) 
compared to controls.  
With regard to speed of responding, there was a Sex x Diet interaction on the latency to make a 
correct response (F1,23 = 7.99, p = 0.010) and on reward latency (F1,23 = 4.89, p = 0.037), but no 
significant effects on the latency to make an incorrect response. In males, AVD-deficient mice had 
a significantly increased latency to a correct response (F1,12 = 5.26, p = 0.041, Figure 2.3a) when 
compared to controls. This effect was seen without a change in reward latency (F1,12 = 1.31, p = 
0.275, Figure 2.3c). In female mice, there was a significant effect of Diet on reward latency (F1,11 = 
6.98, p = 0.023, Figure 2.3d), with the AVD-deficient mice responding quicker to the presentation 
of reward than controls.
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Figure 2.2 Results of manipulating stimulus duration in the 5C-SRT task 
Male results are shown in a, and c, with female results shown in b, and d. The percentage of correct 
responses are shown in a and b, with AVD-deficient male mice making significantly fewer correct responses 
compared to control males. The percentage of omissions is shown in c and d, with AVD-deficient male mice 
making significantly more omissions in the longer (0.6-1.0 s) stimulus durations, compared to control males. 
Mean ± SEM (n = 6-7/group * p <0.05) 
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Figure 2.3 Latency results from manipulating stimulus duration in the 5C-SRT task 
Male results are shown in a, and c, with female results shown in b, and d. The latency to make a correct 
response is shown in a and b, with AVD-deficient male mice taking longer to make correct responses 
compared to control males. The latency to collect reward is shown in c and d, with AVD-deficient female 
mice making quicker responses to collect reward compared to control females. Mean ± SEM (n = 6-7/group 
* p <0.05) 
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2.3.2.3 Multiple Inter-trial Intervals 
The effects of varying the inter-trial interval during testing (1-9 s) was also analysed and averaged 
over three days of testing. Over the different inter-trial intervals, the omission rate and accuracy was 
relatively stable except for an increase in omissions (F1,23 = 130.08, p < 0.001) and a decrease in 
accuracy (F1,23 = 123.51, p < 0.001) after a 1 s inter-trial interval. There was no main effect of Diet 
or Sex on the number of correct responses, incorrect responses, accuracy or omission rates when 
varying the inter-trial interval, or on speed of responding. In male mice, there was a significant 
effect of Diet on the latency to make a correct response (F1,12 = 5.93, p = 0.031), with the AVD-
deficient mice taking longer to make a response. In female mice, there was no significant effect of 
Diet of any measure, including reward latency (F1,11 = 1.56, p = 0.237). 
2.3.2.4 Combined Data 
When analysing both multiple stimulus durations and inter-trial intervals together, there was an 
overall significant effect of Diet in males for the number of correct responses (F1,12 = 5.43, p = 
0.038) and latency to a correct response (F1,12 = 6.64, p = 0.024), while in females there was an 
overall significant effect of Diet on latency to receive a reward (F1,11 = 5.61, p = 0.037). 
2.3.3 5 choice – continuous performance task 
2.3.3.1 Training for 5 choice – continuous performance task 
There was a main effect of Sex (F1,23 = 5.72, p = 0.025) but not of Diet (F1,23 = 0.59, p = 0.451) on 
the days to pass training for 5C-CPT, with females taking less time to pass compared to males 
(Figure 2.4).  
 
Figure 2.4 Days to pass criteria during training for 5C-CPT 
There was a significant main effect of Sex, with females passing training for 5C-CPT in less time than males. 
Mean ± SEM (n = 6-7/group, * p <0.05) 
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Training for the 5C-CPT involved increasing trials to 120 per session with variable inter-trial 
intervals (3 -7 s). During the first two days of training, the ability of the mice to adapt to the change 
in protocol was assessed. However, during the first two days of training, there was a significant 
main effect of Diet (F1,17 = 6.17, p = 0.024) on the number of correct responses, with the AVD-
deficient mice making significantly fewer correct responses compared to controls. When analysed 
separately for Sex, there was no significant difference in females for any measure during training 
and all female mice except one reached criteria for 5C-CPT and went on to testing. In male mice, 
there was a significant effect of Diet on the number of correct responses (F1,8 = 5.45, p = 0.048, 
Figure 2.5a) during the first two days of training with the AVD-deficient mice made significantly 
fewer correct responses. The AVD-deficient male mice made less head entries over these two days 
compared to controls (F1,8 = 5.92, p = 0.041, Figure 2.5c). They also made more omissions but this 
failed to reach significance (F1,8 = 5.22, p = 0.052, Figure 2.5e). 71% (n=5 out of 7) of male control 
mice reached criteria but only 29% (n=2 out of 7) of AVD-deficient mice reached criteria. Due to 
the inability of enough AVD-deficient male mice to reach criteria during training, the male mice 
were not tested on the 5C-CPT.  
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Figure 2.5 Results during training for 5C-CPT  
Training involved increasing trials to 120 per session with variable inter-trial intervals (3 -7 s) (n = 5-
7/group). Male results are shown in a, c, and e, with female results shown in b, d, and f. The percentage of 
correct responses are shown in a and b. There was a significant main effect of Diet on the percentage of 
correct responses given, with the AVD-deficient mice making fewer correct responses. This remained 
significant in males when separated for Sex, but not in females. The number of head entries into the reward 
magazine is shown in c and d, with AVD-deficient male mice making significantly fewer head entries 
compared to control males. The percentage of omissions is shown in e and f, with no significant effect of 
Diet. Mean ± SEM (* p < 0.05)
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2.3.3.2 Testing on 5 choice – continuous performance task 
Initially, all mice could not differentiate between target and non-target trials (d’ = 0) but over the 20 
sessions of 5C-CPT d’ continually increased, demonstrating that all mice successfully learned to 
withhold a response during a non-target trial. AVD-deficient mice had similar levels of 
performance as controls on all measures analysed during the 5C-CPT, including p(Hit) (F1,10 = 0.23, 
p = 0.639, Figure 2.6a), p(FA) (F1,10 = 0.08, p = 0.786, Figure 2.6b), d’ (F1,10 = 0.38, p = 0.551, 
Figure 2.6c) and B” (F1,10 = 0.06, p = 0.820, Figure 2.6d). 
 
Figure 2.6 Results of the 5C-CPT in females 
This figure shows the p(Hit) in (a), p(FA) in (b), d’ in (c) and B” in (d) over the 20 testing sessions (four 
bins of five test sessions each). No significant effect of Diet was seen on any measure. Mean ± SEM (n = 
6/group) 
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2.4 Discussion 
The main finding from this study was that male AVD-deficient BALB/c mice showed deficits in 
attentional processes on the 5C-SRT. However, female AVD-deficient BALB/c mice were not 
different to controls on the attentional aspects of the task, although they did exhibit enhanced 
motivation (reduced latency to retrieve a reward) during the 5C-SRT task. To our knowledge this is 
the first study to show cognitive impairments with vitamin D deficiency in otherwise healthy adult 
rodents, in a model known to have normal serum calcium levels. Therefore, we can accept the 
hypothesis that AVD deficiency in male BALB/c mice can lead to cognitive deficits.  
The male AVD-deficient mice took significantly longer to pass the initial training level for operant 
testing, compared to the control males. This may be due to difficulty in learning the rule initially or 
may be due to a reduction in exploratory behaviour. However, over all of the training levels there 
was no significant effect of the dietary manipulation. Furthermore, the AVD-deficient males were 
not significantly different to the control males in their number of correct responses during training 
(AVD-deficient males 82.56 ± 2.03 and Control males 85.01 ± 0.68, p = 0.245) and all mice 
reached the minimum criteria required during training and therefore could perform the task. This 
allowed different manipulations to be tested that would increase task difficulty and engage the 
prefrontal cortex to a greater degree (Robbins, 2002).  
Male AVD-deficient mice were less accurate; took longer to respond when making a correct choice 
and were more likely to make an omission, without a change in the motivation to collect reward. 
Overall, these findings do not suggest a motor impairment in the AVD-deficient males or deficits in 
motivation. Motor impairments cannot explain a reduction in accuracy and longer response 
latencies without a change in reward latency are more likely to reflect deficits in decision processes 
(Robbins, 2002). Furthermore, according to Robbins (2002) increased omissions not accompanied 
by changes in reward latency may be due to gross impairments in attention. 
The results seen here in the AVD-deficient males correspond to deficits seen following lesions to 
the medial PFC and the longer latency times suggest that the deficits may result in the animals 
trading speed for accuracy (Muir et al., 1996). Lesion studies have also shown that the 
hippocampus is required for acquisition of the task (Bratt et al., 1995) but not once the task has 
been acquired (Kirkby & Higgins, 1998). The 5C-SRT therefore requires both hippocampal-
dependent learning and memory and PFC processes for different aspects of the tasks. These results 
suggest that AVD deficiency could have impacted on global cognitive function, rather than a 
specific cognitive domain.  
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It is well recognized that cognitive disturbances in schizophrenia are due at least in part to altered 
GABA and glutamate neurotransmission in the PFC (Lewis & Moghaddam, 2006). Furthermore, 
reductions in striatal glutamate levels have correlated selectively with performance on cognitive 
tests showing age-related decline (Zahr et al., 2008). This is consistent with AVD deficiency in 
BALB/c male mice, in which we have shown an imbalance between excitatory and inhibitory 
neurotransmission with reductions in glutamate, glutamine and the enzymes GAD65 and 67, as well 
as increased levels of GABA across the whole brain (Groves et al., 2013).  
Post-mortem studies of the dorsolateral PFC of individuals with schizophrenia have shown 
reductions in mRNA levels of both GAD67 and a GABA membrane transporter 1 (GAT1), which is 
responsible for the reuptake of released GABA into nerve terminals, within subsets of parvalbumin 
GABA interneurons (Lewis et al., 2005). Therefore, it is plausible that AVD deficient mice have 
altered activity of GABA interneurons, driven by changes in glutamate or GABA neurotransmission 
resulting in impaired attentional processes in male AVD-deficient BALB/c mice. However, we did 
not directly test this hypothesis in the current study and this would need to be investigated in future 
studies. 
Despite seeing impairments in attention in male mice with AVD deficiency, there were no 
attentional impairments in AVD-deficient female mice in either the 5C-SRT task or the 5C-CPT. 
Neuropsychiatric and neurodegenerative disorders are often sexually dimorphic. For example, 
schizophrenia is more prevalent in young adult males compared to young adult females (Hafner, 
2003); however, depression (Sagud et al., 2002) and MS (Ahlgren et al., 2011) are more prevalent 
in women compared to men.  
Although MS is twice as prevalent in females as compared to males, the cognitive impairments that 
accompany MS are more common and are more severe in males (Beatty & Aupperle, 2002; 
Savettieri et al., 2004). It is possible that sex hormones play a role in gender differences that are 
often seen in these types of disorders. There is evidence to suggest that females may be protected 
from deficits in cognition, but not from other aspects of these disorders, such as the autoimmune 
aspects of MS (Harbo et al., 2013). 
There is a large body of research on the protective effects of oestrogen, including in ischemic brain 
injury (Koh, 2014), for cognitive function, a reduction in AD risk and in schizophrenia (Pompili et 
al., 2012). To determine if this is the mechanism behind a lack of cognitive impairment in female 
AVD-deficient mice, a future study would need to look at the effects of ovariectomising the mice 
and see if that leads to cognitive disturbances in AVD-deficient female mice. Future studies could 
also include testing the effects of AVD deficiency on other forms of cognitive tasks, such as a 
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hippocampal-dependent learning and memory task. This would determine if these deficits are 
specific to attention and PFC function or a more global deficit in performance. Furthermore, due to 
the necessity of using food-restriction with the 5C-SRT, a second test of cognition that doesn’t 
involve food would determine if any additional metabolic stress resulting from food deprivation 
exacerbated the results seen in the AVD-deficient males. 
Future studies should also determine if restoration of vitamin D levels would reverse the deficits 
seen with AVD deficiency, as this would have important health implications in humans. Vitamin D 
supplementation is a relatively easy and affordable treatment option if it could improve cognition in 
vitamin D deficient individuals. However, there is some evidence to suggest that treatment with 
vitamin D after the development of a disorder may be too late. A study looking at the effects of 
vitamin D deficiency on stroke outcomes in rats, indicated that vitamin D deficiency adversely 
affected outcomes of stroke and that treatment with vitamin D post-stroke was ineffective at 
improving outcomes (Balden et al., 2012). 
2.5 Conclusion 
To our knowledge, this is the first study to show cognitive impairments with vitamin D deficiency 
in otherwise healthy adult male mice. Furthermore, we have shown sex differences in the 
susceptibility to vitamin D deficiency that should be explored further, with sex hormones as one 
possible explanation for this finding. This study provides the first clues to determine if preventing 
vitamin D deficiency in human populations may be able to prevent or delay cognitive impairments, 
particularly in at risk groups (McKenna, 1992). 
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Chapter 3 Structural and Diffusion Tensor Imaging in Adult Vitamin D-
Deficient BALB/c Mice 
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3.1 Introduction   
There is growing evidence to suggest that vitamin D deficiency can lead to cognitive impairments 
particularly later in life (Etgen et al., 2012). For example, a study in community dwelling older 
woman showed that participants with deficient serum vitamin D levels had greater cognitive 
impairments on the Pfeiffer Short Portable Mental State Questionnaire, compared to participants 
with sufficient vitamin D levels (Annweiler et al., 2010). Furthermore, a recent prospective study 
has shown that vitamin D deficiency was associated with accelerated decline in cognitive domains 
including episodic memory and executive function (Miller et al., 2015). 
Vitamin D deficiency has also been associated with increased risk of all-cause dementia and AD 
(Littlejohns et al., 2014) as well as magnetic resonance imaging (MRI) indicators of 
cerebrovascular disease including white matter hyperintensities (WMHs) (Buell et al., 2010). 
WMHs are areas of demyelination and axonal loss caused by chronic ischemia (Prins & Scheltens, 
2015). Although, standard MRI can detect pathology such as WMHs, diffusion tensor imaging 
(DTI) may reveal more subtle impairments in white matter tract integrity before it becomes visible 
on standard MRI (Prins & Scheltens, 2015). 
A recent study has shown that vitamin D deficiency in older individuals with memory complaints 
was associated with a disruption in neuronal integrity (Moon et al., 2015). Researchers assessed 
DTI using tract-based spatial statistics (TBSS), a sensitive and objective method to assess changes 
in connectivity in the brain by measuring the anisotropic diffusion of water in white matter tracts 
(Smith et al., 2006). Moon et al. (2015) found that vitamin D deficient patients have lower 
fractional anisotropy (FA) values primarily in frontal regions of the brain, compared to patients with 
sufficient vitamin D levels. FA is a measure of non-specific microstructural integrity (Pfefferbaum 
et al., 2000). In addition, they found that the vitamin D deficient patients also had lower MMSE 
scores compared to the patients with sufficient vitamin D levels. In contrast to these findings, the 
researchers did not detect any differences in cortical thickness between vitamin D deficient and 
vitamin D sufficient patients (Moon et al., 2015).  
Reductions in hippocampal volume in subjects with AD are consistently reported in the literature 
(Jack et al., 1999). However, there was no association between vitamin D and size of the 
hippocampus or amygdala, or total brain volumes after adjustment for intracranial volume, even 
though vitamin D deficiency was significantly associated with Alzheimer’s disease (Buell et al., 
2010). Although there are limited studies addressing the effect of vitamin D deficiency on brain 
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volume and structure in adults, vitamin D does have a well-known role in cell proliferation, 
differentiation, survival and apoptosis (see Chapter 1 for review).  
Both in vitro and in vivo studies have shown that the active form of vitamin D, 1,25(OH)2D, is 
antiproliferative and a pro-differentiator (Banerjee & Chatterjee, 2003). Moreover, studies have 
shown that vitamin D deficiency during development leads to increased proliferation and reduced 
apoptosis via altered gene regulation in rats (Ko et al., 2004). Furthermore, rat pups that were 
exposed to vitamin D deficiency during development had a mild distortion in brain shape and 
increased lateral ventricle volumes, with reductions in differentiation and a lower expression of 
neurotrophic factors, such as nerve growth factor and glial cell line-derived neurotrophic factor 
(Eyles et al., 2003). In contrast, DVD-deficient mice had reductions in lateral ventricular volumes, 
in C57BL/6J adult mice (de Abreu et al., 2010; Harms et al., 2012a) and in BALB/c mice in the 
fetal brain at E17.5 (Hawes et al., 2015). DVD-deficient BALB/c mice also had elevated levels of 
brain derived neurotrophic factor (BDNF) and transforming growth factor β1 at E17.5 (Hawes et 
al., 2015). 
There have been no pre-clinical studies published to date that have looked at the effects of adult 
vitamin D deficiency on cognitive function and DTI. However, I have previously shown that adult 
vitamin D-deficient male BALB/c mice have mild cognitive impairments in attentional processing, 
assessed using the 5C-SRT task (see Chapter 2 for details). 
Therefore, the first aim of this study was to assess control and AVD-deficient male BALB/c mice 
for volumetric differences in total brain volume and in a number of brain regions using automatic 
segmentation methods of 3D MRI images. In addition, the second aim of this study was to use ex-
vivo DTI to measure connectivity in the brain using two well-known methods, voxel based 
morphometry (VBM) and TBSS (Smith et al., 2006), in the control and AVD-deficient male mice. 
It was hypothesized that there would be no structural changes following 10 weeks of dietary 
manipulation in adult mice, however, that there would be disruptions to connectivity in the AVD-
deficient mice.  
3.2 Materials and methods 
3.2.1 Animals and Housing 
Fifteen ten-week old male BALB/c mice (Animal Resources Centre, Canning Vale, WA, Australia) 
were obtained and housed in groups of three-to-four in individually ventilated OptiMICE cages 
(Animal Care Systems, CO, USA), with bedding (Sanichips, Harlan Laboratories, USA) and 
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nesting material at the Queensland Brain Institute Animal House Facility, University of 
Queensland.  
Mice (n = 7 control and 8 AVD-deficient) were assigned to either a control diet or a vitamin D-
deficient diet as detailed in Chapter 2 until they were 20-weeks old. The mice were maintained on a 
12-hour light-dark cycle (lights on at 07:00 h) with ad libitum access to food and water. They were 
housed under incandescent lighting free from UVB radiation. All experimental work was performed 
with approval from the University of Queensland Animal Ethics Committee, under the guidelines of 
the National Health and Medical Research Council of Australia.  
3.2.2 Tissue collection 
Behaviourally naïve mice were anaesthetized by an i.p injection of Lethabarb at 100 mg/kg body 
weight and transcardially perfused with 40 ml of phosphate buffered saline (PBS) and 40 ml of 4 % 
paraformaldehyde (PFA) in 0.1 M PBS. The brains were removed and post fixed in 4 % PFA for 24 
h before being stored in sodium azide (0.05%) in 0.1M PBS (PBS azide) for future analysis. 
3.2.3 Magnetic Resonance Imaging 
Brains were incubated in 0.1% Magnevist® (gadopentetate dimeglumine, Bayer Healthcare 
Pharmaceuticals Inc., NJ, USA) in PBS for 4 days prior to imaging. MRI data were acquired with 
the samples immersed in Fomblin fluid (Solvay Solexis, Italy), using a 16.4 T (89 mm) Bruker 
micro-imaging system (Bruker Biospin, Karlsruhe, Germany) and a 15 mm SAW coil (M2M 
Imaging, USA). High-resolution anatomical images were acquired using three-dimensional (3D) 
gradient-echo FLASH (fast low angle shot) T1/T2*-weighted using repetition time (TR) 50 ms, echo 
time (TE) 12 ms, number of excitation averaging (NEX) 1 at 30 micron isotropic resolution. 3D 
Diffusion-weighted images (DWI) were acquired using Stjskal-Tanner DW spin-echo sequence 
using the following parameters: TR = 400 ms; TE = 22.8 ms; 80 micron isotropic resolution and a 
signal average of 1. DWI data were composed of two images acquired without diffusion weighting 
(b0) and thirty direction DWI (b value of 5000 s/mm2, δ/Δ = 2.5/14 ms). The samples were 
maintained at 22 ° C (Kurniawan et al., 2014).  
3.2.4 Brain volumetric measurements using segmented 3D MRI atlas 
Anatomical MR images were cleaned of any non-brain tissue using a mask created in ITK-SNAP 
(www.itksnap.org). Inter-group differences in brain volumes were mapped using VBM (Ashburner 
& Friston, 2000). Firstly, a study-specific BALB/c template was created using Advanced 
Normalization Tools (ANTs) buildtemplateparallel script (http://picsl.upenn.edu/software/ants/), 
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where high-resolution gradient-echo images of all mice from the study (N = 15) were aligned to a 
common reference space via a 12 degrees-of-freedom affine alignment, followed by 5 iterative 
symmetric diffeomorphic registrations (Avants et al., 2011). Secondly, the resulting BALB/c 
template was registered using ANTs diffeomorphic registration to an adult C57BL/6J MRI atlas that 
contains 18 segmentations of brain structures (Ma et al., 2005). Finally, the warp information from 
the previous steps was used to register the segmented structures back to the individual subjects for 
analysis of inter-group differences in brain region volumes. Volumes for each brain segment were 
calculated using ITK-SNAP. Inter-group statistical analyses of volumes were carried out using a 
student’s t-test. See Table 3.1 for brain regions analysed.  
3.2.5 Voxel based morphometry of diffusion tensor imaging maps 
Non-brain tissue was removed from diffusion magnetic resonance images by creating a mask of 
each brain in ITK-SNAP. DTI maps, consisting of fractional anisotropy (FA), mean diffusivity 
(MD), axial diffusivity (AxialD) and radial diffusivity (RadialD), were generated using MRTrix 
0.2.9 (www.mrtrix.org). A study specific FA template was created using ANTs 
buildtemplateparallel script, and subsequently the other of DTI parameters were co-registered to the 
template space. VBM analyses were performed using FSL randomise (fsl.fmrib.ox.ac.uk) using 
5000 permutations (Nichols & Holmes, 2002), threshold-free cluster enhancement and correction 
for multiple comparisons. The resulting t-map was thresholded > 0.95 to assess statistical 
significance.  
3.2.6 Tract-based Spatial Statistics 
The FA, MD, AxialD, and RadialD maps were assessed for inter-group differences using TBSS as 
previously described (Smith et al., 2006). All FA images were aligned onto the ANTs FA template 
using a nonlinear registration algorithm within the TBSS package and the white matter tracts were 
skeletonized (using FA threshold of 0.3) to create a skeleton template. Subsequently, all DTI maps 
from each subject were skeletonized. The FA skeleton from each sample was registered to the 
template using TBSS nonlinear registration method. The other DTI maps (MD, AxialD, and 
RadialD skeletons) were co-registered to the template by applying the same transformation 
calculated for the FA. TBSS analyses were performed using 5000 permutations (Nichols & Holmes, 
2002), threshold-free cluster enhancement and correction for multiple comparisons. The resulting t-
map was thresholded > 0.95 to assess statistical significance. 
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3.3 Results 
3.3.1 Anatomical measurements using automatic segmentation 
There was no significant effect of Diet (F1,13 = 0.16, p = 0.698) on total brain volumes (Controls = 
387.35 ± 3.90 mm3 and AVD-deficient = 383.69 ± 7.90 mm3). Total brain volumes excluded the 
olfactory bulbs, which are sometimes damaged during brain extraction. There was also no 
significant effect of Diet on any white matter structure volume (F1,13  < 2.20, p > 0.160) or brain 
region volume (F1,13  < 1.49, p > 0.244). See Table 3.1 for details.
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Table 3.1 Volumetric brain analyses 
Brain Volumes (mm3) Control (n = 7) AVD-deficient (n = 8) 
White Matter Structures#   
Anterior commissure 1.59 ± 0.03 1.60 ± 0.03 
CC/Ext capsule 9.43 ± 0.11 9.29 ± 0.26 
Fimbria 1.97 ± 0.02 1.91 ± 0.04 
Internal capsule 1.67 ± 0.01 1.62 ± 0.05 
Brain Regions#   
Amygdala 9.53 ± 0.08 9.46 ± 0.23 
Basal forebrain 9.68 ± 0.11 9.76 ± 0.15 
Rest of midbrain 10.49 ± 0.09 10.29 ± 0.18 
Brain stem 48.11 ± 0.62 46.19 ± 1.36 
Caudate putamen 20.63 ± 0.23 20.55 ± 0.36 
Central grey 3.39 ± 0.05 3.39 ± 0.07 
Cerebellum 41.76 ± 0.95 40.76 ± 1.14 
Globus pallidus 2.12 ± 0.02 2.08 ± 0.05 
Hippocampus 22.98 ± 0.12 22.92 ± 0.37 
Hypothalamus 9.47 ± 0.12 9.47 ± 0.18 
Inferior colliculi 4.19 ± 0.06 4.06 ± 0.10 
Superior colliculi 6.58 ± 0.10 6.55 ± 0.14 
Neocortex 109.02 ± 1.13 109.36 ± 1.98 
Thalamus 20.85 ± 0.26 20.85 ± 0.46 
Total Brain volume$ 387.35 ± 3.90 383.69 ± 7.90 
#The volumes of white matter structures and segmented brain regions were calculated using 
the registration of segmented 3D atlas 
$Total brain volume was calculated excluding the olfactory bulbs. 
There were no significant differences in brain volumes between control and AVD-deficient 
mice.
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3.3.2 Diffusion tensor imaging  
VBM and TBSS analyses of the FA, MD, AxialD, and RadialD maps showed no significant 
differences between control and AVD-deficient mice throughout the brain following threshold-free 
cluster enhancement and correction for multiple comparisons. Mean whole brain values were also 
analysed for FA (F1,13 = 0.47, p = 0.505) and MD (F1,13 = 1.03, p = 0.330) and there were no 
significant differences seen between control and AVD-deficient mice. See Table 3.2. 
Table 3.2 Mean whole brain values for DTI parameters 
Variable Control (n = 7) AVD-deficient (n = 8) 
Whole brain FA 0.225 ± 0.005 0.216 ± 0.002 
Whole brain MD, x10-3 mm2/s 0.301 ± 0.003 0.297 ± 0.003 
There were no significant differences between control and AVD-deficient mice for whole brain DTI 
parameters. 
3.3.3 Post-hoc analysis 
Overall, following correction for multiple comparisons across thousands of voxels there were no 
significant differences observed between control and AVD-deficient mice for any of the DTI 
parameters. Therefore, in the context of the current study, AVD deficiency did not alter 
connectivity or neuronal integrity following 10 weeks of dietary depletion in adult male BALB/c 
mice. However, there may be subtle differences in connectivity that cannot be picked up with a 
whole brain analysis. Therefore, future experiments should rely on a priori hypotheses regarding 
specific brain regions or white matter tracts that may be more susceptible to connectivity changes. 
For example, changes to white matter might be more visible in the larger white matter tracts; or in 
brain regions highly relevant to cognition such as the hippocampus or prefrontal cortex. Moon et al. 
(2015) found lower FA values in vitamin D deficient patients using TBSS primarily in frontal 
regions, including the largest white matter commissure, the corpus callosum.  
3.3.3.1 Corpus callosum and hippocampal commissure 
Therefore, as a hypothesis generating post-hoc analysis, the two largest commissural bundles, the 
corpus callosum and the hippocampal commissure were analysed using TBSS. Compared with 
controls, AVD-deficient mice had lower MD values and to a lessor extent, lower FA values (p < 
0.01, Figure 3.1) in regions of both commissures. 
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Figure 3.1 Post-hoc analysis of TBSS results for MD and FA values 
Red = Controls > AVD-deficient mice (p < 0.01), overlaid on the MNI152 standard image. TBSS, Tract-
based spatial statistics; FA, fractional anisotropy; MD, mean diffusivity.
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3.4 Discussion 
The results from the current study have indicated that AVD deficiency does not produce any gross 
structural abnormalities. Furthermore, this study has also shown that connectivity following whole 
brain analysis, measured by DTI was not altered with AVD deficiency. Post-hoc analysis suggests 
that there may be minor changes in connectivity within the larger white matter tracts, however this 
would need to be further explored in future studies designed to specifically address this.  
At a gross structural level, the brains of AVD-deficient mice were not different to controls across 
four large white matter tracts and fourteen specific brain regions. Although, a developmental 
depletion of vitamin D deficiency can lead to changes in brain shape and size (Eyles et al., 2009b), 
this did not occur following an adult exposure to vitamin D deficiency. This is consistent with the 
limited research performed to date, suggesting that vitamin D deficiency during adulthood does not 
produce changes in brain volumes. 
Although, there is significant epidemiological evidence on the association between vitamin D 
deficiency and cognitive impairment, dementia, AD and cerebrovascular disease (Annweiler et al., 
2010; Buell et al., 2010; Littlejohns et al., 2014), very few studies have looked at the relationship 
between vitamin D deficiency and MRI pathologies in humans (Buell et al., 2010; Moon et al., 
2015). Moreover, this is the first animal study assessing the effects of vitamin D deficiency on DTI. 
Using both VBM and TBSS, there were no differences between control and AVD-deficient mice on 
a range of standard DTI parameters including FA, a measure of microstructural integrity 
(Pfefferbaum et al., 2000). Whereas a single study performed in humans, which was the first of its 
kind, showed that vitamin D deficient patients with memory complaints had lower FA values in 
most areas of the brain (Moon et al., 2015). However, we have not replicated this finding in our 
mouse model.  
Recently, researchers using the same facility and a similar methodology found significant 
differences could be detected at a level of 10-15 % change. Other studies to measure the effect of 
learning and exercise using ex vivo samples showed that they could detect minimum changes as 
low as 3-5 % (Cahill et al., 2015). However, the difference between one mouse brain and another 
may already be 5-10 % due to the fixation effect, plus additional distortion or damage that can 
occur to the brain when they are removed from the skull. Despite these limitations, the current study 
was effective as a preliminary study to determine that there were no large significant changes 
following AVD deficiency. 
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Previous studies have shown that reductions in FA values are consistently found in both AD 
patients, and those patients suffering from mild cognitive impairment (Medina et al., 2006; Zhang 
et al., 2007) and it’s been proposed that changes in white matter microstructural integrity proceeds 
the development of dementia (Medina et al., 2006). The model of AVD deficiency used in the 
current study has previously been shown to produce mild cognitive impairments in attention. Post-
hoc analysis did suggest that there may have been subtle changes in connectivity, which may play a 
role in these impairments; however the changes were not significant enough to be identified using 
the formal analysis of DTI from whole brain.  
The model of AVD deficiency used in the current study is relatively mild in comparison to other 
mouse models of vitamin D deficiency. These mice are only deficient for 10 weeks prior to testing 
and are young adults when first placed on the diet. One of the considerations in choosing this model 
of AVD deficiency was to limit confounding factors such as musculoskeletal deficits and 
hypocalcemia and we have successfully done so. However, it may be that a longer period of 
deficiency would be required before significant disruptions in neuronal integrity are visible using 
DTI. Future studies should examine the effects of an extended period on vitamin D deficiency prior 
to MRI or alternatively, since most of the studies linking vitamin D deficiency to cognitive 
impairment, Alzheimer’s disease and MRI pathology have occurred in elderly populations, a future 
experiment should test the effects of AVD deficiency in older mice and assess both cognitive 
domains and connectivity in the brain using DTI. 
Although, AVD deficiency did not alter gross structures within the brain, this does not preclude 
more subtle effects of AVD deficiency on cell proliferation or differentiation, such as an effect on 
adult hippocampal neurogenesis. Neurogenesis in the adult brain is limited to two main areas, the 
sub ventricular zone and the dentate gyrus of the hippocampus (Gage, 2002). Adult hippocampal 
neurogenesis is important in learning and memory (Yau et al., 2015) and with significant 
associations observed between vitamin D deficiency and cognitive impairment; it is possible that 
AVD deficiency could be altering adult hippocampal neurogenesis, which would not be detected by 
a whole brain MRI analysis. This is explored in Chapter 4. 
3.5 Conclusion 
This is the first study in mice to assess the effects of AVD deficiency on brain structure and 
connectivity using MRI. We can conclude that using the current model of AVD deficiency there 
were no gross structural abnormalities or any significant changes in connectivity measured by DTI 
at the whole brain level. This does not rule out an effect of AVD deficiency on more subtle changes 
in specific areas (such as the corpus callosum or hippocampal commissure) or disturbances in other 
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aspects of brain function, such as neurotransmission or altered rates of proliferation and 
neurogenesis. 
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Chapter 4 Behavioural Effects of Adult Vitamin D Deficiency in BALB/c Mice 
are not Associated with Proliferation or Incorporation of Adult Born 
Hippocampal Neurons 
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4.1 Introduction 
Epidemiological studies suggest that vitamin D deficiency during adulthood may be linked to 
adverse brain-related outcomes, such as cognitive impairment and depression in adults (Balion et 
al., 2012; Anglin et al., 2013); as well as in neuropsychiatric and neurodegenerative diseases (Cui et 
al., 2013a; Eyles et al., 2013). I have now shown that AVD deficiency in BALB/c male mice is 
associated with impaired cognition (Chapter 2), but had no impact on gross brain structure 
following 10 weeks of deficiency (Chapter 3). 
A large population-based study showed that depression status and severity was associated with both 
decreased serum vitamin D and increased serum parathyroid hormone in older individuals 
(Hoogendijk et al., 2008). A recent clinical trial was undertaken in adults suffering from depression 
who were also vitamin D deficient. Participants were given either a single dose of 150,000 IU or 
300,000 IU vitamin D or no treatment and were tested again three months later. The single dose of 
300,000 IU vitamin D not only proved safe but was also associated with a significant improvement 
in depression (Mozaffari-Khosravi et al., 2013).  
It has been hypothesized that hippocampal neurogenesis may play a role in the aetiology of 
depression, although overall studies have shown complex and inconsistent results, as reviewed by 
Miller and Hen (2015). It also remains unclear if this process mediates the link between vitamin D 
status and brain outcomes.  
Vitamin D is known to be anti-proliferative and have pro-differentiation effects, as shown by the 
addition of 1,25(OH)2D to cultures of normal and malignant cell lines (Ylikomi et al., 2002; 
Banerjee & Chatterjee, 2003). Moreover, vitamin D has been shown to regulate a variety of 
neurotrophic factors, including NGF, providing further evidence for its ability to influence neuronal 
proliferation, differentiation, survival and growth (Korsching et al., 1985; Maisonpierre et al., 1990; 
Chao, 1994; Tomac et al., 1995).  
The addition of 1,25(OH)2D to cultures of neonatal subventricular zone led to reduced neurosphere 
formation (Cui et al., 2007), once again supporting the anti-proliferative nature of vitamin D in 
development. However, a recent study has shown that the addition of 1,25(OH)2D to neural stem 
cells harvested from adult mice resulted in significantly enhanced proliferation and also drove them 
towards a more mature differentiated morphology (Shirazi et al., 2015). The neural stem cells 
expressed significantly more NT-3, BDNF, ciliary neurotrophic factor and GDNF when cultured 
with 1,25(OH)2D (Shirazi et al., 2015). Although both studies confirm a role for vitamin D in 
neuronal proliferation, the results were mixed, perhaps due to the limitations involved with cell 
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culture studies. Therefore, in vivo studies are required to clarify the role of vitamin D in neuronal 
proliferation and differentiation.  
Vitamin D deficiency during gestation in Sprague-Dawley rats led to increased cell proliferation in 
embryos via altered gene expression of many cell cycle genes (Ko et al., 2004). Moreover, the 
absence of vitamin D during gestation led to greater proliferation of neuroprogenitor cells, as seen 
by increased neurosphere production from cells dissociated from neonatal rat subventricular zone 
(Cui et al., 2007), providing further evidence from an animal model that the absence of vitamin D 
up-regulates proliferation during development. These studies were based on a developmental model 
of vitamin D deficiency (i.e. the rodents were exposed to low vitamin D only during gestation and 
early life). There is a paucity of information relating to neurogenesis and adult vitamin D 
deficiency. 
A 1α-hydroxylase knockout mouse that lacks the ability to make 1,25(OH)2D, the active form of 
vitamin D,  has been used to assess the effects of 1,25(OH)2D deficiency on various aspects of adult 
hippocampal neurogenesis including proliferation and differentiation (Zhu et al., 2012). In the 1α-
hydroxylase knockout, hippocampal neurogenesis was no different to their wild type or 
heterozygote littermates at three weeks of age (Zhu et al., 2012). However, the complete absence of 
1,25(OH)2D  by eight weeks of age was associated with enhanced proliferation of progenitor cells in 
the dentate gyrus and a decrease in the survival of newborn cells without affecting differentiation 
(Zhu et al., 2012). This study suggested that the absence of vitamin D may be linked to the 
regulation of adult hippocampal neurogenesis. 
In the BALB/c strain, AVD deficiency produced changes in amino acid metabolism within the 
brain, including decreased levels of glutamine and glutamate and increased levels of GABA and 
glycine (Groves et al., 2013). Studies have shown that one of the main molecules catabolized during 
cell proliferation is glutamine, as it is required in large quantities to support cell growth and division 
(Vander Heiden et al., 2009). With AVD-deficient BALB/c mice exhibiting a reduction in brain 
glutamine levels, this lends further support to the hypothesis that adult depletion of vitamin D in the 
BALB/c strain may impair neurogenesis. 
Adult neurogenesis is commonly investigated using markers for proliferation and incorporation of 
new neurons. Ki-67 protein, an endogenous protein only present during active phases of the cell 
cycle, allows the assessment of cell proliferation. A widely used molecule that marks newly 
dividing cells by integrating into DNA during mitosis, 5-Bromo-2’-Deoxyuridine (BrdU), is also a 
useful marker of cell proliferation (Gratzner, 1982). BrdU can be co-localised with a neuron-
specific nuclear protein, neuronal nuclei (NeuN), which is specific for mature neurons and 
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expressed after terminal differentiation. Co-localisation of BrdU with NeuN marks newly generated 
neurons produced during BrdU administration (Mullen et al., 1992) that have incorporated into the 
hippocampus.  
Voluntary wheel running is robustly associated with increased hippocampal neurogenesis in adult 
mice (van Praag, 2008; Clark et al., 2011) and therefore is widely used to stimulate this process 
above low baseline rates. For example, eight-week old BALB/cByJ mice with access to running 
wheels for 43 days had a 450% increase in BrdU+ NeuN+ neurons in the dentate gyrus compared to 
sedentary mice (Clark et al., 2011). Although this protocol does not capture rates of proliferation, 
assessing the number of surviving newborn neurons is a functional readout of the integration of 
newborn neurons into the hippocampus. In combination, the assessment of cell proliferation and 
incorporation in an enhanced neurogenesis model should allow detection of any impact of AVD 
deficiency on these two aspects of adult hippocampal neurogenesis.  
The forced swim test (FST) measures behavioural despair in rodents and is a well established 
behavioural assay related to the assessment of antidepressant agents (Porsolt et al., 1977). We 
previously investigated the effects of AVD deficiency on the FST in group-housed male BALB/c 
mice and showed no impact of the dietary manipulation (Groves et al., 2013). However, BALB/c 
mice are a highly anxious strain and all mice spent a significant time immobile. It was proposed that 
there may have been a ceiling effect that prevented an effect of AVD deficiency from being 
apparent (Groves et al., 2013). In addition to stimulating neurogenesis, voluntary wheel running in 
mice has been shown to reduce immobility in both the FST and tail suspension tests (Duman et al., 
2008; Cunha et al., 2013). To our knowledge, the effect of voluntary wheel running on immobility 
time in the FST has not been previously investigated in BALB/c mice. Impact of AVD deficiency 
on immobility time in the FST may indicate alterations in hippocampal neurogenesis. 
The aims of this study were to test the effects of AVD deficiency on hippocampal neurogenesis. 
Our primary hypothesis was that AVD deficiency would alter proliferation and incorporation of 
adult born hippocampal neurons and that the increase in hippocampal neurogenesis stimulated by 
wheel running would be blunted by AVD deficiency.  We aimed to test this hypothesis by assessing 
the number of Ki67+ cells as a marker of cell proliferation following behavioural tests, and the 
number of BrdU+ NeuN+ cells, as a measure of the number of surviving newborn mature neurons 
integrated into the dentate gyrus, at baseline and following voluntary wheel running. Secondly, we 
hypothesised that AVD-deficient mice would demonstrate behavioural correlates of vitamin D 
deficiency, specifically, spending more time immobile compared to controls in the FST, and this 
would correlate with altered neurogenesis as measured by proliferation and incorporation. We 
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aimed to test this by exploring the effect of wheel running on immobility time the FST, and by 
assessing the correlation between neurogenesis and immobility time.  
4.2 Materials and Methods 
4.2.1 Animals and housing 
A total of 87 BALB/c mice (57 male and 30 female) were used in this study. Ten-week old BALB/c 
mice (Animal Resources Centre, Canning Vale, WA, Australia) were obtained and housed in groups 
of four in individually ventilated OptiMICE cages, with bedding and nesting material at the 
Queensland Brain Institute Animal House Facility, The University of Queensland, Australia.  
The mice were assigned to either a control diet or a vitamin D-deficient diet as detailed in Chapter 2 
for 10 weeks prior to the start of behavioural testing and for the entire duration of the experimental 
procedures. The mice were maintained on a 12-hour light-dark cycle (lights on at 07:00 h) with ad 
libitum access to food and water. They were housed under incandescent lighting free from UVB 
radiation. All experimental work was performed with approval from The University of Queensland 
Animal Ethics Committee, under the guidelines of the National Health and Medical Research 
Council of Australia. 
4.2.2 Experimental Design 
After 10 weeks on the diet, the first wave of mice was separated into the following groups; twenty-
eight mice (n = 5-8/sex/group) were individually housed with running wheels and 28 mice (n = 6-
9/sex/group) were individually housed without running wheels, for the next six weeks. An 
additional four mice (2 male and 2 female) were individually housed without running wheels as 
non-BrdU injected controls. These mice were not included in the behavioural analysis but were 
used as a negative control to ensure that the only BrdU analysed was from the injections of BrdU. 
Mice were placed into the following five groups: Control Runner, Control Non-runner, AVD-
deficient Runner, AVD-deficient Non-runner and No BrdU Control.  
Wheel rotations for running groups were collected in 60 min time bins over the 6-week period using 
automated Wheel Manager software. During the first 10 days of individual housing all mice, 
excluding the non-BrdU controls, received a daily i.p injection of 50 mg/kg of BrdU at the same 
time each day, between 1000-1200 h, to assess hippocampal neurogenesis at the end of the 
behavioural testing. After 16 weeks on the diet, and at the end of running wheel access for the 
Running groups, mice were tested in a 30 min activity monitor test and in the FST (see section on 
behavioural testing below for full details of these methods). These tests were chosen as they are 
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altered by wheel running (Duman et al., 2008) and the forced swim test was included as a measure 
of behavioural despair. 
The second wave of mice included 27 male mice, 14 mice (n = 6-8/group) were individually housed 
with running wheels and 13 mice (n = 6-7/group) were individually housed without running wheels, 
for the next six weeks. These mice were not injected with BrdU, but were only analysed for serum 
25(OH)D levels after 16 weeks on the diet. 
4.2.1 Serum 25(OH)D levels 
At the completion of experimental procedures, mice from the second wave were euthanized by i.p 
injection of an overdose of Lethabarb at 4 ml/kg body weight and a terminal blood sample was 
collected using a 25 gauge needle and a 3 ml syringe via cardiac puncture and blood was transferred 
to 1.5 ml eppindorf tubes. Blood was allowed to clot for 1h and then centrifuged for 5 min at 13,000 
rpm. The sera was separated and then stored at -20 °C until testing. The levels of 25(OH)D was 
measured in serum samples using liquid chromatography-tandem mass spectrometry on a 4000 
QTrap API AB mass spectrometer (Eyles et al., 2009a).  
4.2.2 Behavioural Testing 
4.2.2.1 Activity monitor 
Activity monitors were used to measure baseline locomotion (Walsh & Cummins, 1976). Eight 
open field activity monitors were used. The arenas were 27.5 x 27.5 x 30 cm high and made of clear 
Perspex with two arrays of 16 x 16 infrared beams. One array of beams was low (1 cm above floor) 
so that beams were broken when the animal was present or moving, and another high (8 cm above 
floor) so beams were broken only when the animal reared. Mice were placed in the centre of the 
arena and their activity was monitored for 30 min, in which time the Med Associates software used 
the beam break data to triangulate the position of the mouse and measure the distance travelled by 
the mouse over time. 
4.2.2.2 Forced swim test 
The apparatus used in the forced swim test was a clear round container (20 cm high x 14 cm 
diameter) with a column of water (16 cm deep) maintained at 25 °C. Each mouse was placed in the 
container for six min and recorded using a USB digital camera and recording software. Activity was 
scored using the mobility threshold settings within the Ethovision software by measuring the 
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percentage change in area of the tracked object from one sample to the next. Immobility was 
defined as less than 5% movement using these settings and was validated by a human observer. 
4.2.3 Immunohistochemistry 
To ensure our results were comparable with previous research on exercise induced hippocampal 
neurogenesis, immunohistochemistry was conducted following established protocols (Kempermann 
et al., 1997; Clark et al., 2011). 
4.2.3.1 Perfusions 
All mice were anaesthetized by an i.p injection of Lethabarb at 100 mg/kg body weight 24 h after 
FST and transcardially perfused with 40 ml of PBS and 40 ml of 4 % PFA in 0.1 M PBS. The 
brains were removed and post fixed in 4 % PFA for 24 h before being stored in PBS azide. BrdU 
incorporation was assessed in n = 8 per group. Brains included in the neurogenesis analysis were 
selected blind to behavioural results. Brains were transferred to a 30 % sucrose solution for 24 h and 
then rapidly frozen and 50 µm sections containing the hippocampus were cut coronally using a 
sledge microtome and stored in PBS azide at 4 °C until used. 
4.2.3.2 Double-labelled immunofluorescence 
A one-in-five series was stained to identify newly divided mature neurons. Sections were rinsed 
with PBS azide to remove all trace of sucrose. Sections were incubated in 1M HCl for 20 min at 40° 
C to denature DNA, then rinsed with 0.1M Boric acid for five min. The sections were then 
incubated in Antigen Recovery Solution for 30 min at 60° C, followed by 3x5 min rinses with PBS 
azide. Sections were blocked at RT with a solution of 3 % normal goat serum (NGS) and 0.05 % 
Saponin in PBS azide. Sections were incubated with the primary antibodies; rat anti-BrdU (1:500) 
(Accurate Chemical, NY, USA) and mouse anti-NeuN (1:500) (Merck, Millipore, MA, USA), or 
with the primary antibody, rabbit anti-Ki67 (1:5000) (Abcam, Cambridge, UK) for 56 h at 4° C. 
Sections were then washed for 3x15 min in PBS azide. Secondary antibodies raised in donkey or 
goat were conjugated with fluorescent markers (Alexa fluor-488 anti-rat (1:2000) and Alexa fluor-
647 anti-mouse (1:500) (Jackson Lab. Inc, PA, USA), and Alexa fluor-568 anti-rabbit (1:1000) 
(Thermo Fisher, IL, USA) and the sections were incubated with the secondary antibodies overnight 
at 4° C. Sections were then washed with 1:1000 DAPI in PBS azide for 15 min, followed by 2x15 
washes in PBS azide. Sections were mounted from a solution of chrome alum gelatin onto slides 
with DABCO. 
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4.2.3.3 Image analysis 
Fluorescence images were captured on a Zeiss Axio Imager Z1 microscope using a 20x 0.8NA 
PlanApo objective and Zeiss AxioCam HRm camera. Optical sectioning was achieved using 
ApoTome structured illumination and the large area of the dentate gyrus was captured using the 
tiled imaging and stitching features of Zen 2009 software. Cells that exhibited complete 
incorporation of BrdU and those that exhibited partial accumulation of BrdU were all counted as 
BrdU+ NeuN+ cells. Cells with nuclei completely incorporated with BrdU and colabeled with 
NeuN, have not undergone any divisions. Partially immunolabelled cells, where nuclei were stained 
with NeuN but BrdU was only partially incorporated, have either undergone division after BrdU 
was injected into the animals (daughter cells) or were born late in the accumulation window (Figure 
4.1). For Ki67 immunoreactivity, only Ki67+ cells were included in the analysis. 
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Figure 4.1 Representative images of BrdU incorporation within mature neurons in the dentate gyrus 
A representative image of the dentate gyrus from a Non-Runner (a) and a Runner (b). A close up image from 
the section of the dentate gyrus from the Non-Runner (c), and the Runner (g), DAPI stain showing nuclei (d 
and h), NeuN stain showing mature neurons (e and i) and BrdU staining showing newly born cells (f and j). 
The line arrow points to a mature neuron (stained with NeuN) with complete BrdU incorporation; these cells 
have not undergone cell division after the uptake of BrdU. The arrow head points to a mature neuron (stained 
with NeuN) with only partial BrdU incorporation; these cells have divided following BrdU injection or were 
born late in the accumulation window. The star points to a cell with BrdU incorporation but no co-
localisation with NeuN and is therefore not a neuron (not analysed). Blue – DAPI, Green – NeuN, Red – 
BrdU. 
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4.2.4 Statistical analysis 
Data were analysed using SPSS version 20. All data were analysed for the main effects of Diet 
(control or AVD-deficient) and Sex using ANOVA. Repeated measures ANOVA was used for the 
wheel rotations, activity monitors and the forced swim test results. Significant differences (p < 0.05) 
were followed up with post-hoc t-tests. Correlations between neurogenesis and immobility time 
were assessed using Pearson’s test for correlation. Adult hippocampal neurogenesis was measured 
as the total number of BrdU positive cells co-expressing NeuN averaged per section counted, and 
the number of Ki67 positive cells averaged per section counted, with the total area counted not 
different between groups. 
4.3 Results 
4.3.1 Serum 25(OH)D levels  
There was a main effect of Diet (F1,23 = 737.9, p < 0.001) on serum 25(OH)D levels but no 
significant effect of Running (F1,23 = 1.07, p = 0.313), with no interaction (F1,23 = 0.01, p = 0.940). 
Levels of 25(OH)D were significantly reduced in both AVD-deficient Runners (2.23 ± 0.23 nM) 
and  AVD-deficient Non-runners (3.44  ± 0.67 nM) compared to both Control Runners (31.99 ± 
0.70 nM) and Control Non-runners 33.03 ± 2.21 nM. As no diet by sex interactions were found, 
data from male and female mice were pooled. 
4.3.2 Running wheel activity  
It has been well documented that volitional exercise stimulates adult neurogenesis in mice (Clark et 
al., 2011). In order to ensure propensity for wheel running did not contribute to differences between 
AVD deficient and control mice, we compared mice individually housed with and without running 
wheels for six weeks (n = 5-9/group). There was no significant main effect of Diet (F1,14 = 1.24, p = 
0.285) on the number of wheel rotations measured between Control (M = 15,388±1215 rotations per 
day) and AVD-deficient (M = 13,000±1907 rotations per day) mice. Hence it appears that AVD 
deficiency did not impact on voluntary wheel running in BALB/c mice, and that any differences 
between the groups are not due to variations in volitional exercise. 
4.3.3 Spontaneous locomotion  
In an earlier study (Groves et al., 2013), we found significant differences in spontaneous 
locomotion between male AVD deficient and control BALB/c mice in both novel and familiar open 
field tests. In the novel environment, locomotion was increased for AVD deficient mice, however, 
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in the familiar environment, activity was significantly decreased compared to controls. To further 
explore differences in locomotion we compared the mice housed with and without running wheels 
in novel open field activity monitors. In this study, there was no significant main effect of Diet 
(F1,51 = 1.03, p = 0.314) on the distance travelled in the activity arena. It is possible that our 
previous results are restricted to males only, or that one of a number of possible environmental 
influences were at play in this study.  There was, however, a main effect of Running (F1,51 = 4.66, p 
= 0.036), where Non-runners were more active than Runners with no interaction with diet (F1,51 = 
0.85, p = 0.772) (n = 13-15/per group) (Figure 4.2a). 
4.3.4 Immobility time in the forced swim test 
Our final behavioural test aimed to determine any differences in immobility, a behavioural correlate 
of behavioural despair. There were significant main effects of Diet (F1,27 = 4.67, p = 0.040) and 
Running (F1,27 = 17.71, p < 0.001) on immobility time in the FST, with no interaction (F1,27 = 0.23, 
p = 0.879) (n=7-8/per group). Mice exposed to running wheels had a significant reduction in 
immobility time compared to those without access to running wheels. This result is not unexpected; 
running is associated with an anti-depressant effect reflected by decreased immobility in the FST 
(Cunha et al., 2013). However, AVD-deficient mice spent less time immobile compared to controls 
(Figure 4.2b). These results are converse to those expected if vitamin D plays a role in depression, 
but are consistent with recent research demonstrating that immobility in the FST is independent of 
hippocampal neurogenesis (Holick et al., 2008). 
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Figure 4.2 Results for the activity monitor, forced swim test, BrdU+NeuN+ cell counts and Ki67+ cell 
counts 
The distance travelled in the activity monitors shown in (a) (n=13-15/per group). There was no significant 
effect of Diet but there was a significant main effect of Running. Runners moved less than Non-runners. 
Immobility time during the FST is shown in (b) (n=7-8/per group). There was a main effect of both Diet and 
Running. Wheel running significantly reduced immobility time; moreover AVD deficiency also reduced 
immobility time. The number of Ki67+ cells per mm2 is shown in (c) (n=8/per group). There was no 
significant effect of diet but there was a significant effect of Running. Runners had higher numbers of Ki67+ 
cells compared to Non-runners. BrdU+ NeuN+ cells per mm2 are shown in (d) (n=8/per group). There was a 
significant increase in the number of BrdU+ NeuN+ cells following voluntary running. However, there was no 
significant effect of Diet on baseline cell numbers or cell numbers stimulated by voluntary running. The 
number of Ki67+ cells per mm2 is shown in (d) (n=8/per group). There was no significant effect of diet but 
there was a significant effect of Running. Runners had higher numbers of Ki67+ cells compared to Non-
runners. Mean ± SEM (* p < 0.05 # Main effect of Diet p <0.05) 
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4.3.5 Cell proliferation and incorporation 
While in utero vitamin D deficiency has been shown to lead to increased proliferation in rat 
neonatal neurospheres (Cui et al., 2007), there is some evidence to suggest this effect is limited to 
development (Ko et al., 2004). To determine if AVD deficiency regulated proliferation in BALB/c 
mice, we looked at proliferation of cells in the dentate gyrus following the behavioural tests. There 
was no significant difference between all groups in the area (mm2) of the dentate gyrus in which 
Ki67+ cells were counted (F1,25 < 1.58, p > 0.220). While there was no significant main effect of 
Diet (F1,25 = 0.43, p = 0.517) on the number of Ki67+ cells per mm2 (n = 6-8/per group), we did see 
a significant main effect of Running (F1,25 = 11.29, p = 0.003) where Runners had a greater number 
of Ki67+ cells compared to Non-runners (Figure 4.2c). This suggests that, in BALB/c mice, AVD 
deficiency does not regulate proliferation, and nor does it impact processes that do regulate 
proliferation, such as volitional exercise.  
To determine if AVD deficiency impacted neurogenesis in the adult hippocampus through 
mechanisms other than proliferation, we looked at the number of surviving newborn neurons 
integrated into the dentate gyrus. There was no significant difference between all groups in the area 
(mm2) of the dentate gyrus in which BrdU+ NeuN+ cells were counted (F1,28 < 0.55, p > 0.464). In 
accord with previous research (van Praag, 2008; Clark et al., 2011), there was a significant main 
effect of Running (F1,28 = 74.85, p < 0.001) on the number of BrdU-incorporated cells per mm2, 
with Runners having a higher number of BrdU+ NeuN+ cells compared to Non-runners. There was, 
however, no significant main effect of Diet (F1,28 = 1.82, p = 0.188) on the number of BrdU-
incorporated cells and there was no interaction (F1,28 = 1.00, p = 0.326) (n = 8/per group) (Figure 
4.2d). These findings complement our proliferation results. 
4.3.6 Correlations of cell proliferation and incorporation with immobility time in the 
FST  
There was no significant correlation between Ki67+ cells and time spent immobile (R2 = -0.085, p = 
0.747, N = 17). This finding held true when the groups were separated for Diet, with no significant 
correlation between Ki67+ cells and time spent immobile in Controls (R2 = 0.098, p = 0.788, n = 10) 
or AVD-deficient mice (R2 = -0.345, p = 0.449, n = 7). This finding suggests that immobility time 
is unrelated to proliferation of adult born cells in the dentate gyrus. 
Overall, there was no significant correlation between BrdU+NeuN+ cells and time spent immobile 
(R2 = -0.416, p = 0.077, n = 19), however when the groups were separated, a significant correlation 
between BrdU+NeuN+ cells and time spent immobile was found in control mice (R2 = -0.810, p = 
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0.005, n = 10), but not in AVD-deficient mice (R2 = -0.166, p = 0.670, n = 9). This suggests that 
while AVD deficiency does not impact on the number of dividing cells, or their differentiation into 
mature neurons, it may impact the function of newly generated cells. 
4.4 Discussion 
The main finding from this study was that AVD deficiency did not affect proliferation or 
incorporation of adult hippocampal neurons within the dentate gyrus, at baseline or after voluntary 
wheel running in BALB/c mice. Therefore, we can reject the hypothesis that AVD deficiency 
impairs adult hippocampal neurogenesis through alterations in proliferation or integration into the 
dentate gyrus in BALB/c mice. As predicted, wheel running was associated with a significant 
increase in hippocampal neurogenesis in both male and female mice in this study, however this was 
not altered by AVD deficiency. Furthermore, there was no confounding factor from AVD 
deficiency altering the amount of voluntary wheel running and therefore confounding neurogenesis 
results, because voluntary wheel running was not significantly different between diets. Overall, this 
study provides convincing evidence that any putative link between AVD deficiency and adverse 
brain-related outcomes is not mediated via proliferation or incorporation of new hippocampal 
neurons in BALB/c mice as measured in this study.  
Hippocampal neurogenesis was measured using well-known techniques, using a modified version 
of the protocol used in the Clark et al. (2011) study. We measured the number of BrdU+ NeuN+ 
cells and Ki67+ cells within the dentate gyrus of the hippocampus, within a set number of sections 
from a one in five series. This allowed us to measure two aspects of hippocampal neurogenesis, 
proliferation and integration into the dentate gyrus. We have clearly shown that both these 
processes were not impaired by AVD deficiency. Furthermore, AVD deficiency had no effect on 
processes that enhance proliferation, such as wheel running. 
One of the difficulties in unravelling the mechanisms by which AVD deficiency impacts rodent 
behaviour is in strain variation, not just in response to AVD deficiency but in neurogenesis itself. A 
comparison of neurogenesis in four strains found that while differences in proliferation rates did not 
reach significance, number of new neurons, neuronal differentiation and survival all differed 
(Kempermann et al., 1997). Similar genetic variations are seen following exercise. The number of 
BrdU+ cells varied from 6000 per mm3 to 14000 per mm3 across 12 strains of mice (Clark et al., 
2011).  
The 1α-hydroxylase knockout mouse is most relevant to our study due to the role of 1α-
hydroxylase in the conversion of 25(OH)D to 1,25(OH)2D and the BALB/c background. These mice 
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have an increase in proliferation and a decrease in the survival of newborn neurons in the 
hippocampus at eight weeks of age (Zhu et al., 2012), yet we have shown that after 16 weeks on a 
vitamin D deficient diet, with serum levels of 25(OH)D known to be deplete after six weeks, there 
was no impairment of hippocampal proliferation or integration of new neurons. This shows that 
either the AVD model used in this study may be subtler than a knockout animal model and 
therefore more reflective of vitamin D deficiency in human populations, or alternatively, it may be 
the developmental aspect of the 1α-hydroxylase knockout mouse that leads to hippocampal 
neurogenesis alterations in the adult animal. 
Despite no change in cell proliferation or incorporation with AVD deficiency, there was a 
significant effect of diet on behaviour in the FST. We have previously shown that AVD deficiency 
did not impact immobility time on the FST in group-housed male BALB/c mice. However in this 
study, we chose to use individual housing to allow accurate measurement of individual wheel 
running in both male and female mice and we found that AVD deficiency resulted in a reduction in 
immobility time during the FST. A previous study in Swiss-Webster mice showed a significant 
difference in immobility time between individually housed mice and group-housed mice, showing 
that the FST was sensitive to housing conditions (Karolewicz & Paul, 2001). This study has showed 
that in individually housed BALB/c mice, wheel running for six weeks leads to a reduction in 
immobility time, and that this effect is enhanced for AVD deficient mice.  
We hypothesized that AVD-deficiency would increase immobility compared to controls. Based on 
our results we can reject this hypothesis. AVD deficiency in BALB/c mice does not induce a 
depressive-like phenotype on the FST.  
There are a number of epidemiological studies that show a significant association between vitamin 
D deficiency and depression (Hoogendijk et al., 2008; Anglin et al., 2013) and there have also been 
clinical trials showing reductions in depressive symptoms following vitamin D supplementation 
(Mozaffari-Khosravi et al., 2013), yet this study produced no depressive-like symptoms in the 
AVD-deficient BALB/c mice as measured by immobility time in the FST. It is possible that the 
mice were not on the diet for a long enough period. While the AVD-deficient mice are deplete of 
serum 25(OH)D prior to the start of behavioural testing, it may require a longer period of depletion 
before some symptoms are detectable and this could be addressed in future studies. 
Alternatively, it is possible that a secondary insult may be required to exacerbate the effects of 
vitamin D deficiency to induce depressive-like symptoms (Cui et al., 2013a). For example, many of 
the epidemiological studies that show an association between vitamin D deficiency and depression 
are performed in older adults (Hoogendijk et al., 2008). A recent study performed in rats showed no 
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effect of vitamin D supplementation in young (6 month old) rats, however in older rats (20 month 
old), vitamin D supplementation significantly improved learning and memory (Briones & Darwish, 
2012). Another study showed that long-term vitamin D dietary manipulation in aging rats (11-13 
months old at the start of the study and on diet for 5-6 months), had a significant impact on learning 
with only the rats on a high vitamin D diet able to perform a complex memory task, compared to 
those on low or mid levels (Latimer et al., 2014). Therefore, perhaps combining vitamin D 
deficiency with ageing or another secondary insult such as social stress, could lead to a depressive-
like phenotype in BALB/c mice. 
Similar to the current study, a recent study in a transgenic Alzheimer’s Disease mouse model 
showed a reduction in immobility time during the FST and it was proposed that this result may be 
due to a lack of cognitive flexibility and coping with stress strategies rather than from a change in 
behavioural despair (Torres-Lista & Gimenez-Llort, 2014). However, as determining the 
mechanism leading to the reduction in immobility time with AVD deficiency was beyond the scope 
of our experiments, future studies should include testing the cognitive abilities of AVD-deficient 
mice. 
BrdU+ NeuN+ cells and Ki67+ cells were counted in a subset of the population that also underwent 
the FST. Post-hoc analysis showed that immobility time was not significantly correlated with the 
level of proliferation. Interestingly, however, a significant negative correlation was found between 
BrdU+ NeuN+ cells and immobility time for control mice only, where a greater number of cells 
were correlated with reduced immobility. This effect was not seen for AVD deficient mice, 
potentially suggesting that the role of new neurons differs in the AVD-deficient model. Previous 
studies have shown that in C57BL/6J mice, hippocampal neurogenesis is required for the beneficial 
effects of antidepressants in the FST (reduction in immobility time) (Tyler et al., 2014). However, 
in BALB/c mice ablation of neurogenesis does not prevent the reduction in immobility time seen 
with chronic antidepressant treatment (Holick et al., 2008). Taken together, the results from Holick 
et al. (2008) and the results from this study may suggest that immobility time in the FST is 
independent of changes in neurogenesis in BALB/c mice and that there are other mechanisms 
involved.  
While this study has shown that the number of proliferating cells and the number of newborn 
neurons integrated into the hippocampus were not affected by AVD deficiency, there are other 
measures of interest that may be impacted by AVD deficiency, such as the extent of branching of 
immature neurons rather than cell number, or on the level of apoptosis, or differentiation, which 
should be investigated in future studies. 
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AVD deficiency in the BALB/c strain was associated with a reduction in glutamine and glutamate 
levels in whole brain (Groves et al., 2013). Glutamine is a constituent of proteins and is required in 
large quantities to support cell growth and division (Vander Heiden et al., 2009), but is also very 
important for redox pathways (Mates et al., 2002). Both glutamine and glutamate are used for the 
biosynthesis of the cellular antioxidant, glutathione. Furthermore, glutamine degradation via the 
citric acid cycle leads to the production of nicotinamide adenine dinucleotide phosphate, which is 
also essential for the maintenance of glutathione (Mates et al., 2002).  
Vitamin D has been shown to protect against oxidative stress in in vitro studies through regulation 
of glucose-6-phosphate dehydrogenase (Bao et al., 2008) and γ-glutamyl transpeptidase (Garcion et 
al., 1999), enzymes important in the glutathione pathway. Therefore, the absence of vitamin D 
during adulthood may lead to a depletion of brain glutathione and excessive oxidative stress, 
resulting in impaired brain function and this should be investigated in future studies.  
4.5 Conclusion 
This is the first study to show that AVD deficiency did not impair proliferation or incorporation of 
adult hippocampal neurons at baseline or after voluntary wheel running, despite a behavioural 
alteration on the FST. This suggests that the behavioural effects of AVD deficiency are not 
mediated via early hippocampal neurogenesis processes and that other mechanisms may be 
involved. In light of the fact that there is growing evidence to support the hypothesis that vitamin D 
deficiency in adulthood is related to adverse brain outcomes, it is now important to unravel the 
mechanisms by which vitamin D deficiency alters brain function. 
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Chapter 5 Preliminary Hippocampal Proteomics Provides Convergent 
Evidence of Adult Vitamin D Deficiency Impacting on Glutamate and GABA 
Neurotransmission 
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5.1 Introduction 
Vitamin D is a neurosteroid that exerts its effects either as a transcription factor regulating gene 
expression (Ramagopalan et al., 2010) or via rapid nongenomic actions through signal transduction 
systems (Falkenstein et al., 2000). The genomic effects of vitamin D are pleiotropic with over 2,700 
VDREs found genome wide (Ramagopalan et al., 2010). There is considerable evidence to show 
that vitamin D has many functions in the brain, including calcium homeostasis and signaling, 
regulation of neurotrophic factors, neuroprotection, and modulating neurotransmission and synaptic 
plasticity. However, much of this research has been performed in cell cultures with the addition of 
vitamin D or in vivo following treatment with 1,25(OH)2D. For example, vitamin D added to 
primary rat hippocampal cultures, had a neuroprotective effect against excitotoxic insults and down-
regulated L-VGCC expression (Brewer et al., 2001).  
The addition of vitamin D to cultured embryonic hippocampal cells not only increased NGF but 
also increased neurite outgrowth and decreased mitosis (Brown et al., 2003). Furthermore, the 
injection of 1,25(OH)2D into the rat hippocampus, was protective against brain inflammation via 
regulation of iNOS (Garcion et al., 1998).  
The effects of vitamin D deficiency during early periods of brain development has also been 
studied, for review see Eyles et al. (2013). Using a rat model, DVD deficiency has been extensively 
studied, including the analysis of gene and protein expression in different regions of the brain at 
different stages of development (Ko et al., 2004; McGrath et al., 2008). In the hippocampus of adult 
rats following DVD deficiency, analysis of protein expression levels revealed changes in 
mitochondrial function, calcium homeostasis, synaptic plasticity and neurotransmission (Almeras et 
al., 2007). 
While there is large number of epidemiological studies with significant associations between 
vitamin D deficiency in adulthood and a range of neuropsychiatric and neurodegenerative disorders 
(Balion et al., 2012; Anglin et al., 2013; Annweiler et al., 2013), there is limited research on how 
the absence of vitamin D in the adult brain may be involved in the development of these disorders. 
In previous research using BALB/c mice, we have shown that amino acid metabolism is altered, 
with reduced levels of glutamate and glutamine and elevated levels of GABA and glycine, within 
whole brain tissue. Furthermore, we found that levels of GAD65 and GAD67, which are involved 
in the metabolism of glutamate and GABA, were down-regulated in AVD-deficient mice (Groves et 
al., 2013). These results suggest that the balance between excitatory and inhibitory 
neurotransmission may be altered with AVD deficiency.  
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An imbalance in glutamate/GABA systems has been implicated in a range of neurological disorders 
including schizophrenia, autism and cognitive impairment (Lewis & Moghaddam, 2006; Nelson et 
al., 2006; Kehrer et al., 2008). Another study in adult rats showed that eight weeks of a vitamin D 
depleted diet led to decreased induction of LTP in the hippocampus of anesthetized animals, 
compared to a control diet or vitamin D supplemented diet (Salami et al., 2012). It is well known 
that glutamate neurotransmission plays a central role in LTP (Bashir et al., 1993). However, there is 
an important gap in the knowledge here in relation to what proteins are being affected by the 
absence of vitamin D to elicit these changes in excitatory and inhibitory neurotransmitter systems. 
Therefore, the aim of this study was to use proteomics to screen hippocampal tissue for possible 
candidate proteins that are expressed differentially with AVD deficiency. With the changes in 
neurochemistry observed in this model, the hypothesis was that AVD deficient BALB/c mice would 
show changes in the expression of proteins specifically involved with glutamate and GABA 
signaling. Furthermore, we predicted that AVD deficiency would affect biological processes that 
were identified in vitamin D treatment studies, such as changes in synaptic plasticity, calcium 
regulation and neuroprotection.  
5.2 Materials and methods 
5.2.1 Animals and housing 
Sixteen ten-week old male BALB/c mice (Animal Resources Centre, Canning Vale, WA, Australia) 
were obtained and housed in groups of 4 in individually ventilated OptiMICE cages (Animal Care 
Systems, CO, USA), with bedding (Sanichips, Harlan Laboratories, USA) and nesting material at 
the Queensland Brain Institute Animal House Facility, University of Queensland.  
Mice (n = 8 control and 8 AVD-deficient) were assigned to either a control diet or a vitamin D-
deficient diet as detailed in Chapter 2 until they were 20-weeks old. The mice were maintained on a 
12-hour light-dark cycle (lights on at 07:00 h) with ad libitum access to food and water. They were 
housed under incandescent lighting free from UVB radiation. All experimental work was performed 
with approval from the University of Queensland Animal Ethics Committee, under the guidelines of 
the National Health and Medical Research Council of Australia.  
5.2.2 Tissue collection and serum 25(OH)D levels 
The mice were euthanized by CO2, a terminal blood sample was collected via cardiac puncture, 
followed by decapitation. Serum was collected as per the details in Chapter 4. The level of 
25(OH)D was measured in the serum samples using liquid chromatography-tandem mass 
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spectrometry (Sciex Instruments, ON, Canada) on a 4000 QTrap API AB mass spectrometer (Eyles 
et al., 2009a). 
The whole brain was removed and the whole hippocampus was collected using a mouse 1mm brain 
block (David Kopf Instruments, California, USA) and free-hand dissection using The Mouse Brain 
in Stereotaxic Coordinates as a reference (Franklin, 2012). Tissue was frozen on dry ice and stored 
at -80° C until further processing.  
5.2.3 Tissue preparation 
Hippocampal tissue from two mice from each cage, totaling 8 mice (n = 4 control and 4 AVD-
deficient) was used in the proteomics analysis. The hippocampal tissue was homogenized and then 
sonicated in 8M urea, 20mM Tris, 4% Chaps and 1% DTT lysis buffer with 1X protease and 
phosphatase inhibitors (Roche Diagnostics, Castle Hill, AUS). The samples were placed on a rotator 
and spun slowly for 4 h, followed by centrifugation at 15° C for 30 min at 13,000 g. The 
supernatant was removed and placed into a new tube. Protein concentration of the supernatant was 
determined using a Bradford assay following the standard protocol.  
5.2.4 Isobaric tag for relative and absolute quantification labeling 
For each sample, 100 µg of protein was reduced with 2.5 mM tris(2-carboxyethyl)phospshine at 60 
ºC for 1 h and cysteine residues alkylated with 10 mM methyl methanethiosulfonate (room 
temperature for 15 min). Protein was precipitated with 4 volumes of ice-cold acetone overnight at -
20° C. Protein was collected by centrifugation and the pellet resuspended in 0.5 M 
tetraethylammonium bromide containing 0.1 % sodium dodecyl sulfate. Protein was digested with 
sequencing grade trypsin (Promega, WI, USA) overnight. For each sample, the isobaric tag for 
relative and absolute quantification (iTRAQ) reagent (AB Sciex, CA, USA) was added to the digest 
and incubated for 1 h at room temperature. After labeling the eight-labeled peptide samples were 
pooled and evaporated to dryness in a speed vac. 
5.2.5 Strong cation exchange peptide fractionation 
The labeled peptide mix was resuspended in 0.1 % acetic acid containing 2% acetonitrile. 
Chromatography was performed on an 1100 series high performance liquid chromatography 
(HPLC) (Agilent, CA, USA) equipped with a fraction collector. Samples were fractionated using a 
Zorbax 300-strong cation exchange (SCX) column (5 µm, 4.6 x 50 mm, Agilent, CA, USA) using a 
linear gradient from 0 – 250 mM ammonium acetate containing 2 % acetonitrile at 0.5 mL per 
minute with 30 s fractions. Fractions were combined accordingly to give a total of 15 fractions. 
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Combined fractions were desalted using Empore C-18 7mm/ 3 mL solid phase extraction cartridges 
(Agilent, CA, USA). 
5.2.6 Mass spectrometry  
Peptides were dissolved in 1% formic acid and injected onto a Shimadzu Prominence nanoLC 
system (Shimadzu, Kyoto, Japan) at a flow rate of 1 µL/min onto a Vydac Everest C18 300 A, 5 
µm, 150 mm x 150 µm column (Grace, Colombia, MD, USA). Chromatographic separation was 
performed using a linear gradient 10 – 60% solvent B (0.1% formic acid, 90% acetonitrile) over 48 
min. Mobile phases consisted of solvent A (1% acetonitrile, 0.1% formic acid) and solvent B. The 
HPLC eluent was interfaced to a TripleTOF 5600 LC/MS/MS system using a Nanospray III 
ionisation source (Applied Biosystems, Forster City, CA). Source conditions included an ion spray 
voltage of 2700 V, nebulizer gas flow of 10, curtain gas flow of 30, interface heater temperature at 
150° C and collision-induced dissociation settings included CAD gas of 10 and a declustering 
potential of 80 V. MS TOF spectra were acquired across the range m/z 350 – 1800 for 0.5 s 
followed by 20 data-dependent MS/MS measurements on pre-cursor ions (100 counts/s threshold, 
+2 to +5 charge state, collision energy of 40 with collision energy spread of 15). Data was acquired 
and processed using Analyst TF 1.5™ software (AB Sciex, CA, USA). 
5.2.7 Protein identification and quantification 
ProteinPilot™ v4.5 software (Applied Biosystems, Forster City CA) utilising the Paragon 
Algorithm was used for the identification of proteins. MS/MS data was searched against the Uniprot 
FASTA formatted database. Search parameters included trypsin as the digestion enzyme, MMTS as 
cys-modification, biological modifications allowed (using the set provided with the software) and 
‘thorough’ search setting. The criterion for a positive identification was a confidence score of ≥ 
95% and a minimum of 2 peptides per protein.  
5.2.8 Statistical analysis 
Data were analysed using SPSS version 20. All data were analysed for the effects of Diet (control or 
AVD-deficient) using ANOVA. Proteins were considered significantly different between control 
and AVD-deficient diets when a p-value of less than 0.05 was given. Without correcting for 
multiple comparisons, a dataset of these proteins was generated with fold change (FC) from control 
and the UniProtKB protein codes for analysis using Ingenuity Pathway Analysis (IPA) (Ingenuity 
System Inc, Redwood City, CA). 
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5.2.9 Ingenuity pathway analysis 
Data was analysed using the ‘Core Analysis’ function in IPA. Data was analysed in the context of 
canonical pathways, biological processes and networks. The proteins included in the analysis were 
not corrected for multiple comparisons, so that a larger list of candidate proteins (the dataset) could 
be analysed using IPA. However, results from the pathway analysis were only considered 
significant with p-values less than 0.01. Significance of the canonical pathways was tested by the 
Fisher Exact test p-value. The significance calculated was a measurement of the likelihood that the 
pathway is associated with the dysregulated proteins by chance. Canonical pathways were ordered 
by significance and the ratio value (number of significant proteins in a given pathway, divided by 
total number of molecules that make up that pathway). 
Bio functions were grouped in: Diseases and Disorders, Molecular and Cellular Functions and 
Physiological System Development and Function. Proteins from the dataset that were associated 
with bio functions in the Ingenuity Pathways Knowledge Base were considered for analysis. 
Fischer’s exact test was used to calculate a p-value determining the probability that each bio 
function assigned to the dataset was due to chance alone. 
Networks were generated when differentially regulated genes could be related according to 
previously known associations, but independently of established canonical pathways. Networks 
were associated to bio functions according to the molecules involved based on Ingenuity Pathways 
Knowledge Base. 
5.3 Results 
5.3.1 Serum 25(OH)D levels 
There was a main effect of Diet (F1,14 = 319.05, p < 0.001) on serum 25(OH)D levels. Levels of 
25(OH)D were significantly reduced in AVD-deficient mice (5.72 ± 0.35 nM) compared to Control 
mice (38.78 ± 1.82 nM). As expected, the AVD-deficient mice had levels of 25(OH)D at the lower 
level of detection. 
5.3.2 Differentiated proteins 
This study identified 2,648 proteins, 1,373 of these proteins had 2 or more peptides identified with 
> 95 % confidence. All other proteins had less peptides (0 or 1) identified with 95 % confidence. 
Levels of 45 proteins were significantly different between control and AVD-deficient mice (p < 
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0.05) and 32 of these had a FC >1.5 (Figure 5.1). Of the significantly different proteins, 15 proteins 
were up-regulated following AVD deficiency and 30 proteins were down-regulated (Table 5.1).  
                      
Figure 5.1 A volcano plot of all the proteins identified with more than two peptides 
The green dots show proteins that were down-regulated with AVD deficiency and the red dots are proteins 
that were up-regulated with AVD deficiency. Dots shown above the dotted line are significantly different 
between controls and AVD-deficient mice (p < 0.05).  
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Table 5.1 Proteins significantly different between control and AVD-deficient BALB/c mice 
Proteins significantly different (p <0.05) in order from lowest p-value to highest. 
Protein 
No. 
Accession 
No. Gene Name Protein Name Peptides % Cov  
Mean 
Cont 
Mean 
AVD FC P-value 
422 Q9WV80 Snx1 Sorting nexin-1  3 5.75 1.0001 1.2605 1.2603 0.001 
1007 Q99LI8 Hgs  
Hepatocyte growth factor-regulated tyrosine kinase 
substrate  4 3.23 1.0047 0.7119 -1.4112 0.002 
1374 Q56A07 Scn2b Sodium channel subunit beta-2  2 5.58 0.8280 1.2618 1.5238 0.002 
1063 P63325 Rps10 40S ribosomal protein S10  2 13.94 1.2953 2.3771 1.8351 0.003 
673 O54774 Ap3d1 AP-3 complex subunit delta-1  6 3.67 1.2388 0.6064 -2.0427 0.005 
984 Q9R0P5 Dstn  Destrin  3 15.15 0.7890 1.7844 2.2615 0.005 
1189 Q9Z2D6 Mecp2 Methyl-CpG-binding protein 2  2 3.31 1.0342 0.6078 -1.7015 0.005 
163 Q8BGQ7 Aars  Alanine--tRNA ligase, cytoplasmic  8 6.71 1.0410 0.7817 -1.3316 0.006 
747 Q61595 Ktn1  Kinectin  3 1.58 1.0268 0.5136 -1.9992 0.008 
1241 Q9CYR6 Pgm3  Phosphoacetylglucosamine mutase 3 4.98 0.9864 0.7734 -1.2754 0.008 
329 Q9D051 Pdhb  
Pyruvate dehydrogenase E1 component subunit 
beta 5 10.03 0.7227 1.4883 2.0593 0.008 
1420 Q3UBX0 Tmem109  Transmembrane protein 109  3 7.41 1.0633 0.6594 -1.6125 0.008 
1745 Q8VDP6 Cdipt  
CDP-diacylglycerol--inositol 3-
phosphatidyltransferase  2 4.7 0.9876 1.6796 1.7006 0.009 
1593 Q9WV54 Asah1  Acid ceramidase  2 3.05 0.8656 1.3823 1.5969 0.010 
732 Q60605 Myl6 Myosin light polypeptide 6  4 21.85 0.9320 0.3505 -2.6588 0.010 
1069 Q9D883 U2af1  Splicing factor U2AF 35 kDa subunit  2 8.79 0.7820 0.4190 -1.8663 0.010 
553 Q68EF6 Begain Brain-enriched guanylate kinase-associated protein  3 5.50 0.9216 0.4622 -1.9936 0.014 
1104 P27671 Rasgrf1 Ras-specific guanine nucleotide-releasing factor 1  3 2.46 0.9780 0.6214 -1.5738 0.015 
631 P15105 Glul  Glutamine synthetase 4 8.58 0.8174 1.4467 1.7698 0.016 
667 Q9CXZ1 Ndufs4  
NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 4 2 12.00 1.0614 0.5591 -1.8983 0.016 
558 Q8C8N2 Scai Protein SCAI  3 7.10 0.8066 1.2477 1.5468 0.017 
1272 Q9ES28 Arhgef7 Rho guanine nucleotide exchange factor 7  2 2.90 0.9912 0.5186 -1.9114 0.018 
287 P63024 Vamp3  Vesicle-associated membrane protein 3  6 38.83 0.9981 0.5565 -1.7936 0.020 
538 Q9CYZ2 Tpd52l2 Tumor protein D54  3 18.18 0.9264 0.4654 -1.9906 0.021 
45 P60469 Ppfia3 Liprin-alpha-3 11 9.88 1.0726 0.8688 -1.2345 0.024 
1608 O54724 Ptrf  Polymerase I and transcript release factor 2 4.59 1.1661 0.6941 -1.6800 0.024 
1030 P51855 Gss Glutathione synthetase  4 7.38 0.8774 0.5838 -1.5029 0.025 
263 P12023 App  Amyloid beta A4 protein 6 6.75 1.0800 0.7106 -1.5198 0.026 
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601 Q8C854 Myef2  Myelin expression factor 2 2 3.89 1.0670 1.7657 1.6548 0.029 
529 O35874 Slc1a4  Neutral amino acid transporter A 3 7.52 0.7254 1.0378 1.4306 0.030 
95 P02468 Lamc1  Laminin subunit gamma-1  9 5.41 0.9576 0.6145 -1.5582 0.031 
50 Q9QYX7 Pclo  Protein piccolo  21 3.37 1.2671 0.8413 -1.5061 0.032 
536 B1AXV0 Frrs1l  DOMON domain-containing protein FRRS1L  3 11.6 1.0615 1.2256 1.1545 0.033 
1032 P31648 Slc6a1  
Sodium- and chloride-dependent GABA transporter 
1  3 3.84 1.3463 1.7726 1.3166 0.034 
103 P09405 Ncl  Nucleolin  10 9.19 1.1258 0.6735 -1.6715 0.036 
858 Q80VP1 Epn1 Epsin-1  2 2.44 0.9593 1.3059 1.3613 0.038 
293 Q8CHU3 Epn2  Epsin-2  4 6.72 1.0502 0.6278 -1.6727 0.038 
2185 Q9D8B7 Jam3 Junctional adhesion molecule C  2 5.16 0.9084 0.5570 -1.6309 0.039 
703 Q922D8 Mthfd1 C-1-tetrahydrofolate synthase 2 2.67 0.8567 0.6992 -1.2252 0.040 
199 Q80U49 Kiaa0284  Protein KIAA0284 7 4.70 1.0813 0.6964 -1.5528 0.041 
543 P61089 Ube2n  Ubiquitin-conjugating enzyme E2 N  5 17.76 1.1432 0.8175 -1.3984 0.043 
2209 Q61290 Cacna1e  
Voltage-dependent R-type calcium channel subunit 
alpha-1E  2 0.75 1.3296 0.8312 -1.5996 0.045 
1157 Q8K010 Oplah  5-oxoprolinase 2 1.63 0.9406 1.3386 1.4231 0.048 
630 P48320 Gad2 Glutamate decarboxylase 2 2 4.44 0.8542 0.4905 -1.7416 0.048 
1444 Q924M7 Mpi  Mannose-6-phosphate isomerase  3 4.96 1.1433 0.5007 -2.2834 0.049 
Abbreviations = Accession No. is the UniProtKB protein code, % Cov = % Coverage (95 CI), FC = Fold Change, Cont = Control AVD = AVD-deficient 
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5.3.3 Pathway and functional analysis 
5.3.3.1 Canonical Pathways 
Analysis using IPA showed the top canonical pathway affected by AVD deficiency as the γ-
glutamyl cycle (p = 0.0004) (Table 5.2), which is involved with the synthesis of glutathione, 
biosynthesis of reductants and may be involved with amino acid transport (Vina et al., 1989). Other 
identified significant canonical pathways were Glutamine Biosynthesis I (p = 0.002), Glutamate 
Receptor Signaling (p = 0.006), Glutathione Biosynthesis (p = 0.006) and GABA Receptor 
Signaling (p = 0.008). See Table 5.2 for the full list of significant (p < 0.01) canonical pathways.  
Table 5.2 Significant canonical pathways identified using Ingenuity Pathway Analysis 
Significant (p < 0.01) canonical pathways in order of significance. Ratio values are the number of proteins 
dysregulated out of the number of proteins in the pathway. 
Canonical Pathways p-value Ratio values 
γ-glutamyl Cycle        0.0004 0.13 
Glutamine Biosynthesis I        0.002 1.00 
D-mannose Degradation        0.002 1.00 
Epithelial Adherens Junction Signaling        0.003 0.02 
Glutamate Dependent Acid Resistance        0.004 0.50 
Tight Junction Signaling        0.005 0.02 
Sertoli Cell-Sertoli Cell Junction Signaling        0.005 0.02 
Glutamate Receptor Signaling        0.006 0.04 
Glutathione Biosynthesis        0.006 0.33 
GABA Receptor Signaling        0.008 0.03 
Agrin Interactions at Neuromuscular Junction        0.008 0.03 
 
5.3.3.2 Bio Functions 
The top six most significant bio functions associated with the dataset were ‘Small Molecule 
Biochemistry’ (p-value 0.000001 – 0.009, 19 molecules), ‘Cell-To-Cell Signaling and Interaction’ 
(p-value 0.000001 – 0.009, 17 molecules), ‘Molecular Transport’ (p-value 0.000001 – 0.009, 17 
molecules), ‘Cellular Assembly and Organisation’ (p-value 0.000002 – 0.009, 15 molecules), 
‘Amino Acid Metabolism (p-value 0.000002 – 0.008, 10 molecules) and ‘Behaviour’ (p-value 
0.000002 – 0.009, 10 molecules). These bio functions are listed in Table 5.3. 
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Within these significant bio functions, IPA identified a number of biological processes associated 
with the dysregulated proteins including release of amino acids and neurotransmitters, uptake and 
metabolism of amino acids, plasticity of synapse, quantity of vesicles and synapses, retraction of 
dendrites and remodeling of actin filaments; as well as behaviours involved in emotion, contextual 
conditioning, fear, and learning and memory. For a list of the most significant (p < 0.001) functions 
associated with the dysregulated proteins refer to Table 5.3.  
5.3.3.3 Networks 
The most significant biologically relevant network (Figure 5.2, score 69 and 26 proteins) involved 
functions corresponding to ‘Behaviour’, ‘Cellular Assembly and Organisation’ and ‘Cell 
Morphology’. 
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Table 5.3 The top six most significant bio functions identified using Ingenuity Pathway Analysis 
Including detailed lists of biological processes that may be impacted by the dysregulated proteins within each 
bio function to p < 0.001. If a biological process was identified in two bio functions, it is still only listed 
once. 
Bio Functions p-value  No. of Molecules 
Small Molecule Biochemistry 0.000001 – 0.009 19 
 - release of neurotransmitter  - 0.000001 6 
 - release of amino acids  - 0.000002 5 
 - metabolism of amino acids  - 0.00003 5 
 - modification of L-glutamic acid  - 0.00009 2 
 - transport of amino acids  - 0.0002 4 
 - uptake of amino acids  - 0.0004 3 
 - synthesis of amino acids  - 0.005 3 
 - metabolism of glutamine  - 0.005 2 
 - release of L-glutamic acid  - 0.005 3 
 - accumulation of ceramide  - 0.005 2 
 - secretion of catecholamine  - 0.006 3 
Cell-To-Cell Signaling and Interaction 0.000001 – 0.009 17 
 - binding of lymphoma cell lines  - 0.00007 3 
 - plasticity of synapse  - 0.0001 4 
 - quantity of synapse  - 0.0004 3 
 - binding of carcinoma cell lines  - 0.0005 2 
 - neurotransmission  - 0.0006 6 
Molecular Transport 0.000001 – 0.009 17 
 - secretion of molecule  - 0.00001 9 
 - transport of molecule  - 0.0003 13 
Cellular Assembly and Organisation 0.000002 – 0.009 15 
 - quantity of vesicles  - 0.000002 5 
 - quantity of synaptic vesicles  - 0.0001 3 
 - retraction of dendrites  - 0.0002 2 
 - translocation of vesicles  - 0.0003 2 
 - retraction of neuritis  - 0.0003 3 
 - remodeling of actin filaments  - 0.0003 2 
 - quantity of synapse  - 0.0003 3 
 - enlargement of endosomes  - 0.0004 2 
 - secretion of vesicles  - 0.0008 2 
Amino Acid Metabolism 0.000002 – 0.008 10 
Behaviour 0.000002 – 0.009 10 
 - emotional behaviour  - 0.000002 7 
 - contextual learning  - 0.00001 2 
 - contextual conditioning  - 0.00004 4 
 - conditioning  - 0.0001 5 
 - cued conditioning  - 0.0002 3 
 - fear  - 0.0003 3 
 - long-term memory  - 0.0003 3 
 - active avoidance response  - 0.0003 2 
 - discrimination  - 0.0005 2 
 - startle response  - 0.0007 3 
 - spatial learning  - 0.0009 4 
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Figure 5.2 The top biologically relevant network identified by Ingenuity Pathway Analysis  
The network impacts on functions corresponding to ‘Behaviour’, ‘Cellular Assembly and Organisation’ and 
‘Cell Morphology’. Red denotes proteins up-regulated and green denotes proteins that are down-regulated in 
the dataset. 
 
5.4 Discussion 
This study has shown that the expression levels of 45 proteins have been altered in the hippocampus 
with AVD deficiency. IPA has implicated a number of canonical pathways affected by AVD 
deficiency including the γ-glutamyl cycle, important for the production of glutathione, an important 
antioxidant; and glutamate and GABA receptor signaling and glutamine biosynthesis. Furthermore, 
IPA has identified some key biological functions that may be affected by AVD deficiency including 
small molecule biochemistry, cell-to-cell signaling and interaction, molecular transport, cellular 
assembly and organisation, amino acid metabolism and behavioural outcomes. 
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5.4.1 γ-glutamyl cycle 
The top recognized pathway altered by AVD-deficiency was the γ-glutamyl cycle with significant 
changes to the level of two enzymes; glutathione synthetase was down-regulated and 5-
oxoprolinase was up-regulated as shown in Figure 5.3. A secondary significant canonical pathway 
was also identified involving glutathione, which was glutathione biosynthesis. We have previously 
published a reduction in glutamate levels and an increase in glycine levels with AVD deficiency in 
whole brain (Groves et al., 2013) and these changes have also been added to Figure 5.3. 
Furthermore, vitamin D treatment has previously been shown to up-regulate γ-glutamyl 
transpeptidase and increase glutathione levels in vitro (Garcion et al., 1999) (also noted on Figure 
5.3). 
5-oxoprolinase may be up-regulated in an attempt to compensate for lower glutamate levels and 
with a reduction in glutamate plus a reduction in the level of glutathione synthetase; this would 
theoretically lead to lower levels of glutathione. Glutathione has many biological functions 
including detoxification of free radicals, organic peroxides and reactive non-radicals. It is also 
important in the maintenance of the cellular thiol pool and for regeneration of other antioxidants, 
such as vitamin C (Dringen, 2000). Importantly, a reduction in glutathione would lead to increased 
levels of oxidative stress. 
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Figure 5.3 The impact of AVD deficiency on the γ-glutamyl cycle 
Elevated levels of glycine and reduced levels of glutamate were observed in AVD-deficient BALB/c mice in 
a previous study (Groves et al., 2013). In vitro treatment of vitamin D has previously been shown to 
stimulate γ-glutamyl transpeptidase, which resulted in increased levels of glutathione (Garcion et al., 1999). 
Finally, in this study we observed a decrease in glutathione synthetase and an increase in 5-oxoprolinase. 
Figure modified from Singh et al. (2013). 
 
5.4.2 Glutamate, glutamine and GABA 
Four out of the eleven significant canonical pathways identified by IPA, involved glutamate, 
glutamine and GABA. Previous research has shown a reduction in levels of glutamine and 
glutamate with AVD deficiency in BALB/c mice in whole brain, with increased levels of GABA 
(Groves et al., 2013). The results of the proteomics in this study have shown that AVD-deficiency 
has up-regulated glutamate-ammonia ligase. As glutamine is essential for many cellular and 
metabolic processes (Smith & Wilmore, 1990; Vander Heiden et al., 2009), low levels of glutamine 
would stimulate the enzyme, glutamate-ammonia ligase to be up-regulated in an attempt to increase 
glutamine levels.  
The proteomic results also show an up-regulation in the transporter responsible for the re-uptake of 
glutamate from the synaptic cleft and in the transporter responsible for re-uptake of GABA. In 
addition, the proteomics has shown convergent evidence that GAD65 is down-regulated, as we have 
seen previously in AVD-deficient mice (Groves et al., 2013). Within the significant bio function 
‘Small Molecule Biochemistry’ the dysregulated proteins could have significant downstream effects 
on the release of neurotransmitters. For example, reductions in VAMP3 and CACNA1E, both 
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proteins down-regulated in this study, have previously been shown to decrease release of glutamate 
from astrocytes and glutamatergic neurons respectively (Long et al., 2009; Liu et al., 2011).  
5.4.3 Synaptic Plasticity 
Dysregulated proteins in the proteomics dataset may also have significant effects on other 
biological processes including quantity of synaptic vesicles, plasticity and quantity of synapses, 
retraction of dendrites and remodeling of actin filaments. For example, reduced MECP2, down-
regulated in this study, has been previously shown to decrease the number of synapses formed, lead 
to a reduction in synaptic response and an increased retraction of dendrites (Chao et al., 2007; 
Nguyen et al., 2012). Furthermore, reductions in APP, MECP2, PPFIA3 and RASGRF1, all 
proteins down-regulated in the proteomics, have previously been reported to reduce synaptic 
plasticity (Schoch et al., 2002; Moretti et al., 2006; Tomiyama et al., 2010; Lee et al., 2011).  
RASGRF1 normally facilitates neurite outgrowth in response to NGF and BDNF (Talebian et al., 
2013). NGF has previously been shown to be upregulated in vitro in response to 1,25(OH)2D 
(Brown et al., 2003) and reduced in neonatal mice exposed to developmental vitamin D deficiency 
(Feron et al., 2005). Many of the same proteins involved in ‘Cellular Assembly and Organisation’ 
were also involved with the ‘Behaviour’ biological processes. For example, reductions in MECP2 
and RASGRF1 have been shown to impair spatial learning and memory (Giese et al., 2001; Moretti 
et al., 2006). 
5.4.4 Integrated Network 
IPA has indicated that there is a significant network of associated dysregulated proteins that impact 
on ‘Behaviour’, ‘Cellular Assembly and Organisation’, and ‘Cell Morphology’. These results 
suggest that AVD deficiency may lead to altered behaviour, including impaired learning and 
memory, through molecular processes affecting cellular assembly and organisation, such as synapse 
formation and plasticity and changes in dendritic arborisation.  
5.4.5 Developmental versus adult vitamin D deficiency 
Hippocampal proteomic analysis has previously been performed in a DVD deficiency rat model 
using 2D gel electrophoresis (Almeras et al., 2007). In their study 23 differentially expressed 
proteins were identified in the hippocampus; however none of these proteins were identified as 
significantly altered in the current study of AVD deficiency. This may be due to the differences in 
the models, for example the use of Sprague Dawley rats versus BALB/c mice, or due to the 
difference in the experimental procedures and sample preparation. A comparison study of 2D 
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difference gel electrophoresis, cleavable isotope-coded affinity tags and iTRAQ proteomics showed 
limited overlap of differentially expressed proteins between the three methods suggesting that they 
are complementary in nature and cannot be used interchangeably (Wu et al., 2006).  
Despite no overlap in differentially expressed proteins between DVD deficiency and AVD 
deficiency, there were common dysregulated biological functions between the two models, which 
included redox balance, neurotransmission, synapse plasticity, and cytoskeleton maintenance 
(Almeras et al., 2007). This may suggest that the role vitamin D plays in development and 
adulthood may be via similar biological mechanisms. 
5.4.6 Limitations and Strengths 
The purpose of this study was to generate hypotheses by finding links between vitamin D 
deficiency and specific pathways or biological processes that can be followed up in future studies. 
For this reason only a small number of male mice were used and we targeted a very specific area of 
the brain, the hippocampus. For a more complete analysis of protein changes following AVD 
deficiency, other brain areas should also be analysed. Furthermore, increasing the sample size may 
provide a greater number of dysregulated proteins to follow up. 
One of the drawbacks to using iTRAQ proteomics is the limited availability of isobaric tags. There 
are eight different isobaric tags available and therefore this limits the number of samples in any run 
to eight. Performing separate runs would introduce variability to the experiment and therefore for 
the purpose of hypothesis generation it was decided to perform one run with eight samples. Despite 
this drawback, iTRAQ has been shown to be much more sensitive than both 2D difference gel 
electrophoresis and cleavable isotope-coded affinity tags, identifying significantly more peptides 
from each protein and a greater number of differentiated proteins without affecting accuracy (Wu et 
al., 2006). 
The results from this preliminary proteomic study have provided a number of exciting pathways 
that might be affected by AVD deficiency to follow up on. However, the protein expression 
changes have not been validated, either by replication of the iTRAQ experiment or by an alternative 
method such as through western blot confirmation or by performing ELISA’s on a few key proteins. 
Therefore, the results must be considered as preliminary results and in need of technical, proteomic 
or biological validation of the candidate proteins. For example, a key pathway identified following 
analysis was that of the γ-glutamyl cycle, suggesting that glutathione levels would be reduced by 
AVD deficiency, and this is explored in Chapter 6.  
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The proteomic results have provided a list of up and down-regulated proteins. However, this study 
cannot tell you if these proteins are altered by vitamin D directly, altered through down-stream 
effects of vitamin D-targeted gene changes, or as a result of compensatory effects. Following up the 
individual pathways identified through IPA will provide a more complete picture on how these 
protein changes evolved.  
5.4.7 Future Directions 
This study has shown that multiple pathways that involve glutathione, glutamate and GABA have 
been dysregulated by AVD deficiency, including glutathione biosynthesis, glutamate and GABA 
receptor signaling and glutamine biosynthesis. Furthermore, IPA has implicated AVD deficiency in 
changes to neurotransmission and amino acid metabolism. Changes to amino acid metabolism that 
alter the availability of glutamate and glutamine could then have downstream effects on 
neurotransmission and glutathione maintenance. Alternatively, elevated oxidative stress could 
deplete glutathione stores, leading to reductions in glutathione components, such as glutamate, 
which would then lead to impaired neurotransmission. Future experiments should address these 
issues. For example, if oxidative stress is driving all these changes, treating AVD-deficient mice 
with n-acetylcysteine, a molecule known to increase glutathione levels (De Rosa et al., 2000), 
should correct reductions in glutamate levels and changes in neurotransmission. 
Future studies should also test markers of oxidative stress. For example, 8-oxo-deoxyguanosine is a 
marker of DNA oxidation and is commonly assessed using immunohistological techniques (Steullet 
et al., 2010). Furthermore, if changes seen here, to the γ-glutamyl cycle and glutathione 
biosynthesis, lead to increased oxidative stress, this could leave AVD-deficient mice more 
vulnerable to secondary insults or exacerbate underlying conditions (Cui et al., 2013a).  
One important consequence of both oxidative stress and deficits in glutathione levels that has been 
repeatedly reported in the literature is impairments to parvalbumin (PV) interneurons (Steullet et 
al., 2010; Cabungcal et al., 2013a; Hardingham & Do, 2016). PV interneurons are fast-spiking 
interneurons with high metabolic demand and therefore may be more susceptible to oxidative stress 
compared to other neurons (Cabungcal et al., 2013b). Future studies should test if AVD deficiency 
leads to changes in PV interneurons in the hippocampus and PFC using immunohistochemistry. 
Furthermore, if alterations in PV interneurons are observed, impairments to gamma oscillations may 
be responsible for the cognitive deficits observed with AVD deficiency (Hardingham & Do, 2016). 
The effects of AVD-deficiency on hippocampal-dependent learning and memory are explored in 
Chapter 6 and future experiments should also be conducted to assess changes in synaptic plasticity 
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and dendritic arborisation in the animals to pursue the findings in this study. This could elucidate 
one possible mechanism behind the effects of AVD deficiency.   
5.5 Conclusion 
AVD deficiency in male BALB/c mice has impacted on a number of canonical pathways involving 
glutathione, glutamate, glutamine and GABA. AVD-deficient mice have a number of proteins 
dysregulated involved in amino acid metabolism, transport, uptake, and neurotransmitter release. 
This study has provided convergent evidence on the effects of AVD deficiency on glutamatergic 
and GABAergic neurotransmission. Finally, the proteomics results has also elucidated other 
biological pathways, processes and functions that may be impacted by AVD deficiency and 
therefore generated a number of hypotheses that need to be followed up in future studies.  
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Chapter 6 Reductions in Glutathione and Impairments in a Hippocampal-
Dependent Learning and Memory Task in Male AVD-Deficient BALB/c 
Mice 
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6.1 Introduction 
There is increasing evidence from epidemiological studies that vitamin D deficiency is associated 
with cognitive impairments, particularly in older individuals (Balion et al., 2012). Furthermore, 
epidemiological studies have shown that a decrease in cognitive performance and decline is 
associated with increased oxidative stress in the elderly (Berr et al., 2000; Pratico et al., 2002; 
Baierle et al., 2015). For example, a study in elderly patients from Brazil reported a significant 
association between markers of oxidative stress and cognitive parameters, as measured by the 
MMSE, Verbal fluency and the Boston Naming Test (Baierle et al., 2015). Another study showed 
that cognitive decline over a four-year period was associated with increased markers of oxidative 
stress and a lower antioxidant status (Berr et al., 2000). Therefore, it is possible that increased 
oxidative stress may lead to cognitive impairments. 
Vitamin D has been shown to have a role in antioxidant metabolism via downregulation of the 
expression of iNOS (Garcion et al., 1998) and regulation of gamma glutamyl transpeptidase 
(Garcion et al., 1999), an enzyme important in the glutathione pathway. More recently, an in vivo 
study has shown that treatment with 1,25(OH)2D leads to upregulation of glutathione reductase and 
glutamate cysteine ligase, enzymes involved in glutathione synthesis, and to an increase in 
glutathione levels (Jain & Micinski, 2013). In addition, two proteins involved in the production of 
glutathione were altered by AVD deficiency, identified in the proteomics analysis of the 
hippocampus in Chapter 5, suggesting that the biosynthesis of glutathione would be impaired. 
Therefore, it is likely that AVD-deficient BALB/c mice have reductions in glutathione levels and 
that this could contribute to cognitive impairment. 
Furthermore, proteomic analysis identified a number of dysregulated proteins within the 
hippocampus in AVD-deficient BALB/c mice that have functions in cellular assembly and 
organisation, including synapse formation and plasticity, and changes in dendritic arborisation 
(Chapter 5). Dysregulation of these proteins, as seen with AVD deficiency, are predicted to impair 
spatial learning and memory, among other behaviours.  
The active place avoidance (APA) task is a spatial learning and memory task for rodents that is 
dependent on avoidance of an aversive event. This is different to the 5C-SRT task that was used in 
Chapter 2, which was reward based and required food-restriction. The APA has greater complexity 
than the more widely used Morris water maze, and yet only requires a single trial per day 
(Cimadevilla et al., 2000; Vukovic et al., 2013). The APA test has been shown to be hippocampal-
dependent during both acquisition and for performance once the procedure is learnt (Cimadevilla et 
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al., 2001). This is due to the continuous rotation of the apparatus and the animal having to 
continually update their place information in relation to the shock zone (Cimadevilla et al., 2000; 
Vukovic et al., 2013). Furthermore, the role of hippocampal neurogenesis has been more clearly 
established for the acquisition of the APA, as seen in a study in which ablation of immature neurons 
produced deficits in acquiring the task (Vukovic et al., 2013).  
There is currently no published data on using the APA in BALB/c mice and therefore one aim of 
this study was to establish the APA in the BALB/c strain for the first time, to ensure that they are 
capable of learning this task. We have shown that AVD deficiency is not associated with altered 
adult hippocampal neurogenesis, in the form of altered proliferation or the survival of newborn 
neurons within the dentate gyrus of the hippocampus (Chapter 4), however, this does not preclude 
an effect of AVD deficiency on spatial learning and memory via oxidative stress, or by other 
mechanisms highlighted by the analysis of the proteomics data reported in Chapter 5.  
The primary aim of this study was to assess the effects of AVD deficiency in male BALB/c mice on 
their performance in a hippocampal-dependent learning and memory task, the APA. The hypothesis 
was that male AVD-deficient BALB/c mice would show impairments on the APA. A secondary 
aim of this study was to assess glutathione levels using HPLC, with the hypothesis that there would 
be a reduction in glutathione levels in AVD-deficient mice. We have previously showed that males, 
but not females, were impaired on the 5C-SRT task (Chapter 2). Therefore, the current experiments 
focused on the effects of AVD deficiency in male mice. 
6.2 Materials and methods 
6.2.1 Animals and housing 
Thirty-eight male BALB/c mice (Animal Resources Centre, Canning Vale, WA, Australia) were 
included in this study in two cohorts. The first cohort included 23 (n = 11 control and 12 AVD-
deficient mice) nine-week-old male BALB/c mice and the second cohort included 15 (n = 8 control 
and 7 AVD-deficient mice) ten-week-old mice. Mice were obtained and housed in groups of 4 as 
detailed previously in Chapter 2. Cohort 1 mice underwent testing on the APA for five days, at 
nine-weeks old, prior to being placed on diet at 10-weeks old. After the APA testing, the mice were 
placed into dietary groups, ensuring that there was no significant difference between the two groups 
and at 20-weeks old underwent re-testing on the APA to test for the effects of AVD deficiency.  
At 10-weeks of age, all mice (including the mice from Cohort 2) were placed on either a control 
diet or a vitamin D-deficient diet as detailed in Chapter 2, until they were 20-weeks old. The mice 
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were maintained on a 12-hour light-dark cycle (lights on at 07:00 h) with ad libitum access to food 
and water. They were housed under incandescent lighting free from UVB radiation. All 
experimental work was performed with approval from the University of Queensland Animal Ethics 
Committee, under the guidelines of the National Health and Medical Research Council of Australia.  
6.2.2 Active place avoidance 
The apparatus for the APA (Bio-Signal Group, NY, USA) consisted of an elevated arena with a grid 
floor surrounded by a 30 cm high transparent circular barrier, producing an enclosed arena 77 cm in 
diameter. The arena was located in a room with visual cues placed on the walls. The arena, 
including the grid floor, rotated clockwise at a speed of 1 rpm and an electric shock could be 
delivered through the grid floor. The position of the animal in the arena was tracked using an 
overhead camera linked to Tracker software (Bio-Signal Group, NY, USA). During trials, a mouse 
was placed in the arena and trained to avoid a 60° shock zone, the positioning of which was kept 
constant in relation to the room and to the external visual cues; the mouse's “start” position was 
always opposite the shock zone, near the barrier of the arena (Figure 6.1).  
On Day 1 (habituation day), the mice were free to explore the arena with no shock given, for 5 min. 
On the next 4 consecutive days, Days 2 to 5 (test days), entrance into the shock zone led to the 
delivery of a brief foot shock (500 ms, 60 Hz, 0.5 mA). If, after the initial shock, the animal 
remained in the shock zone, further shocks were delivered at 1.5 s intervals until the animal moved 
out of the zone. Each test session lasted 10 min and recorded tracks were analysed offline using 
Track Analysis software (Bio-Signal Group, NY, USA). To assess the extent of learning, the 
following parameters were measured: number of foot shocks delivered during the 10 min trial, 
latency to first entry into the shock zone, and the distance travelled during the trial.  
The second APA test that was performed at 20-weeks old, had the location of the shock zone and 
start zones moved, compared to the initial APA at 9-weeks old, to increase the difficulty of the task. 
The extra-maze cues were also changed for the second APA test (Figure 6.1). 
 96 
 
Figure 6.1 The active place avoidance arena layout 
The layout in (a) was used pre-dietary manipulation. The location of the shock zone and entry position was 
moved as per layout in (b) for the second APA test. The extra-maze cues were also changed for the second 
APA test. 
 
6.2.3 Tissue collection 
Mice from Cohort 1 were anaesthetized by an i.p injection of Lethabarb at 100 mg/kg body weight 
24 h after the APA and transcardially perfused with 40 ml of PBS and 40 ml of 4 % PFA in PBS. 
The brains were removed and post-fixed in 4 % PFA for 24 h before being stored in PBS azide for 
future analysis not included in this thesis. 
Mice from Cohort 2 were euthanized by i.p injection of an overdose of Lethabarb at 4 ml/kg body 
weight, followed by decapitation. The whole brain was removed and the left hand cerebrum was 
collected using free-hand dissection. Tissue was frozen on dry ice and stored at -80° C until further 
processing for HPLC analysis. 
6.2.4 High performance liquid chromatography analysis 
Tissue extracts were analysed for total glutathione based on the method described by (Khan et al., 
2011). Basically, analyses were performed on an Agilent 1100 series HPLC system equipped with a 
Coulochem III electrochemical detector with a glassy carbon electrode (ESA Inc., MA, USA). 
Analyte separation was performed on a Jupiter C18 5 µm 300A column (4.6 x 250 mm, 
Phenomenex, NSW, Australia) using an isocratic mobile phase consisting of 3 % methanol and 0.1 
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% trifluoroacetic acid in water. The column flow rate was 0.7 ml/min and analytes were detected 
using an electrochemical detector in DC mode, using a detector potential of 900 mV and 1000 mV 
potential for the guard cell. The data was acquired and processed using Chemstation software 
(Agilent, CA, USA). 
6.2.5 Statistical Analysis 
Results were analysed for statistical significance using SPSS (version 20.0) software. All data were 
analysed for the main effects of Diet (control or AVD-deficient) using ANOVA or, where 
appropriate, repeated measures ANOVA. Significant differences (p < 0.05) were followed up with 
post-hoc t-tests. 
6.3 Results 
6.3.1 Active place avoidance – pre Dietary manipulation 
All mice learnt to avoid the shock zone over the four test days (F1,22 = 34.40, p < 0.001, Figure 6.2c) 
and their latency to enter the shock zone was significantly increased over the four days of testing 
(F1,22 = 13.08, p < 0.001, Figure 6.2a). The distance travelled during the 10 min test was 
significantly reduced over the course of the four test days for all mice (F1,22 = 29.29, p < 0.001, 
Figure 6.2e). 
6.3.2 Active place avoidance – post Dietary manipulation 
There was a significant effect of Diet (F1,21 = 15.52, p = 0.001, Figure 6.2b) on the latency to enter 
the shock zone over the test days, with controls showing an increased latency compared to AVD-
deficient mice. There was no significant effect of Diet (F1,21 = 0.60, p = 0.446) on the maximum 
time to avoid shock over the course of the test days but there was a significant effect of Diet (F1,21 = 
5.30, p = 0.032) on Day 2, with a shorter maximum time to avoid in the AVD-deficient mice 
(209.18 s ± 31.93 in Controls and 124.67 s ± 19.52 in AVD-deficient mice). 
The number of shocks received by all mice was significantly reduced over the test days (F1,21 = 
47.49, p < 0.001). Furthermore, there was no significant effect of Diet (F1,21 = 2.62, p = 0.121, 
Figure 6.2d) on the number of shocks over the four test days. On the final test day, Day 5, the 
number of shocks failed to reach significance (F1,21 = 4.10, p = 0.056). However, when analysing 
the first 5 min of Day 5, AVD-deficient mice received significantly more shocks compared to 
controls (F1,21 = 6.27, p = 0.021) (1.09 shocks ± 0.28 in controls and 3.83 shocks ± 1.01 in AVD-
deficient mice), but not in the second 5 min (F1,21 = 0.01, p = 0.947) of Day 5 (1.55 shocks ± 0.41 in 
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controls and 1.58 shocks ± 0.38 in AVD-deficient mice). Furthermore, there was no significant 
difference in the number of shocks between the first 5 min and the second 5 min by control mice 
(F1,10 = 1.10, p = 0.320). However, there was a significant reduction in shock number for AVD-
deficient mice in the second 5 min (F1,11 = 5.75, p = 0.035), suggesting that they were still learning 
how to avoid the shock zone. 
There was no significant main effect of Diet (F1,21 = 2.95, p = 0.180) on the distance travelled over 
the five days of testing. There was however, a significant Diet x Day interaction (F1,21 = 3.85, p = 
0.015, Figure 6.2f), with AVD-deficient mice exhibiting hyperlocomotion compared to controls 
towards the end of the testing. On Day 1, there was no significant effect of Diet (F1,21 = 1.89, p = 
0.184) on the distance travelled during habituation to the arena. On test days, when shock was 
applied to the shock zone, there was still no effect of Diet (F1,21 = 0.19, p = 0.667) on the distance 
travelled on Day 2. However, there was a significant effect of Diet (F1,21 = 5.55, p = 0.028) over the 
four test days, with AVD-deficient mice travelling more than the controls. 
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Figure 6.2 Results for the active place avoidance 
The results of the APA prior to dietary manipulation are shown in a, c and e with the results of the second 
APA post-dietary manipulation shown in b, d and f. During the first APA, all mice increased their latency to 
enter the shock zone over the four test days (a) and in the second APA, there was a significant difference 
between controls and AVD-deficient mice in their latency to enter the shock zone (b), AVD-deficient mice 
had a reduced latency compared to controls. All mice significantly reduced the number of shocks they 
received over the four test days (during both APA tests) and overall there was no significant effect of Diet (c 
and d). Finally, the distance travelled in the arena is shown in e and f. During the second APA post-dietary 
manipulation, AVD-deficient travelled further than controls. Mean ± SEM (n = 11-12, * p < 0.05) 
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Assessing the difference between the number of shocks received on the final day of testing before 
being placed on diet, compared to the number of shocks on the final day of testing after dietary 
manipulation, there was a significant Diet x Day (F1,21 = 5.14, p = 0.034, Figure 6.3) effect. AVD-
deficient mice received significantly more shocks during the second APA test compared to control 
mice. 
 
Figure 6.3 Final day of the active place avoidane 
The difference in the number of shocks received on the last day of testing pre-diet compared to post-diet. 
There was a significant increase in shocks received in AVD-deficient mice, but no significant difference in 
controls. Mean ± SEM (n = 11-12, * p < 0.05) 
 
6.3.3 Glutathione levels 
There was a significant effect of Diet (F1,13 = 26.43, p < 0.001, Figure 6.4) on total glutathione 
levels, with a significant decrease in the levels of glutathione in AVD-deficient mice (513.27 µm ± 
53.72 for controls and 210.91 µm ± 12.22 for AVD-deficient mice).  
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Figure 6.4 Total glutathione levels 
Total glutathione levels in brain tissue from the left cerebrum. AVD-deficient mice had a significant 
reduction in total glutathione levels. Mean ± SEM (n = 7-8 * p < 0.05) 
 
6.4 Discussion 
I have established for the first time that BALB/c mice are capable of learning the APA task. 
Furthermore, this study has shown that AVD-deficient male mice have impaired performance on 
this task. As a secondary aim, total brain glutathione was measured in a separate cohort of male 
mice, showing that AVD-deficient mice have a significant reduction of glutathione. The mice 
underwent testing on the APA prior to starting the dietary manipulation, this was to ensure that 
BALB/c mice could learn to avoid the shock zone and show a significant improvement over the 
four days. All mice successfully learned to avoid the shock zone and increased their latency to enter 
the shock zone. When the mice were retested following the dietary manipulation, the extra-maze 
cues and the location of the shock zone were changed. This was to ensure the task involved both 
memory and learning, as they were still required to learn the new cues and locations.  
After 10 weeks on the diet, in the second round of APA testing, during both habituation and on the 
first test day, there was no difference in the distance travelled in the arena. Therefore, baseline 
locomotion was not altered in the AVD-deficient mice. However, over the remaining test days, 
AVD-deficient mice exhibited hyperlocomotion compared to controls.  
Previous studies in BALB/c mice have shown that AVD deficiency enhanced their response to heat 
and produced quicker responses to shock, in an active avoidance paradigm that was without spatial 
cues (Groves et al., 2013), therefore the increased locomotion could be a response to shock. 
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However, this does not explain their decreased latency to avoid the shock zone at the start of each 
day.  
The difference in latencies to first enter the shock zone each day, between AVD-deficient mice and 
controls, could show that the consolidation of memories from one day to the next is impaired with 
AVD deficiency. Furthermore, the differences seen overall on this task between AVD-deficient 
mice and controls, suggests that while the AVD-deficient mice were able to learn the requirements 
of this task over time, their learning appears to be delayed compared to controls.  
AVD-deficiency led to a reduction in whole brain glutathione levels compared to controls. 
Glutathione is an endogenous antioxidant important for neutralising reactive oxygen species, in 
detoxification, in immune responses, and also has a wide range of cellular reactions including 
regulation of protein and gene expression (Townsend et al., 2003). Although total glutathione levels 
were measured as an indication of oxidative stress, a more complete analysis of the glutathione 
antioxidant system is now warranted. For example, measuring the ratio of oxidised to reduced 
glutathione, as well as measuring the levels of enzymes important in the antioxidant function of 
glutathione, such as glutathione peroxidase and glutathione reductase, would better indicate the 
oxidation status of the AVD-deficient mice (Urso & Clarkson, 2003). 
Alterations in glutathione homeostasis that lead to greater oxidative stress have been implicated in a 
range of neuropsychiatric and neurodegenerative diseases, including cognitive impairment (Zhao & 
Zhao, 2013; Baierle et al., 2015; Black et al., 2015). Furthermore, increased oxidative stress can 
lead to an elevated stress response, and stimulation of apoptosis pathways, resulting in ‘sick’ cells 
and ultimately cell death (Townsend et al., 2003). Increased oxidative stress can also lead to 
impairments in PV interneurons and alterations to neuronal synchronization resulting in cognitive 
deficits (Hardingham & Do, 2016). 
Following the induction of oxidative stress, synaptic membranes have been shown to have elevated 
markers of oxidative stress including lipid peroxides and protein carbonyls, and a change in 
membrane surface potential. These changes could result in reduced membrane fusion between nerve 
terminal membranes and synaptic vesicles, produce a subsequent decline in neurotransmission and 
result in impaired learning and memory (Urano et al., 1997; Fukui et al., 2002). 
Acquisition of the APA task requires adult neurogenesis as shown in the study in which ablation of 
immature neurons within the hippocampus, produced deficits in acquiring the task (Vukovic et al., 
2013). Although, we have not measured levels of immature neurons following AVD deficiency, we 
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have previously shown that levels of both proliferating cells and the survival of newborn neurons in 
the dentate gyrus of the hippocampus were not altered by AVD deficiency.  
In addition to altered glutathione biosynthesis, the results from the proteomic analysis of the 
hippocampus suggested that AVD deficiency may be impacting on branching, synapse formation 
and synapse plasticity, rather than cell numbers. Previous research has shown that increased 
dendritic arborisation and density of dendritic spines was associated with higher performance in 
spatial learning and memory tasks (Leggio et al., 2005).  
Using the Ts65Dn genetic mouse model of Down Syndrome it was shown that hippocampal-
dependent cognitive deficits were associated with lower synapse density and dendritic arbors that 
were less branched and less spinous (Kurt et al., 2004). Furthermore, there has been extensive 
research on the necessity of synaptic plasticity, long-term depression (LTD), and LTP for learning 
and memory (Elgersma & Silva, 1999), therefore, it is possible that AVD-deficient mice may have 
impairments in LTP or LTD and this should be investigated in future experiments. 
Future experiments will be needed to discover the mechanism behind AVD deficiency’s impact on 
hippocampal-dependent learning and memory. Experiments should include analysing the degree of 
dendritic arborisation of immature neurons within the hippocampus of AVD-deficient and control 
mice. Furthermore, future studies should examine changes in synapse formation and strength; as 
well as investigate how proteins shown to be dysregulated following AVD deficiency (Chapter 5) 
could lead to these changes. Finally, markers of oxidative damage should be assessed in the brain of 
AVD-deficient mice, as this may be a key mechanism in the effects of AVD deficiency. 
This study has shown that the APA can be retested in the same animals and still be sensitive to 
show an effect of AVD-deficiency, therefore this test could be used to determine if repletion of 
vitamin D could reverse the deficits seen and also be used to test possible treatments, such as 
antioxidant treatments. 
6.5 Conclusion 
With epidemiological studies showing an association between AVD deficiency and cognitive 
impairment and decline, it is important to assess and unravel this link in a rodent model. This study 
has now provided further evidence that AVD deficiency leads to cognitive impairments in male 
BALB/c mice and that AVD deficiency leads to reduced glutathione levels. The direct implication 
of oxidative stress as the mechanism for cognitive impairment should now be explored further. 
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Chapter 7 AVD Deficiency Exacerbated Impairments Caused by Social Stress 
in BALB/c and C57BL/6J Mice 
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7.1 Introduction 
Neuropsychiatric disorders such as schizophrenia have complex aetiology involving both genetic 
factors and environmental influences (McDonald & Murray, 2000). The idea that multiple factors 
may contribute to the development of a disorder, led to the creation of the ‘two-hit hypothesis’ 
(Maynard et al., 2001). However, recent genome wide association studies show that within the 
genetics of schizophrenia alone, prior to any environmental exposures, there are thousands of 
genetic variants of small effect sizes that lead to an increased risk of developing schizophrenia 
(Wray & Visscher, 2010). Moreover, there are multiple environmental risk factors that can 
influence the development of disorders. For example, epidemiological studies have identified a 
number of non-genetic risk factors for schizophrenia including pregnancy and birth complications, 
maternal infection, immigration, adverse life events, and substance abuse (McDonald & Murray, 
2000). 
Therefore, it is likely that the accumulation of multiple risk factors leads to the development of 
complex neuropsychiatric disorders. However, using animal models it is not feasible to look at 
many ‘hits’ and therefore a ‘two-hit hypothesis’ may be a more reasonable approach. For example, 
a recent study investigated the consequences of combining prenatal immune activation with stress 
during puberty in mice. They found that the prenatal insult markedly increased the vulnerability of 
offspring to subsequent stress. Furthermore, the interaction between the two ‘hits’ led to 
behavioural alterations relevant to neuropsychiatric disorders, including deficits in sensorimotor 
gating as assessed by prepulse inhibition (PPI) of the acoustic startle response (ASR) (Giovanoli et 
al., 2013).  
Epidemiological studies show that first generation, dark-skinned migrants to cold climates have 
increased risk of developing psychosis (Cantor-Graae & Selten, 2005). It was proposed that social 
stress related to being a member of a minority ethnic group in a foreign country may contribute to 
this increased risk (Dealberto, 2010). Another hypothesis given was that it may be vitamin D 
deficiency, after moving from a country with high sun exposure to one of limited exposure, that 
increased their risk of developing psychosis (Dealberto, 2010). Developmental vitamin D 
deficiency has been shown to be a risk factor for the development of schizophrenia later in life 
(McGrath et al., 2010a), however recent animal experiments have suggested that vitamin D 
deficiency during adulthood also compromises brain function.  
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7.1.1 Vitamin D’s neuroprotective properties 
Vitamin D has been shown to be neuroprotective against a range of neuronal insults including 
excitoxicity and ischemia, both directly and via regulation of NGF and GDNF (Kume et al., 2000; 
Wang et al., 2001; Wang et al., 2002b). 1,25(OH)2D treatment upregulates antioxidant molecules, 
such as glutathione and iNOS, protecting against free radicals (Garcion et al., 2002; Jain & 
Micinski, 2013). Furthermore, a recent study in PD has shown that vitamin D supplements 
prevented a decline in PD-related outcomes compared to those on placebo, suggesting a protective 
effect of vitamin D against PD. 
Vitamin D deficiency has now been shown to reduce glutathione levels in BALB/c mice, potentially 
leaving the mice at risk for increased oxidative stress (Chapter 6). Therefore, the absence of vitamin 
D could leave an individual more vulnerable to a second ‘hit’. For example, it was recently shown 
in a stroke model, that vitamin D deficient rats had greater infarct volumes compared to controls 
and this corresponded with greater impairments, post-stroke, in sensorimotor behavioural testing 
(Balden et al., 2012). Furthermore, the vitamin D deficient animals had significantly lower levels of 
IGF-1, a neuroprotectant molecule usually elevated after injury, compared to controls (Balden et al., 
2012).  
7.1.2 Modelling a two-hit hypothesis 
Social stress can be assessed in rodents using a number of different approaches, but chronic social 
defeat has been shown to have long lasting effects on behaviour and brain function (Golden et al., 
2011). Using this procedure, mice are exposed to repeated bouts of social defeat by a larger 
aggressive mouse and then further subjected to continuous psychological stress from sensory 
interaction through a clear perforated divider in their home cage (Golden et al., 2011). This protocol 
has been repeatedly shown to produce social avoidance in a subset of ‘susceptible’ mice. 
Susceptible mice show behavioural and physiological changes suggestive of depressive and anxiety 
symptoms, while ‘resilient’ mice do not (Golden et al., 2011). For example, a study in rats showed 
that socially defeated animals displayed weight loss and an enhanced and prolonged response to 
acoustic startle (Pulliam et al., 2010). 
A recent study reported that BALB/c and C57BL/6J mice show a different susceptibility to social 
defeat stress, with only the BALB/c mice exhibiting long-term social withdrawal (Razzoli et al., 
2011). Furthermore, BALB/c mice displayed greater effects of AVD deficiency when compared 
directly with C57BL/6J mice (Groves et al., 2013). AVD-deficient BALB/c mice also displayed 
enhanced acoustic startle, suggesting an altered response to stressful stimuli (Groves et al., 2013).  
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Therefore, the aim of the current study was to examine the effects of a two-hit model combining 
AVD deficiency and chronic social defeat in both BALB/c and C57BL/6J mice on behaviour, using 
a social interaction paradigm and PPI of the ASR, two tests relevant to neuropsychiatric disorders 
and psychosocial stress. It was proposed that AVD deficiency would leave the mice more 
vulnerable to the second hit of social stress, and that these effects would be greater in the 
‘susceptible’ BALB/c strain 
7.2 Materials and methods 
7.2.1 Animals and housing 
Thirty male BALB/c mice, 23 male C57BL/6J mice and 16 CD-1 male mice were used in this 
study. Ten-week-old BALB/c and C57BL/6J mice (Animal Resources Centre, Canning Vale, WA, 
Australia) were obtained and housed in groups of 4 as detailed in Chapter 2. The mice were 
assigned to either a control diet or a vitamin D-deficient diet for 10 weeks prior to the start of 
behavioural testing; and for the entire duration of the experimental procedures. Dietary 
manipulation and housing has been detailed previously in Chapter 2. The 16 CD-1 male mice 
(Animal Resources Centre, Canning Vale, WA, Australia) were used as the aggressor mice in a 
social defeat paradigm, and were obtained at 9-10 months old and housed individually in OptiMICE 
cages (Animal Care Systems, CO, USA). The CD-1 mice were maintained on standard mouse chow 
(Specialty Feeds, WA, Australia, Appendix 2). All experimental work was performed with 
approval from the University of Queensland Animal Ethics Committee (QBI/202/13/NHMRC), 
under the guidelines of the National Health and Medical Research Council of Australia. 
7.2.2 Experimental design 
BALB/c and C57BL/6J mice were tested separately, and after a minimum of 10 weeks on diet the 
mice were further separated into one of two groups for social treatment, either Separated (SEP) or 
Social Defeat (DEF). SEP mice were placed two per cage with a perforated Plexiglas divider 
between them (n=7-8 BALB/c, n=5-6 C57BL/6J). These mice were moved to a new cage daily for 
10 days, so that each day the mice were in a new cage with a new cage mate. At the end of the 10 
days, the mice remained separated until the end of behavioural testing, 2 weeks later. The DEF mice 
underwent 10 days of social defeat using the protocol described by (Golden et al., 2011) (detailed in 
Section 7.2.5) and then were housed two per cage with a perforated Plexiglas divider between them 
to the end of behavioural testing, 2 weeks later.  
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7.2.3 Body weight 
Body weight was measured on Day 1 prior to the start of the 10-day social stress paradigm and on 
Day 11 to assess the effects of the stress paradigm on food intake and body weight maintenance. 
7.2.4 Serum biochemistry 
At the completion of experimental procedures, mice were euthanized by i.p injection of an overdose 
of Lethabarb at 4 ml/kg body weight and a terminal blood sample was collected via cardiac 
puncture. Serum was collected as per the details in Chapter 4. The level of 25(OH)D was measured 
in the serum samples using liquid chromatography-tandem mass spectrometry (Sciex Instruments, 
ON, Canada) on a 4000 QTrap API AB mass spectrometer (Eyles et al., 2009a). To measure a 
range of other biochemical parameters, serum samples from 32 mice (n = 4/diet/social 
treatment/strain) were sent to IDEXX Laboratories (Brisbane, Australia). For the full list of 
biochemical parameters measured, see Table 7.2. 
7.2.5 Chronic social defeat 
Sixteen ex-breeder 9-10 month old CD-1 male mice (Animal Resources Centre, Canning Vale, WA, 
Australia) were used as aggressive residents. DEF mice from both diets were exposed to a different 
unfamiliar CD-1 resident mouse each day for 10 days, for up to 10 min of interaction. During this 
exposure all subject mice showed signs of subordination (i.e submissive postures, withdrawal, 
fleeing, lying on its back, or freezing), assessed visually by the experimenter. After the interaction 
period, subject mice were separated from the aggressive resident by placing a Plexiglas perforated 
divider (to allow sensory contact) between them in the resident’s home-cage. The mice were housed 
in this way for the next 24 h, with food and water provided ab libitum. 
7.2.6 Behavioural testing 
7.2.6.1 Social interaction test 
A modified version of the social interaction test described by (Golden et al., 2011) was used to 
measure approach/avoidance behaviour toward an unfamiliar target, 24 hours after the final defeat. 
Social interaction was measured in a 30 x 30 cm arena with a metal wire cage (12 x 5 cm x 8 cm 
high) at one end (Figure 7.1). In the first phase of the test, subjects were individually placed in the 
arena opposite the metal wire cage while it was empty and their movement was recorded for 150 s 
(habituation phase) using a USB digital camera and recording software. They were returned to their 
home-cage for 30 s. In the second phase of the test, an unfamiliar aggressive CD-1 mouse was 
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confined within the metal wire cage and the subject was placed back in the arena for a further 150 s 
and their movement was again recorded (interaction phase). The test was performed under red light 
conditions. 
The duration of the subject’s presence within the interaction zone (defined as a 5 cm wide area 
surrounding the wire cage) and in the avoidance zone (defined as the far corners opposite the metal 
cage, 7.5 cm square) (Figure 7.1) as well as the average distance of the test mouse to the centre 
point of the metal cage and the total distance travelled (cm) were obtained using Ethovision v9 
software (Noldus Information Technology, The Netherlands). 
                 
Figure 7.1 Social interaction arena layout 
 
7.2.6.2 Prepulse inhibition of the acoustic startle response 
PPI of the ASR was used to measure sensorimotor gating (Harms et al., 2008) using startle 
chambers (SR-Lab, San Diego Instruments, CA, USA), which consisted of a Plexiglass cylinder (5 
cm diameter x 12 cm long) mounted on an elevated Plexiglass base within a dark chamber. A 
speaker situated 24 cm above the cylinder was used to provide background noise within the chamber 
set to 70 dB as well as the acoustic pulses of white noise throughout the testing. 
Testing began with an acclimatisation period of 300 s of 70 dB background noise. The mice then 
underwent a total of 130 trials (26 different blocks of 5 trials). To assess within-session habituation 
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(WSH), startling pulses of 110 dB were presented at the start (post acclimatisation) and end of the 
testing. The mice were exposed to a range of pulse intensities (80, 90, 100, 110 and 120 dB) to 
measure ASR and a range of prepulse to pulse intervals (8, 16, 32, 64, 128 and 256 ms) before a 
120 dB pulse to measure PPI. The median values for each block of 5 trials were used for analysis, 
with PPI being calculated with the formula: %PPI = [(startle amplitude of ASR trial - startle 
amplitude on prepulse trial)/startle amplitude of ASR trial] x 100 (Harms et al., 2008). 
7.2.7 Statistical analysis 
Results were analysed for statistical significance using SPSS (version 20.0) software. All data were 
analysed for the main effects of Diet (control or AVD-deficient), Social Treatment (SEP or DEF), 
and Strain (C57BL/6J or BALB/c) using ANOVA or, where appropriate, repeated measures 
ANOVA. Significant differences (p < 0.05) were followed up with post-hoc student t-tests.  
7.3 Results 
7.3.1 Body Weight 
Starting body weights were not different for Social Treatment (F1,43 = 0.34, p = 0.562) and Diet 
(F1,43 = 0.40, p = 0.530) groups, but were significantly different between Strains (F1,43 = 42.91, p < 
0.001) with C57BL/6J mice weighing more than BALB/c mice. At the end of the Social Treatment, 
the change in bodyweight was significantly different for Social Treatment (F1,43 = 5.99, p = 0.019) 
but not for Strain (F1,43 = 0.93, p = 0.339) or Diet (F1,43 = 2.38, p = 0.130) groups, with DEF mice 
losing weight compared to SEP mice (Table 7.1), providing conformation that the social defeat 
protocol worked. 
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Table 7.1 Summary of results for social defeat and social interaction not included in Figure 7.2  
Mean ± SEM 
Social Defeat and  
Interaction 
BALB/c  
Control SEP 
BALB/c 
AVD SEP 
BALB/c  
Control DEF 
BALB/c  
AVD DEF 
C57BL/6J  
Control SEP 
C57BL/6J  
AVD SEP 
C57BL/6J  
Control DEF 
C57BL/6J  
AVD DEF 
Social Defeat  
- Ave Duration (s) ⎯ ⎯ 417.5 ± 13.2 382.5 ± 24.9 ⎯ ⎯ 600.0 ± 0 600.0 ± 0 
Habituation  
- Ave Dist to CD-1 (cm) 13.4 ± 1.9 14.0 ± 1.1 13.6 ± 1.9 15.1 ± 2.4 9.0 ± 1.5 10.5 ± 0.4 9.3 ± 0.8 10.5 ± 0.2 
Habituation  
- Dist travelled (cm) 599.9 ± 63.6 722.2 ± 71.5 636.6 ± 69.5 805.3 ± 98.5 774.0 ± 165.0 822.7 ± 44.0 713.9 ± 67.3 725.0 ± 43.5 
Habituation 
- Interaction Zone (s) 80.58 ± 14.03 64.16 ± 4.78 44.93 ± 10.97 50.43 ± 12.92 93.45 ± 18.14 87.02 ± 19.40 91.02 ±10.47 105.87 ± 7.20 
Habituation 
- Avoidance Zone (s) 16.88 ± 11.99 19.10 ± 8.16 6.69 ± 2.11 27.35 ± 13.77 6.06 ± 1.99 6.91 ± 1.00 5.98 ±1.85 6.96 ±1.25 
Interaction 
- Dist travelled (cm) 475.6 ± 63.0 474.8 ± 89.3 284.9 ± 34.0 175.9 ± 31.7 599.8 ± 62.1 582.4 ± 56.3 380.9 ± 75.7 493.7 ± 41.7 
Starting  
Body Weight (g) 27.4 ± 0.6 26.9 ± 0.8 25.6 ± 1.0 26.8 ± 0.4 32.3 ± 1.9 32.2 ± 0.8 33.0 ± 1.7 30.9 ± 1.4 
Finishing  
Body Weight (g) 26.9 ± 0.6 27.1 ± 0.8 23.5 ± 0.8 25.3 ± 0.8 31.5 ± 1.4 31.7 ± 0.9 27.9 ± 1.1 29.4 ± 0.7 
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7.3.2 Serum biochemistry 
There was a significant main effect of Strain (F1,43 = 152.41, p < 0.001) and Diet (F1,43 = 937.07, p < 
0.001) on 25(OH)D levels, with higher levels seen in C57BL/6J mice compared to BALB/c mice 
and higher levels in Controls compared to AVD-deficient mice, see Table 7.2 for details. As 
expected, the AVD-deficient mice had levels of 25(OH)D at the lower level of detection. 
There was a significant main effect of Strain (F1,17  > 4.38, p < 0.047) on the level of a number of 
other biochemical parameters including sodium, potassium, glucose, calcium, total protein, 
albumin, bilirubin, aspartate aminotransferase, and creatine kinase.  
There was a significant main effect of Social Treatment (F1,17  = 5.49, p = 0.032) on the level of 
total serum protein, with a Strain x Diet interaction (F1,17  = 4.51, p = 0.049). When analysing the 
strains separately, there was a significant effect of Social Treatment (F1,11  = 6.27, p = 0.029) on 
total serum protein levels in C57BL/6J mice, but no effect of Diet (F1,11  = 4.26, p = 0.063), with 
reduced levels in the Social Defeat mice. There were no significant effects in BALB/c mice. 
Analysing the strains separately, there was only a significant effect of Social Treatment (F1,12  = 
4.86, p = 0.048) on sodium levels in BALB/c mice, with lower levels in DEF mice compared to 
SEP mice. There were no significant effects of Diet on any measure when strains were analysed 
separately.  
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Table 7.2 Summary of results for biochemical parameters 
Mean ± SEM 
Biochemistry 
(n = 4/group) 
BALB/c  
Control SEP 
BALB/c 
AVD SEP 
BALB/c  
Control DEF 
BALB/c  
AVD DEF 
C57BL/6J  
Control SEP 
C57BL/6J  
AVD SEP 
C57BL/6J  
Control DEF 
C57BL/6J  
AVD DEF 
25-OHD3 (n = 5-8) 26.85 ± 0.56 2.21 ± 1.11 28.57 ± 2.06 2.99 ± 1.23 62.15 ± 4.11 1.90 ± 0.36 66.54 ± 2.89 1.02 ± 0.30 
Sodium 161 ± 1 161 ± 1 159 ± 1 159 ± 1 156 ± 1 156 ± 1 158 ± 4 157 ± 1 
Potassium 6 ± 0 6 ± 0 6 ± 0 6 ± 0 10 ± 2 8 ± 1 8 ± 0 7 ± 1 
Chloride 113 ± 1 111 ± 0 110 ± 1 112 ± 1 108 ± 1 108 ± 1 114 ± 3 110 ± 1 
Glucose 8 ± 1 9 ± 1 7 ± 2 15 ± 5 28 ± 8 27 ± 2 18 ± 7 20 ± 4 
Urea 8 ± 0 8 ± 0 9 ± 1 9 ± 0 8 ± 1 8 ± 1 8 ± 1 10 ± 3 
Calcium 2.1 ± 0.1 2.1 ± 0.0 1.7 ± 0.4 2.0 ± 0.0 2.4 ± 0.1 2.5 ± 0.1 2.4 ± 0.1 2.3 ± 0.3 
Phosphate 3 ± 0 3 ± 0 3 ± 1 3 ± 0 4 ± 1 4 ± 0 4 ± 1 4 ± 0 
Protein Total 50 ± 1 50 ± 1 40 ± 8 50 ± 1 56 ± 2 54 ± 2 53 ± 0 43 ± 5 
Albumin 24 ± 1 24 ± 0 20 ± 4 25 ± 0 27 ± 1 29 ± 1 28 ± 1 29 ± 5 
Globulin 25 ± 0 25 ± 1 20 ± 4 26 ± 1 28 ± 3 25 ± 1 25 ± 0 15 ± 9 
A:G Ration 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 0 ± 1 
Bilirubin Total 1 ± 0 1 ± 0 0 ± 0 1 ± 0 3 ± 1 2 ± 0 3 ± 1 1 ± 1 
Alkaline Phosphatase 78 ± 4 93 ± 8 69 ± 15 81 ± 6 87 ± 18 69 ± 9 63 ± 14 51 ± 9 
Aspartate Aminotransferase 273 ± 57 178 ± 11 138 ± 5 172 ± 44 476 ± 143 374 ± 129 315 ± 84 247 ± 121 
Alanine Aminotransferase 46 ± 7 30 ± 2 25 ± 2 28 ± 7 410 ± 244 217 ± 96 92 ± 31 78 ± 48 
Creatine Kinase 42 ± 11 58 ± 8 39 ± 11 41 ± 10 39 ± 8 33 ± 8 25 ± 2 31 ± 8 
Cholesterol 3 ± 0 3 ± 0 2 ± 0 3 ± 0 4 ± 0 4 ± 0 3 ± 1 3 ± 0 
Triglyceride 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 
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7.3.3 Social defeat duration 
In the socially defeated mice, there was no significant effect of Diet (F1,22 = 1.52, p = 0.230) on the 
duration of the daily defeats. There was a significant effect of Strain (F1,22 = 198.83, p < 0.001) on 
the duration of the daily defeats. Defeats were terminated by the experimenter early in BALB/c 
mice due to the intensity of the defeats (multiple attacks within a 60 sec time period, despite 
defensive behaviour shown by the BALB/c mice), however all C57BL/6J mice completed the full 
ten min defeat each day for the 10 days (Table 7.1). 
7.3.4 Social interaction test 
7.3.4.1 Habituation phase 
During the habituation phase of the social interaction test there was no significant main effect of 
Diet or Social Treatment on any measure, there was however a significant main effect of Strain on 
the average distance to the metal cage (F1,44 = 13.88, p = 0.001), with the C57BL/6J mice having a 
shorter average distance compared to the BALB/c mice (Table 7.1).  
7.3.4.2 Interaction phase 
During the interaction phase there were four main measures analysed; the average distance to the 
CD-1, distance travelled, time in the interaction zone and time in the avoidance zone. 
7.3.4.2.1 Average distance to CD-1 
There were significant main effects of Diet (F1,44 = 4.64, p = 0.037), Strain (F1,44 = 19.19, p < 0.001) 
and Social Treatment (F1,44 = 30.48, p < 0.001) on the average distance to CD-1 with a Strain x 
Social Treatment interaction (F1,44 = 15.31, p < 0.001). Analysing the strains separately, there was a 
significant effect of Social Treatment in C57BL/6J (F1,19 = 4.69, p = 0.043) and in BALB/c mice 
(F1,25 = 31.88, p < 0.001), with DEF mice having a greater average distance to CD-1 compared to 
SEP mice. There was also a significant effect of Diet (F1,25 = 4.70, p = 0.040) in the BALB/c strain 
only, with AVD-deficient mice having a greater distance to CD-1 compared to control mice (Figure 
7.2a and b).  
7.3.4.2.2 Distance travelled during interaction 
There was a significant main effect of Social Treatment (F1,44 = 21.05, p < 0.001) and Strain (F1,44 = 
13.80, p = 0.001) but not of Diet (F1,44 = 0.01, p = 0.935) and no interaction. C57BL/6J mice 
travelled further than BALB/c mice and SEP mice travelled further than DEF mice (Table 7.1). 
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7.3.4.2.3 Time spent in the interaction zone 
There was a significant main effect of Strain (F1,44 = 33.48, p < 0.001) and Social Treatment (F1,44 = 
15.49, p < 0.001), but not of Diet (F1,44 = 0.11, p = 741) on the time spent in the interaction zone. 
The DEF mice spent less time in the interaction zone compared to SEP mice and BALB/c mice 
spent less time in this zone compared to C57BL/6J mice (Figure 7.2c and d). 
7.3.4.2.4 Time spent in the avoidance zone 
There were significant main effects of Strain (F1,44 = 10.11, p = 0.003), Social Treatment (F1,44 = 
6.34, p = 0.016) and Diet (F1,44 = 4.86, p = 0.033) on the time spent in the avoidance zone. When 
analysing the strains separately, there was no significant effect of Social Treatment or Diet in the 
C57BL/6J mice. In the BALB/c mice, there was a significant effect of Social Treatment (F1,25 = 
6.32, p = 0.019) and Diet (F1,25 = 4.75, p = 0.039) on the time spent in the avoidance zone. DEF 
mice spent more time in the avoidance zone compared to SEP mice and AVD-deficient mice spent 
more time in the avoidance zone compared to control mice (Figure 7.2e and f). 
 
 
 
 
  
 116 
 
Figure 7.2 Results of the social interaction test 
The results of the social interaction test in BALB/c mice (a, c and e) and in C57BL/6J mice (b, d and f). 
The average distance to the CD-1 mouse was significantly further in DEF mice compared to SEP mice in 
both strains (a and c), however in the BALB/c strain (a), there was also a significant increase in the average 
distance to the CD-1 mouse in AVD-deficient SEP mice compared to control SEP mice. The time spent in 
the interaction zone was significantly less for DEF mice compared to SEP mice in both strains (b and d), 
with no significant differences between AVD-deficient and control mice in either strain. The time spent in 
the avoidance zone was significantly greater in DEF mice compared to SEP mice in BALB/c mice only (e), 
furthermore AVD-deficient mice spent significantly (# main effect of Diet, p < 0.05) more time in the 
avoidance zone compared to controls (e). Mean ± SEM (*p < 0.05)  
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7.3.5 Prepulse inhibition of the acoustic startle response 
7.3.5.1 Acoustic startle response 
There was a significant Strain x Diet x Social Treatment interaction (F1,43 = 12.54, p = 0.001) with 
significance found in the main effects of Strain, Social Treatment and Diet in the ASR. In the 
BALB/c strain (Figure 7.3a and c), there was a Diet x Social Treatment interaction (F1,24 = 4.38, p = 
0.047). Post-hoc t-tests showed a significant difference between DEF controls and SEP control 
mice, with DEF leading to a blunted ASR but no significant difference between Social Treatments 
in AVD-deficient mice. In C57BL/6J mice (Figure 7.3b and d), there was a main effect of Diet 
(F1,19 = 15.79, p = 0.001) but not of Social Treatment (F1,19 = 1.67, p = 0.212), with a Diet x Social 
Treatment interaction (F1,19 = 7.52, p = 0.013). In the DEF mice, AVD deficiency led to a blunted 
ASR compared to controls and compared to SEP mice. 
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Figure 7.3 Results for the acoustic startle response 
ASR in BALB/c (a and c) and C57BL/6J (b and d) mice. There was a significant Diet x Social Treatment 
interaction in BALB/c mice. Post-hoc t-tests showed a significant difference between DEF controls and SEP 
control mice, with DEF leading to a blunted ASR but no significant difference between Social Treatments in 
AVD-deficient mice. In C57BL/6J mice, AVD deficiency led to a blunted acoustic startle response in DEF 
mice (d). Mean ± SEM (*p < 0.05) 
 
7.3.5.2 Within-session habituation 
There was a significant main effect of Strain (F1,43 = 6.16, p = 0.017) and Diet (F1,43 = 9.31, p = 
0.004) on the response to the initial 110 dB pulse given at the start of the session, with AVD-
deficient mice reacting less than controls and BALB/c mice reacting less than C57BL/6J mice. Due 
to the effect of Diet on the response to the initial pulse, AVD-deficient mice showed no WSH (F1,19 
= 0.01, p = 0.933), however, control mice did show a significant WSH (F1,24 = 6.58, p = 0.017) 
(Figure 7.4). There was no effect of Social Treatment on the initial pulse (F1,43 = 1.61, p = 0.212) or 
on WSH (F1,43 = 0.03, p = 0.876).  
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Figure 7.4 Results for within-session habituation 
WSH in BALB/c strain (a and c) and in C57BL/6J strain (b and d), SEP mice shown in a and b, with DEF 
mice shown in c and d. Overall, AVD deficiency led to a significantly reduced response to the initial 110 dB 
pulse. Due to this reduced initial response, AVD-deficient mice had no WSH, although controls did show 
WSH. Mean ± SEM (*p < 0.05) 
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7.3.5.3 Prepulse inhibition 
There were no significant differences in PPI scores for Strain (F1,43 = 0.70, p = 0.407), Diet (F1,43 = 
0.23, p = 0.633) or Social Treatment (F1,43 = 0.18, p = 0.671) (Figure 7.5). When strains were 
analysed separately, there were still no significant differences seen.  
  
   
Figure 7.5 Results for prepulse inhibition of the acoustic startle response 
There were no significant differences on PPI scores. Mean ± SEM 
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7.4 Discussion 
The main finding from this study was that AVD deficiency exacerbated impairments caused by 
social stress and the degree of impairment was dependent on strain. In BALB/c mice but not 
C57BL/6J mice, AVD deficiency exacerbated the social deficit seen following social stress 
compared to controls. In the ASR, the main difference was seen in the C57BL/6J mice; when AVD 
deficiency was combined with social defeat, it led to a blunted ASR, compared to either treatment 
on their own. In addition, AVD deficiency altered WSH across both strains due to a blunted initial 
response. Therefore we can accept the hypothesis that combining two-hits leads to greater 
detrimental outcomes compared to either treatment alone. 
Biochemical parameters were measured in a subset of mice from each group and although there 
were strain differences for a number of parameters, there was no significant difference between 
AVD-deficient mice and control mice on any measure other than vitamin D levels. Importantly, 
calcium and phosphate levels, which are known to be regulated by vitamin D (Holick, 2007) were 
not altered in the AVD-deficient mice. Therefore, we can conclude that the model of AVD 
deficiency used in the current study and in the previous chapters has limited confounding factors 
and we can be more confident that alterations reported using this model have occurred due to the 
effects of vitamin D deficiency. 
7.4.1 Relevance to neuropsychiatric disorders 
Social avoidance is a negative symptom of schizophrenia (Hansen et al., 2009), a symptom of 
autism (Richer, 1976) and it is also a symptom of depression and anxiety (Gorman, 1996). A 
previous study in group-housed BALB/c and C57BL/6J mice showed no social interaction 
impairments with AVD deficiency (Groves et al., 2013). Although the current study showed that 
chronic social defeat led to a mild social deficit in C57BL/6J mice, AVD deficiency did not 
exacerbate the mild social deficit caused by the chronic social defeat. However in BALB/c mice, 
AVD deficiency did exacerbate the social deficits following chronic social defeat and also increased 
the deficit following the milder separated housing condition.  
Impairments in PPI of the ASR are relevant to schizophrenia (Moriwaki et al., 2009), however ASR 
on its own is generally not considered important as a behavioural readout for schizophrenia. It has 
been suggested that PPI is difficult to assess when the ASR itself has been modulated by a specific 
treatment, as we have seen in these experiments. However, we did not see any significant difference 
in PPI. The % PPI values in the C57BL/6J mice are comparable to previously published data using 
this strain; with the same protocol and equipment that was used in the current study (Harms et al., 
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2008). Although, results using the BALB/c strain have not previously been published using this 
protocol, there was no significant difference in % PPI between the two strains in this study. PPI 
values do vary depending on the particular protocol used, as well as the facility and batch of mice. 
For example, a study by (van den Buuse, 2013) showed higher rates of % PPI and ASR in the 
BALB/c strain compared to the C57BL/6J strain and compared to the BALB/c mice in this study.  
The relevance of altered ASR is not as easily defined, although changes in fear and anxiety can alter 
ASR (Davis et al., 1997), as can changes in stress response pathways (Wang et al., 2002a). 
Furthermore, enhanced response to acoustic startle has been previously proposed to reflect aspects 
of traumatic psychosocial stress (Pulliam et al., 2010).  
AVD deficiency in group-housed BALB/c mice has previously been shown to increase the ASR 
compared to controls (Groves et al., 2013). In this experiment there was no significant main effect 
of diet on the ASR when analysing BALB/c mice separately. It is possible that the combination of 
social stress and AVD deficiency has blunted the ASR back to levels comparable to controls. 
However, there were differences in housing between the current study and the previous study 
(Groves et al., 2013) and the different housing conditions may have impacted on the ASR response. 
The level of ASR in this experiment was comparable to the controls in the previous study (Groves 
et al., 2013). In C57BL/6J mice, there was a significant effect on ASR when AVD deficiency was 
combined with chronic social defeat leading to a blunted ASR. Studies in humans have shown 
blunted startle in unipolar and bipolar depression (Forbes et al., 2005; Dichter & Tomarken, 2008), 
and in Parkinson’s disease patients (Bowers et al., 2006), suggesting that it may be indicative of a 
depressive-like phenotype. 
7.4.2 Limitations 
The duration of the social defeats were often terminated early by the experimenter (average of six 
and a half min, in lieu of the standard 10 min duration), due to the aggressive nature of the social 
defeats for the BALB/c strain. Due to the intensity of the protocol in the BALB/c mice, there may 
have been ceiling effects that would prevent all differential effects of diet from being seen. 
Interestingly, we noted effects of AVD deficiency in the separated mice in the BALB/c strain and 
propose that being separated from cage mates during this period was enough to produce a mild 
social stress in this strain. Therefore, a better control such as group-housed mice should be used in 
any future experiments. Furthermore, a milder form of social stress such as social isolation or 
restraint stress may be enough of a second hit in this strain. 
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By contrast, the C57BL/6J strain was a more robust, larger sized, aggressive strain compared to the 
BALB/c strain and was more resilient to the social defeat paradigm. All bouts of defeat lasted the 
full 10 min, however all mice were submissive towards the CD-1 mice and there was a significant 
difference in behaviour between the separated C57BL/6J mice and the social defeat C57BL/6J 
mice. However, overall the C57BL/6J mice were more resilient to social defeat compared to the 
BALB/c mice.  
7.4.3 Future Directions 
This experiment is the first to analyse the effects of combining the two adult environmental 
exposures of vitamin D deficiency and social stress. Future studies should extend the behavioural 
tests to address a more comprehensive screen of domains relevant to neuropsychiatric disorders, 
such as tests of anxiety, psychomimetic-induced locomotion and cognitive impairments. Other 
important experiments would be to look at changes in brain neurochemistry. Perhaps in future 
experiments, alternatives to social stress as the ‘second hit’ could be used, for example cannabis use 
is a risk factor for the development of schizophrenia and could be combined with AVD deficiency.  
There is also growing evidence of an association between vitamin D deficiency and a substantially 
increased risk of all-cause dementia and AD (Littlejohns et al., 2014). Future experiments could test 
the additional effect of vitamin D deficiency on already well-characterized animal models of 
Alzheimer’s disease. It is possible that a lack of neuroprotection caused by vitamin D deficiency 
may exacerbate the symptom severity of diseases such as Alzheimer’s disease. 
7.5 Conclusion 
We found that AVD deficiency exacerbated impairments caused by social stress and the degree of 
impairment was strain dependent. These results extend our previous work related to developmental 
vitamin D exposures, and indicate that AVD deficiency may leave the brain more vulnerable to 
stress-related second hits. Furthermore, these findings could provide a mechanism of action 
underpinning the increased risk of psychosis in dark skinned migrants to cold climates; or the 
increased risk of AD, or PD severity in vitamin D deficient individuals. 
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Chapter 8 General Discussion 
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8.1 Introduction 
There is increasing evidence from epidemiological studies to suggest that vitamin D deficiency 
during adulthood is associated with adverse brain outcomes (Eyles et al., 2013; Groves et al., 
2014), however a causal relationship has not yet been established. We have previously shown in a 
mouse model that vitamin D deficiency during adulthood impacts on a range of brain functions 
(Groves et al., 2013) and should therefore be considered as a biologically plausible risk factor for 
the development of neuropsychiatric and neurodegenerative disorders. The purpose of this thesis 
was to extend our understanding of how vitamin D deficiency is impacting on brain function and 
provide evidence towards deciphering the mechanisms by which this occurs.  
Based on a preliminary proteomic study, I found convergent evidence of an effect of AVD 
deficiency on glutamate and GABA signaling, enabling a greater understanding of how AVD 
deficiency may be altering neurotransmission. Furthermore, we have established that AVD 
deficiency impacts on glutathione synthesis leading to a reduction in glutathione levels within the 
brain, which would potentially increase exposure to oxidative stress. Oxidative stress has been 
identified as a risk factor for a number of neuropsychiatric and neurodegenerative disorders (Zhao 
& Zhao, 2013; Baierle et al., 2015; Black et al., 2015) and therefore, this may be one key 
mechanism for the effects of AVD deficiency. 
This study has also shown for the first time that AVD deficiency was associated with cognitive 
impairments in otherwise healthy male mice on two separate tasks; (a) an operant-based task to 
measure attentional processes, and (b) a hippocampal-dependent spatial learning and memory task. 
Additionally, pathway analysis of the proteomic results has highlighted a number of dysregulated 
proteins known to impact on synaptic plasticity, which may be responsible for the alterations in 
cognitive performance. Mindful that the proteomics data requires confirmation and/or replication, 
we note with interest the convergent findings with other findings from the AVD deficiency models.  
Despite significant evidence towards an effect of vitamin D on proliferation and differentiation 
during development (see Chapter 1 for review), there were no cellular level changes in adult 
hippocampal neurogenesis in AVD-deficient mice. Furthermore, I found that brain volume and 
structure were not different between controls and AVD-deficient mice using MRI, nor were there 
any changes to connectivity in the brain as measured by diffusion tensor MRI of the whole brain. 
The lack of gross morphological changes, combined with the neurochemical, proteomic and 
behavioural changes associated with AVD Deficiency suggest that this model is associated with a 
subtle phenotype.   
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The findings in Chapter 7 support the hypothesis that AVD-related brain changes may exacerbate 
other neurological insults. This finding is consistent with previous results related to stroke models 
in which vitamin D deficiency led to larger infarct volumes and greater post-stroke behavioural 
impairments (Balden et al., 2012). In addition, clinical trials of vitamin D supplementation in adults 
with PD suggest that low vitamin D exacerbates the progression of this neurodegenerative disorder 
(Suzuki et al., 2013). The findings from this thesis may have implications for understanding the role 
of vitamin D deficiency in clinical settings. While speculative, low vitamin D alone may not be 
sufficient to precipitate a neurological disorder, but may be sufficient to amplify the progression of 
other independent disorders. Thus, low vitamin D status may contribute to greater disability and 
reduce chance of recovery from neurodegenerative disorders.  
Although the exact mechanisms by which AVD deficiency is impacting on brain function has not 
been elucidated, the results from this thesis have provided some key findings on the impact of AVD 
deficiency in glutathione synthesis, synaptic plasticity and glutamate and GABA signaling. 
8.2 Glutamate and GABA signaling 
We have previously shown that AVD deficiency in male mice leads to reduced glutamate levels and 
increased GABA levels, measured by HPLC in whole brain; and a small but significant reduction in 
the GAD65/67 enzymes in whole brain, measured by western blot (Groves et al., 2013). We have 
now provided convergent evidence to show that there is a significant reduction in GAD65 in the 
hippocampus of male BALB/c mice using proteomic analysis.  
Studies in knockout mice have shown that ablation of GAD67 results in neonatal lethality and 
reductions in GABA levels to 7% of wildtype mice (Asada et al., 1997). GABA is necessary during 
development to regulate neocortical neurogenesis (LoTurco et al., 1995). However, in GAD65 
knockout mice, there was no change to GABA levels and it was shown that GAD65 is not required 
for development but is important for modulating inhibitory neurotransmission in response to 
increased demand (Asada et al., 1996). GAD65 is localized to axon terminals and is reversibly 
bound to the membrane of synaptic vesicles (Kaufman et al., 1991; Christgau et al., 1992). Further 
studies in the GAD65 knockout mice have shown that GAD65 mediates activity-dependent GABA 
synthesis (Patel et al., 2006) but moreover, has a significant impact on GABA release during 
sustained activation, possibly through mobilization of vesicles or replenishment of vesicles at the 
synapse (Tian et al., 1999). Therefore, it is feasible that the reduction in GAD65 protein expression 
associated with AVD deficiency could have an impact on GABAergic inhibitory neurotransmission.  
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Another important protein involved in GABA signaling that was found to be upregulated by AVD 
deficiency was GAT1 (or SLC6A1). GAT1 is also localized to GABAergic interneuron axons and 
nerve terminals and is responsible for GABA reuptake from the synaptic cleft (Minelli et al., 1995). 
With reductions in GABA synthesis, due to lower levels of the GAD65 enzyme, it is plausible to 
suggest that this would lead to upregulation of GAT1 in an attempt to restore intracellular GABA 
levels. Reductions in GAD65 in a pathophysiological pain model, did accompany elevated levels of 
GAT1, although it was unclear which protein expression level change preceded the other (Ford et 
al., 2015).  
A protein identified in the proteomics involved in glutamate signaling was CACNA1E, 
downregulated by AVD deficiency; this protein, also called CAv2.3, is the α1E subunit of the R-type 
calcium channel. The molecular basis and physiological function of the R-type channel are still 
relatively unclear, due to a lack of specific blockers for the channel; however it has been identified 
as neuron specific (Wu et al., 1998). Furthermore, R-type calcium channels do contribute to 
calcium influx during presynaptic action potentials and have been shown to evoke enough 
glutamate release on their own to initiate an action potential in the postsynaptic neuron (Wu et al., 
1998). Cav2.3 expression is high in the dentate granule layer and CA3 regions of the hippocampus 
(Day et al., 1996). In addition, Cav2.3 containing calcium channels are involved in synaptic 
plasticity, by participating in the calcium influx during the induction phase of presynaptic LTP in 
mossy fibres of the hippocampus (Breustedt et al., 2003). 
Cav2.3 calcium channel knockout mice have impaired mossy fibre LTP (Breustedt et al., 2003) but 
intact LTP measured in CA1 pyramidal neurons (Kubota et al., 2001). These mice exhibit impaired 
spatial memory in the Morris water maze, with a longer latency to find the platform during training 
and a reduced duration in the target quadrant during the probe trial compared to wild-type mice 
(Kubota et al., 2001). Mossy fibre synapses are required for spatial learning and drug-induced 
blockade of mossy fibre synapses will result in similar deficits in the Morris water maze as seen by 
the loss of Cav2.3 calcium channels (Lassalle et al., 2000). 
With a reduction in Cav2.3 expression levels within the hippocampus in the AVD-deficient mice, 
calcium influx into presynaptic terminals would be reduced. Reductions in calcium influx may 
impair glutamatergic neurotransmitter release, impact on mossy fibre LTP, and therefore, impair 
spatial learning. These protein level changes are not only consistent with previous findings of 
altered glutamate and GABA neurotransmitter changes (Groves et al., 2013) but could actually lead 
to the impaired spatial learning and memory seen with AVD deficiency. 
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8.3 AVD deficiency and oxidative stress  
Using both proteomics and HPLC, we have shown that the γ-glutamyl cycle has been dysregulated 
following AVD deficiency leading to a reduction in total glutathione levels within the brain. In vivo 
and in vitro studies have previously shown that the addition of 1,25(OH)2D also regulates proteins 
involved in glutathione biosynthesis and leads to increased glutathione levels (reviewed in Chapter 
1). Oxidants are formed as a normal part of aerobic metabolism but can be formed at an accelerated 
rate during pathophysiological conditions or when the body’s natural antioxidant mechanisms fail 
(Sies, 1997). Oxidative stress occurs when there is an imbalance between antioxidants and oxidants 
in favour of the oxidants, and with the reduction in glutathione, it is likely that AVD-deficient mice 
were exposed to chronic oxidative stress. 
Oxidative stress can lead to cell membrane dysfunction, DNA damage and inactivation of proteins, 
eventually leading to cell death. Studies have shown that people with mild cognitive impairment 
have higher levels of oxidative stress compared to healthy controls (Pratico et al., 2002). 
Furthermore, a study performed in rats showed that even in young animals (3 months of age), 
induction of oxidative stress led to impairments in spatial learning and memory (Fukui et al., 2002). 
Induced oxidative stress, via exposure to 100 % oxygen for 48 h, produced an abnormal 
accumulation of synaptic vesicles in swollen nerve terminals and a reduction in neurotransmission 
(Urano et al., 1997). In addition, following the induction of oxidative stress, synaptic membranes 
were shown to have elevated markers of oxidative stress including lipid peroxides and protein 
carbonyls, and a change in membrane surface potential. It was proposed that this would result in 
reduced membrane fusion between nerve terminal membranes and synaptic vesicles and produce 
the subsequent decline in neurotransmission shown previously (Urano et al., 1997; Fukui et al., 
2002). 
Exposure to chronic oxidative stress with AVD deficiency could therefore result in the cognitive 
impairments seen in this model, and the predicted effects on synapse formation and release, and 
neurotransmission obtained from the Ingenuity pathway analysis.  
8.4 AVD deficiency and cognition 
Lesion studies of the cortico-striatal pathways involved in attentional processes have shown that 
damage to the medial PFC, using quinolinic acid, replicates the findings in AVD-deficient mice 
with deficits in accuracy and lengthening of choice latencies (Robbins, 2002). Lesions of other 
cortico-striatal regions produce other deficits including impulsive responding or altered motivation, 
which we did not see with AVD-deficiency (Robbins, 2002).  
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Furthermore, the phenotype seen with AVD deficiency in males is similar to that produced 
following an infusion of picrotoxin, a GABAA receptor antagonist that dose-dependently reduces 
GABA currents, into the medial PFC of rats. Picrotoxin infusion led to deficits in accuracy and 
omissions, without altering impulsive or motivational behaviours on the 5C-SRT task (Pezze et al., 
2014).  
In Sprague-Dawley rats on a modified 3C-SRT in lieu of the 5C-SRT task, using two different 
GABAA receptor antagonists, researchers showed consistent results with that of picrotoxin effects; 
reduced accuracy and increased omissions, with no other alterations (Pehrson et al., 2013). They 
also tested the effects of GAD inhibition, with 3-mercaptopropionic acid, into the anterior cingulate 
cortex or systemic administration in Sprague-Dawley rats, on the 3C-SRT with no significant 
alterations in attention (Pehrson et al., 2013). These results suggest that reductions in GAD65 seen 
with AVD deficiency may be secondary to GAT1 upregulation, or altered expression of other 
proteins involved in GABAergic neurotransmission. There is consistent evidence from these 
previous rodent studies that disruption of GABAergic neurotransmission within the medial PFC and 
other areas of the cortico-striatal pathways does impact on aspects of the 5C-SRT. 
Performance on the 5C-SRT is also impaired by a variety of NMDA receptor antagonists including 
3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid, PCP and MK-801; although the effects of 
these drugs on attention are usually combined with a loss of executive control in the form of 
increased premature and perseverative responses (Smith et al., 2011; Carli & Invernizzi, 2014). We 
did not see a loss of executive control in AVD-deficient mice, however, we have previously shown 
reductions in glutamate levels within whole brain (Groves et al., 2013) and it is therefore plausible 
that alterations in glutamatergic neurotransmission plays a role in impaired attentional processes 
seen with AVD deficiency.  
There are currently no animal studies looking directly at the effects of oxidative stress on the 5C-
SRT task. However, the HPLC finding of reduced total glutathione in AVD-deficient male mice 
was within the whole brain and therefore, if AVD deficiency produced chronic oxidative stress 
across the whole brain, it is likely that cognitive impairments would not be restricted to the 
hippocampus.  
Human studies have shown significant associations between cognitive impairments and cognitive 
decline with systemic oxidative stress and lower antioxidant status (Berr et al., 2000; Berr, 2002; 
Baierle et al., 2015). Although many different tests are used to examine cognition in humans, the 
MMSE is used frequently, which measures global cognition including aspects of attention and 
hippocampal-dependent learning (Folstein et al., 1975; Berr et al., 2000). 
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Using GABAA receptor antagonists in the medial PFC, such as infusions of picrotoxin do induce a 
similar phenotype to AVD deficiency on the 5C-SRT, however infusions of picrotoxin into the 
ventral hippocampus induced hyperactivity, decreased startle reactivity and disrupted prepulse 
inhibition in rats (Bast et al., 2001). These effects were not seen in AVD-deficient mice.  
Studies have shown that the ventral hippocampus has a preferential role in anxiety-related 
behaviours and it is the dorsal hippocampus that is involved in spatial learning and memory 
(Bannerman et al., 2004). However, studies using GABAA receptor antagonists infused into the 
dorsal hippocampus suggest a beneficial role on cognition (Torkaman-Boutorabi et al., 2013; 
Yousefi et al., 2013). GABAergic neurotransmission is controlled by a complex interplay of a 
whole range of proteins and a number of candidate proteins that may be involved have been 
identified in the proteomics analysis of the hippocampus. 
Analysing the differentiated proteins from the proteomics using Ingenuity provided us with 
interesting candidate pathways that may underpin the changes found in hippocampal-dependent 
learning and memory in AVD deficiency. The analysis revealed that a number of proteins 
downregulated with AVD deficiency were involved in synapse formation, vesicle formation and 
release, synapse strength and plasticity. Reductions in APP, PPFIA3, MECP2 and RASGRF1 have 
all previously been reported to impair synaptic plasticity and are all downregulated in AVD-
deficient mice (Bredt & Nicoll, 2003; Moretti et al., 2006; Senechal et al., 2008; Talebian et al., 
2013).  
RASGRF1 normally facilitates neurite outgrowth in response to NGF and BDNF (Talebian et al., 
2013), yet is decreased with AVD deficiency. RASGRF1 knockout mice have impaired long-term 
memory but intact learning and short-term memory in an emotional conditioning task (Brambilla et 
al., 1997). In addition, hippocampal-dependent learning using the Morris water maze was impaired 
in these mice (Giese et al., 2001). MECP2 loss-of-function mutant mice have impaired spatial 
learning and memory on the Morris water maze, impaired contextual conditioned fear memory and 
show deficits in hippocampal-dependent long-term social memory (Moretti et al., 2006). In 
addition, they have abnormal synaptic structure and function (Moretti et al., 2006). Although these 
studies show deficits with the complete absence of the protein of interest, they do provide evidence 
that these proteins are important for proper synaptic plasticity and favourable learning and memory. 
I have not tested AVD deficiency on the Morris water maze, however I used an alternative 
hippocampal-dependent learning and memory task, the APA. 
There are limited numbers of studies using the APA to assess GABAergic neurotransmission on 
hippocampal-dependent learning and memory, although, one study using an agonist of the GABAB 
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receptor, showed disruption of spatial avoidance using the active place avoidance (Stuchlik & 
Vales, 2009). Studies using the active place avoidance have been used to show impairments in 
glutamatergic neurotransmission with systemic administration of MK-801, a non-competitive 
NMDA receptor antagonist. MK-801 treatment leads to increased travel on the arena, increased 
errors and reduced time avoiding the shock zone in Long-Evans rats (Stuchlik & Vales, 2005). 
Adult hippocampal neurogenesis is important for different aspects of the active avoidance task. For 
example, immature doublecortin-positive neurons are required for acquisition of spatial learning 
and reversal learning but not for retrieval of stored long-term memories (Vukovic et al., 2013). 
However, another study in which adult-born neurons in the hippocampus were ablated showed no 
deficit in learning the initial location of the shock zone but had impaired cognitive flexibility when 
the rules of the task were changed (Burghardt et al., 2012). Finally, stimulation of adult 
hippocampal neurogenesis with exercise improves performance in spatial learning and memory 
tasks (van Praag et al., 2005). Despite showing impairments on the hippocampal-dependent active 
place avoidance, AVD-deficient mice do not have alterations in adult hippocampal neurogenesis, as 
measured by cell proliferation and newborn mature neurons. 
There is a large body of research on the role of vitamin D in proliferation, differentiation and 
apoptosis during development (see Chapter 1 for review). One study also revealed that the absence 
of 1,25(OH)2D led to abnormal adult hippocampal neurogenesis using 1α hydroxylase knockout 
mice (Zhu et al., 2012). Based on this previous research, we hypothesised that the AVD-deficient 
mice would have alterations in adult hippocampal neurogenesis, with expected results to show 
increased proliferation but decreased survival of newly born neurons. However, we did not see any 
significant changes in the numbers of new neurons. We did show an absence of a correlation 
between neurogenesis and behaviour in AVD-deficient mice that was evident in control mice 
(Chapter 4). Therefore, it is likely the function of these neurons that have been altered by AVD 
deficiency, possibly through alterations in dendritic branching or synaptic plasticity. 
8.5 AVD deficiency and social defeat 
When exposed to a social stress paradigm, AVD-deficient mice had greater impairments in a social 
avoidance test when exposed to both a mild separated housing stress or a more intensive social 
defeat paradigm. Previously, group housed male BALB/c mice showed no social interaction deficits 
with AVD deficiency (Groves et al., 2013), yet the addition of a secondary insult once mice were 
already vitamin D deficient, led to greater avoidance behaviour during social interaction.  
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Previous studies have suggested that vitamin D deficiency may contribute to vulnerability to 
secondary insults or disorders, such as stroke or Parkinson’s disease symptoms (Balden et al., 2012; 
Suzuki et al., 2013). The results from the Chapter 7 on social avoidance adds to literature 
suggesting that vitamin D deficiency does exacerbate secondary insults, including chronic social 
stress.  
Chronic social defeat is considered an animal model of depression (Hollis & Kabbaj, 2014), 
because it induces anhedonia, learned helplessness, anxiety, social avoidance and freezing 
behaviours (Venzala et al., 2012). In addition, chronic antidepressant treatment with venlafaxine 
has been shown to reduce the depressive effects of chronic social defeat, although not with 
fluoxetine treatment (Venzala et al., 2012).  
Higher levels of BDNF in the hippocampus are both necessary and sufficient for resilience to 
chronic stress (Bergstrom et al., 2008) and reductions in BDNF induce depressive-like behaviours 
and anhedonia (Taliaz et al., 2011). Furthermore, other neurotrophic factors are also reduced in rats 
susceptible to chronic stress (Bergstrom et al., 2008). Vitamin D has been shown to stimulate a 
range of neurotrophic factors as reviewed by (Garcion et al., 2002) and therefore, vitamin D 
deficiency may lead to reductions in neurotrophic factors important for neuroprotection against 
chronic stress. Furthermore, chronic stress has been shown to induce elevated levels of oxidative 
stress (Fontella et al., 2005; Patki et al., 2013). With lower levels of total glutathione in AVD-
deficient mice, they would be more vulnerable to the effects of oxidative stress and therefore, this 
may have led to greater deficits following chronic social defeat, as seen in the social avoidance test.  
Altered glutamate synaptic transmission, in the form of reduced vesicular glutamate transporter 1 
(VGLUT1) also enhances vulnerability to stress-induced social avoidance and enhanced anxiety 
and depressive-like behaviours (Tordera et al., 2007; Venzala et al., 2012). VGLUT1 heterozygous 
knockout mice also have impairments in long-term memory (Tordera et al., 2007). A wide range of 
components involved in glutamatergic neurotransmission including receptors and transporters and 
pre- and post-synaptic components have been associated with susceptibility to chronic stress as 
reviewed by Franklin et al. (2012).  
AVD-deficient mice showed greater susceptibility to chronic social stress compared to control mice 
and although the socially defeated mice were not tested for depressive-like behaviours other than 
social avoidance, it is plausible to suggest, based on previous research (Venzala et al., 2012), that 
AVD-deficient mice might be more vulnerable to the induction of a depressive-like phenotype 
following social stress. However, AVD deficiency on its own may be insufficient to induce the 
phenotype because previous studies using the FST as a measure of behavioural despair have shown 
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that group-housed male AVD-deficient mice showed similar levels of immobility to controls 
(Groves et al., 2013). Furthermore, individually housed male and female AVD-deficient BALB/c 
mice have reduced immobility (decrease in behavioural despair) compared to control mice (Chapter 
4).  
Drugs that impact on glutamate neurotransmission have been shown to reduce immobility in the 
FST. For example, the NMDA antagonist, ketamine leads to rapid and robust antidepressant effects 
(Maeng & Zarate, 2007), as do AMPA receptor agonists (Farley et al., 2010). The analysis of 
protein expression in the hippocampus suggested that AVD deficiency impacts on several aspects of 
neurotransmission, both glutamatergic and GABAergic. Therefore, this result may be more 
suggestive of altered neurotransmission, than a specific antidepressant-related outcome.  
AVD-deficient male BALB/c mice were impaired on both a PFC-striatal circuitry requiring 
attention task and a hippocampal-dependent spatial task. We have also previously shown effects of 
AVD deficiency on an anxiety measure and response to external stimuli (Groves et al., 2013), 
suggesting possible involvement of the amygdala and brain stem. Furthermore, we have shown 
altered social behaviour following exposure to a fear-mediated social defeat and altered behavioural 
despair. These combined results provide evidence for global effects of AVD deficiency on 
behaviour and brain function. 
8.6 Sex-dependent AVD-deficient changes 
Female mice were included for analysis when measuring attentional processes and adult 
hippocampal neurogenesis, including the FST. Overall, both female and male AVD-deficient mice 
exhibited a decrease in behavioural despair (as measured by immobility on the FST), with no 
change in adult hippocampal neurogenesis. However, the results from the 5C-SRT task showed that 
only male AVD-deficient mice had impairments in attention and only female AVD-deficient mice 
had an enhanced motivation for reward. These results suggest that there is an interaction between 
sex and AVD deficiency. 
Previous human studies have shown that vitamin D status may differentially impact on sex 
hormones. For example, vitamin D deficiency has been associated with lower testosterone levels in 
men (Wehr et al., 2010) and vitamin D supplementation has been shown to increase testosterone 
levels in men (Pilz et al., 2011). Yet, higher levels of vitamin D have been associated with lower 
progesterone and oestradiol in young women (Knight et al., 2010).  
Sex-specific alterations in behaviour when using animal models is common (Curry, 2001; Kokras & 
Dalla, 2014), and it is not unusual for neuropsychiatric disorders and neurodegenerative diseases to 
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have sex-related difference in behavioural and neurobiological outcomes (Sagud et al., 2002; 
Canuso & Pandina, 2007). For example, prevalence of mild cognitive impairment has been shown 
to be higher in men (Petersen et al., 2010). Furthermore, oestradiol treatment has been shown to 
enhance cognition in animals and humans (Luine, 2014). Depression is another disorder with 
gender differences with higher incidence in women compared to men, but moreover, prevalence 
differs during the life span. Incidence is the same between males and females in children and the 
elderly but differs during childbearing years, suggesting a possible role of female sex hormones 
(Sagud et al., 2002). 
It is plausible to suggest that the female BALB/c mice might be protected from some of the 
detrimental effects of AVD deficiency and more susceptible to other effects due to the presence of 
oestrogen. However, this was beyond the scope of this thesis and would need to be investigated in 
future experiments.  
8.7 Limitations and Future Directions 
The finding of reduced glutathione with AVD deficiency suggests that future experiments should 
investigate the extent of oxidative stress in this model. For example, studies analysing markers of 
oxidative damage both at a tissue level and at the level of the synapse could indicate if the 
glutathione deficit seen with AVD deficiency is enough to induce sufficient oxidative damage to 
alter neurotransmission. Furthermore, treatment with N-acetyl cysteine, a molecule known to 
increase glutathione levels, may reverse the effects of AVD deficiency on cognition by restoring 
oxidative balance. There is also evidence from the proteomic analysis to suggest that AVD 
deficiency may be altering the expression of proteins necessary for optimal neurotransmission and 
synapse formation and this may be unrelated to oxidative stress. 
Using proteomics the effects of AVD deficiency on protein expression in the hippocampus was 
analysed and a number of candidate proteins were identified, however this was limited to one brain 
region, ideally future experiments should include analysis of other brain regions. Furthermore, the 
results from the proteomics analysis are preliminary and require further validation, via technical or 
proteomic replication. Although, proteomics is useful to generate hypotheses based on protein 
expression changes, it cannot identify which protein changes are a direct result of vitamin D 
deficiency compared to proteins that may be altered due to compensatory changes. To enable us to 
unravel the mechanism by which AVD deficiency impacts on the brain, it is important to 
differentiate between the two forms of protein expression changes.  
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The active from of vitamin D, 1,25(OH)2D, is highly pleotropic with over 2700 VDREs within the 
genome that are able to alter the transcription of wide range of genes in the presence of vitamin D 
(Ramagopalan et al., 2010). Ideally, an experiment to analyse the genome upstream of the proteins 
altered by AVD deficiency for VDREs could highlight those genes that vitamin D, or the absence of 
vitamin D, directly regulates at a transcriptional level.  
Furthermore, a number of biological processes were identified by proteomic pathway analysis that 
could be altered by AVD deficiency and these should be followed up. For example, a number of 
proteins involved in synapse formation, synapse plasticity, neurotransmission and dendritic 
arborisation were highlighted as being differentially expressed with AVD deficiency. Although we 
have shown that hippocampal-dependent learning and memory are altered by AVD deficiency, we 
have not as yet, identified which key biological processes may be responsible for the deficit seen. 
Further research at the level of the synapse needs to be undertaken in the future to unravel 
mechanisms of the impairments seen with AVD deficiency. 
We have shown that AVD deficiency leaves male BALB/c mice vulnerable to the effect of social 
stress and is suggestive that they are also more vulnerable to depressive-like behaviours compared 
to controls. Therefore, future experiments should follow up the two-hit exposures with a range of 
behavioural tests including measures of depression and cognition. Furthermore, these results also 
have important implications for clinical research. For example, a randomised, double-blind, 
controlled trial in PD’s patients has recently shown that vitamin D3 supplementation stabilised and 
prevented deterioration of PD symptoms (Suzuki et al., 2013). However, more clinical trials are 
needed in a wider range of disorders, including AD. 
There is growing evidence for an association between vitamin D deficiency and AD in 
epidemiology (Littlejohns et al., 2014; Keeney & Butterfield, 2015). Furthermore, animal studies 
have shown that vitamin D treatment reduces the load of Aβ and aids in the clearance of Aβ 
(Briones & Darwish, 2012). Future experiments should explore the combined effects of AVD 
deficiency and AD pathology to determine if vitamin D deficiency exacerbates the symptoms of 
AD. Furthermore, experiments in aging mice are now warranted, particularly since a vast majority 
of epidemiological findings are from studies in elderly populations. There may be much greater 
effects of AVD deficiency in more vulnerable populations, such as aged animals, or after a longer 
time period on the vitamin D-deficient diet because 10 weeks is still a relatively short period of 
dietary manipulation in mice. 
Some of the research for this thesis has been performed only in males, where ideally it should all be 
performed in both males and females. The proteomic analysis was performed on a small scale due 
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to the limitations of the iTRAQ method and therefore only male mice were analysed. Furthermore, 
the experiments that followed up hypotheses generated by the proteomics were restricted to males, 
because it was unknown if female mice might have different unpredicted outcomes due to different 
protein expression patterns with AVD deficiency. Finally, the social defeat paradigm used in the 
two-hit exposure could not be effectively performed in females. Future experiments should expand 
to include both male and females. Of particular interest, would be to determine if female AVD-
deficient BALB/c were impaired on the hippocampal-dependent active place avoidance or protected 
from impairments in a similar way to the attentional 5C-SRT task results. Furthermore, it would be 
an interesting finding to determine if protein expression changes were different between males and 
females, to help explain why there may be cognitive differences between the sexes. 
8.8 Conclusion 
The results from the research covered in this thesis indicate that exposure to vitamin D deficiency 
during adulthood in mice is sufficient to impair cognition, alter brain function and leave mice more 
vulnerable to a secondary exposure. The results from the two-hit study have confirmed that BALB/c 
mice are more susceptible to the effects of AVD deficiency compared to C57BL/6J mice, even 
when an additional insult was added, indicating that differing genetics most likely plays a role in the 
adverse outcomes associated with AVD deficiency, and this may be relevant to human populations. 
The findings from this thesis support the epidemiological link between vitamin D deficiency in 
adulthood and adverse outcomes including cognitive impairment and vulnerability to secondary 
insults. Furthermore, the results from the thesis have provided new clues that may lead us to unravel 
the mechanisms as to how the absence of vitamin D can lead to such detrimental outcomes.   
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Appendix 1 
Specialty Feeds Diet - Soya Oil Maize Starch Modification of AIN93G Rodent Diet 
a) Base components of the Control and AVD-deficient mouse feed  
Ingredients  
Casein (Acid) 200 g/Kg 
Sucrose 100 g/Kg 
Soya Bean Oil 70 g/Kg 
Cellulose 50 g/Kg 
Maize Starch 404 g/Kg 
Dextrinised Starch 132 g/Kg 
DL Methionine 3.0 g/Kg 
Calcium Carbonate 13.1 g/Kg 
Sodium Chloride 2.6 g/Kg 
AIN93 Trace Minerals 1.4 g/Kg 
Potassium Citrate 2.5 g/Kg 
Potassium Dihydrogen Phosphate 6.9 g/Kg 
Potassium Sulphate 1.6 g/Kg 
Choline Chloride (75%) 4.1 g/Kg 
Oxicap E2 0.14 g/Kg 
AIN93 Vitamins 15 g/Kg 
Vitamin K 0.23% 0.87 g/Kg 
Values given are prior to irradiation with 25 kGy 
b) Vitamin Composition of Control and AVD-deficient mouse feed 
Calculated Total Vitamins  
Vitamin A (Retinol) 6000 IU/Kg 
Vitamin D (Cholecalciferol) 1500 IU/Kg (Control) 
0 IU/Kg (AVD-deficient) 
Vitamin E (α Tocopherol acetate) 115 mg/Kg 
Vitamin K (Menadione) 3.5 mg/Kg 
Vitamin C (Ascorbic acid) None added 
Vitamin B1 (Thiamine) 9.1 mg/Kg 
Vitamin B2 (Riboflavin) 9.3 mg/Kg 
Niacin (Nicotinic acid) 45 mg/Kg 
Vitamin B6 (Pyridoxine) 11 mg/Kg 
Pantothenic Acid 24.5 mg/Kg 
Biotin 300 µg/Kg 
Folic Acid 3 mg/Kg 
Inositol None added 
Vitamin B12 (Cyancobalamin) 152 µg/Kg 
Choline 2380 mg/Kg 
Values given are prior to irradiation with 25 kGy 
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c) Mineral Composition of Control and AVD-deficient mouse feed 
Calculated Total Minerals  
Calcium 0.47% 
Phosphorous 0.35% 
Magnesium 0.08% 
Sodium 0.15% 
Chloride 0.16% 
Potassium 0.40% 
Sulphur 0.23% 
Iron 68 mg/Kg 
Copper 7.0 mg/Kg 
Iodine 0.2 mg/Kg 
Manganese 19 mg/Kg 
Cobalt No data 
Zinc 46 mg/Kg 
Molybdenum 0.15 mg/Kg 
Selenium 0.3 mg/Kg 
Cadmium No data 
Chromium 1.0 mg/Kg 
Fluoride 1.0 mg/Kg 
Lithium 0.1 mg/Kg 
Boron 2.5 mg/Kg 
Nickel 0.5 mg/Kg 
Vanadium 0.1 mg/Kg 
Values given are prior to irradiation with 25 kGy 
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Appendix 2 
Specialty Feeds Standard Mouse Chow 
a) Base components of the standard mouse diet 
Ingredients  
A fixed formula ration using Wheat, Barley, Lupins, Soya meal, Fish meal, Mixed 
vegetable oils, Canola oil, Calcium carbonate, Dicalcium phosphate, Magnesium oxide, 
and a Vitamin and trace Mineral premix 
 
b) Vitamin Composition of the standard mouse diet 
Calculated Total Vitamins  
Vitamin A (Retinol) 19500 IU/Kg 
Vitamin D (Cholecalciferol) 2000 IU/Kg  
Vitamin E (α Tocopherol acetate) 110 mg/Kg 
Vitamin K (Menadione) 20 mg/Kg 
Vitamin C (Ascorbic acid) No data 
Vitamin B1 (Thiamine) 80 mg/Kg 
Vitamin B2 (Riboflavin) 30 mg/Kg 
Niacin (Nicotinic acid) 145 mg/Kg 
Vitamin B6 (Pyridoxine) 28 mg/Kg 
Pantothenic Acid 60 mg/Kg 
Biotin 410 µg/Kg 
Folic Acid 5 mg/Kg 
Inositol No data 
Vitamin B12 (Cyancobalamin) 152 µg/Kg 
Choline 1600 mg/Kg 
Values given are prior to autoclaving 
c) Mineral Composition of the standard mouse diet 
Calculated Total Minerals  
Calcium 0.80% 
Phosphorous 0.70% 
Magnesium 0.20% 
Sodium 0.20% 
Potassium 0.70% 
Sulphur 0.20% 
Iron 590 mg/Kg 
Copper 24 mg/Kg 
Iodine 0.5 mg/Kg 
Manganese 115 mg/Kg 
Cobalt 1.0 mg/Kg 
Zinc 90 mg/Kg 
Molybdenum 1.2 mg/Kg 
Selenium 0.4 mg/Kg 
Cadmium 0.04 mg/Kg 
Values given are prior to autoclaving 
